

\*\*\*\*\*

MPsrch\_pp protein - protein database search, using Smith-Waterman algorithm

Release 2.1D John F. Collins, Biocomputing Research Unit.  
Copyright (c) 1993, 1994, 1995 University of Edinburgh, U.K.  
Distribution rights by IntelliGenetics, Inc.

Run on: Tue Mar 3 11:19:37 1998; MasPar time 2.63 Seconds  
Tabular output not generated. 58.067 Million cell updates/sec

Title: >US-08-137-117D-117  
Description: (1-11) from US08137117D.pep  
Perfect Score: 70  
Sequence: 1 RASQDISSYLN 11

Scoring table: PAM 150  
Gap 15

Searched: 111726 seqs, 13889129 residues

Post-processing: Minimum Match 0%  
Listing first 45 summaries

Database: a-geneseq30  
1:part1 2:part2 3:part3 4:part4 5:part5 6:part6 7:part7  
8:part8 9:part9 10:part10 11:part11 12:part12 13:part13  
14:part14 15:part15 16:part16 17:part17 18:part18  
19:part19 20:part20 21:part21 22:part22 23:part23

Statistics: Mean 17.502; Variance 52.635; scale 0.333

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	70	100.0	126	5	R29015	4.74e-01
2	70	100.0	126	5	R29013	4.74e-01
3	70	100.0	127	5	R28670	4.74e-01
4	67	95.7	108	20	W00834	1.05e+00
5	67	95.7	108	20	W04177	1.05e+00
6	67	95.7	109	17	R52039	1.05e+00
7	67	95.7	127	22	W11815	1.05e+00
8	67	95.7	127	22	W11817	1.05e+00
9	67	95.7	127	5	R29010	1.05e+00
10	67	95.7	131	14	R45553	1.05e+00
11	67	95.7	268	8	R44226	1.05e+00
12	67	95.7	273	9	R52865	1.05e+00
13	66	94.3	128	5	R09426	1.37e+00
14	66	94.3	128	19	W06215	1.37e+00
15	64	91.4	11	20	W13920	2.31e+00
16	64	91.4	95	12	R2058	2.31e+00
17	64	91.4	95	12	R2065	2.31e+00
18	64	91.4	107	10	R54260	2.31e+00
19	64	91.4	107	19	W01284	2.31e+00
20	64	91.4	107	19	W01283	2.31e+00

21	64	91.4	107	10	R54261	Anti-HIV gp120 immuno	2.31e+00
22	64	91.4	108	23	W13521	Anti-melanoma light c	2.31e+00
23	64	91.4	108	23	W13530	Anti-melanoma light c	2.31e+00
24	64	91.4	113	20	W13524	Light chain #2 for an	2.31e+00
25	64	91.4	114	20	W13922	Light chain #1 for an	2.31e+00
26	64	91.4	127	7	R39265	Mouse C4G1 Ig light-c	2.31e+00
27	64	91.4	132	22	W22842	Human anti-tumour ant	2.31e+00
28	64	91.4	214	6	R30776	H52L6-158 murine anti	2.31e+00
29	64	91.4	214	7	R43338	Completely humanised	2.31e+00
30	64	91.4	214	19	W00373	Anti-CD18 chimeric an	2.31e+00
31	64	91.4	233	6	R30777	pH52-9.0 humanised m	2.31e+00
32	63	90.0	104	19	W01285	VL region of HIV neut	3.00e+00
33	63	90.0	104	9	R54318	Anti-HIV gp120 immuno	3.00e+00
34	63	90.0	107	7	R41283	Moderate-risk modifie	3.00e+00
35	63	90.0	107	7	R38614	Low-risk modified (pr	3.00e+00
36	63	90.0	109	6	R30764	Consensus humanised a	3.00e+00
37	63	90.0	109	9	R47041	Sequence of the conse	3.00e+00
38	63	90.0	127	19	R99003	MAB VLI7E5 light chain	3.00e+00
39	62	88.6	11	17	R52523	Gloop-2 light chain c	3.89e+00
40	62	88.6	104	9	R54322	Anti-HIV gp120 immuno	3.89e+00
41	62	88.6	107	6	R30769	huxCD3v9, humanised m	3.89e+00
42	62	88.6	107	6	R30768	Murine anti-CD3 MAB U	3.89e+00
43	62	88.6	108	4	R21286	Murine VL kappa group	3.89e+00
44	62	88.6	108	10	R54062	Anti-cancer monoclon	3.89e+00
45	62	88.6	128	5	R29579	CLN-IgG kappa.	3.89e+00

ALIGNMENTS

RESULT 1  
ID R29015 standard; Protein; 126 AA.  
AC R29015;  
DE 30-MAR-1993 (first entry)  
DE PUC-RV1-PM1a.  
KW Human; antibody; interleukin-6; receptor; IL-6R; CDR; PCR;  
KW complementarity determining region; mouse; monoclonal; hybridoma;  
KW plasmid; polymerase chain reaction; amplify.  
OS Synthetic.  
FH Key Location/Qualifiers  
FT Peptide 1..19  
FT /note= "Leader peptide"  
FT Region 20..42  
FT /label= FR1  
FT Region 43..53  
FT /label= CDR1  
FT Region 54..68  
FT /label= FR2  
FT Region 69..75  
FT /label= CDR2  
FT Region 76..107  
FT /label= FR3  
FT Region 108..116  
FT /label= CDR3  
FT Region 117..126  
FT /label= FR4  
FN WO9219759-A.  
PD 12-NOV-1992.  
PD 24-APR-1992; J00544.  
PR 25-APR-1991; JP-095476.  
PR 19-FEB-1992; JP-032084.  
PR (CHUS ) CHUGAI SEIYAKU KK.  
PI Bendig MM, Jones ST, Saldanha JW, Sato K, Tsuchiya M;  
DR WPI; 92-398882/48.  
DR N-PSDB; Q31366.  
DR Reconstituted human antibody to human interleukin-6 receptor -  
PT has low antigenicity and contains mouse V-region complementarity  
PT determining regions  
PS Disclosure; Page 144-5; 207pp; Japanese.  
CC The sequences given in R29012-15 are portions of monoclonal antibodies  
CC which were encoded by plasmids derived from mouse hybridomas. The DNA  
CC encoding complementarity determining regions (CDR's) was isolated by  
CC polymerase chain reaction. These antibodies recognise human  
interleukin-6 receptor (IL-6R). The mouse hybridoma cells were

CC transformed with the plasmids encoding these genes which caused the  
 CC secretion of these antibodies from the hybridoma cells.  
 SQ Sequence 126 AA;

Query Match 100.0%; Score 70; DB 5; Length 126;  
 Best Local Similarity 100.0%; Pred. No. 4.74e-01;  
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 43 rasqdisssyn 53  
 |||||  
 QY 1 RASQDISSYN 11

## RESULT 2

ID R29013 standard; Protein; 126 AA.

AC R29013;

DT 30-MAR-1993 (first entry)

DE pUC-RVh-PM1a.

KW Human; antibody; interleukin-6; receptor; IL-6R; CDR; PCR;

KW complementarity determining region; mouse; monoclonal; hybridoma;

KW plasmid; polymerase chain reaction; amplify.

OS Synthetic.

FH Key Location/Qualifiers

FT Peptide 1..19

FT /note= "Leader peptide"

FT Region 20..42

FT /label= FR1

FT Region 43..53

FT /label= CDR1

FT Region 54..68

FT /label= FR2

FT Region 69..75

FT /label= CDR2

FT Region 76..107

FT /label= FR3

FT Region 108..116

FT /label= CDR3

FT Region 117..126

FT /label= FR4

FT WO9219759-A.

PD 12-NOV-1992.

PF 24-APR-1992; J00544.

PR 25-APR-1991; JP-095476.

PR 19-FEB-1992; JP-032084.

PA (CHUS ) CHUGAI SEIYAKU KK.

PI Bendig MM, Jones ST, Saldanha JW, Sato K, Tsuchiya M;

DR WPI; 92-398882/48.

DR N-PSDB; Q31361.

PT Reconstituted human antibody to human interleukin-6 receptor -

PT has low antigenicity and contains mouse V-region complementarity

PT determining regions

PS Disclosure; Page 140-1; 207pp; Japanese.

CC The sequences given in R29012-15 are portions of monoclonal antibodies

CC which were encoded by plasmids derived from mouse hybridomas. The DNA

CC encoding complementarity determining regions (CDR's) was isolated by

CC polymerase chain reaction. These antibodies recognise human

CC interleukin-6 receptor (IL-6R). The mouse hybridoma cells were

CC transformed with the plasmids encoding these genes which caused the

CC secretion of these antibodies from the hybridoma cells.

SQ Sequence 126 AA;

Query Match 100.0%; Score 70; DB 5; Length 126;

Best Local Similarity 100.0%; Pred. No. 4.74e-01;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 43 rasqdisssyn 53

|||||

QY 1 RASQDISSYN 11

## RESULT 3

ID R28670 standard; Protein; 127 AA.

AC R28670;

DT 30-MAR-1993 (first entry)  
 DE pPW-k3 protein product.  
 KW Human; antibody; interleukin-6; receptor; IL-6R; light chain; L; H;  
 KW heavy chain; variable region; mouse; monoclonal; hybridoma; PMI;  
 KW plasmid; pPW-k3; pPW-h1.  
 OS Synthetic.

FH Key Location/Qualifiers

FT Peptide 1..20

FT /note= "Signal peptide"

FT Protein 21..127

FT /note= "Mature peptide"

PN WO9219759-A.

PD 12-NOV-1992.

PF 24-APR-1992; J00544.

PR 25-APR-1991; JP-095476.

PR 19-FEB-1992; JP-032084.

PA (CHUS ) CHUGAI SEIYAKU KK.

PI Bendig MM, Jones ST, Saldanha JW, Sato K, Tsuchiya M;

DR WPI; 92-398882/48.

DR N-PSDB; Q30755.

PT Reconstituted human antibody to human interleukin-6 receptor -

PT has low antigenicity and contains mouse V-region complementarity

PT determining regions

PS Disclosure; Page 121-122; 207pp; Japanese.

CC The sequences given in R28670-71 were encoded by plasmids which were

CC used in example to illustrate the production of a human antibody which

CC recognises human interleukin-6 receptor (IL-6R). The antibody

CC comprises light (L) chain and heavy (H) chain variable regions which

CC were derived from a mouse monoclonal antibody produced from the

CC hybridoma PMI which contained the plasmids pPW-k3 and pPW-h1.

SQ Sequence 127 AA;

Query Match 100.0%; Score 70; DB 5; Length 127;

Best Local Similarity 100.0%; Pred. No. 4.74e-01;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 44 rasqdisssyn 54

|||||

QY 1 RASQDISSYN 11

## RESULT 4

ID W00834 standard; Protein; 108 AA.

AC W00834;

DT 20-MAY-1997 (first entry)

DE Variable light chain of anti-human Fas ligand antibody NOK-1.

KW Variable region; light chain; human; Fas ligand; monoclonal;

KW antibody; NOK-1; hybridoma; inhibition; apoptosis; assay;

KW diagnosis; disease; hepatitis; infectious mononucleosis;

KW systemic lupus erythematosus.

OS Mus musculus.

PN W09629350-A1.

PD 26-SEP-1996.

PF 21-MAR-1996; J00734.

PR 20-MAR-1995; JP-087420.

PR 27-OCT-1995; JP-303492.

PA (SUME ) SUMITOMO ELECTRIC IND CO.

PI Kayagaki N, Nakata M, Okumura K, Yagita H;

DR WPI; 96-443140/44.

DR N-PSDB; T39560.

PT Monoclonal antibody specifically recognising the Fas ligand - useful

PT for the detection of Fas ligands either on cell surface or in

PT solution

PS Claim 41; Pages 93-94; 133pp; Japanese.

CC The present sequence is the light chain variable region of the

CC anti-human Fas ligand monoclonal antibody (MAB) NOK-1. NOK-1 is

CC produced by the hybridoma NOK-1 (FERM BP-5044), which was prepared

CC by immunising mice with transformed human Fas ligand expressing COS

CC cells, and fusing spleen cells isolated from the mice with myeloma

CC P3x6Ag8.653 (ATCC CRL-1580) cells. The MAB recognises the human

CC Fas ligand on the cell surface or in solution, and can be used to

CC inhibit the apoptosis inducing cell surface Fas ligand/Fas

CC reaction. The MAB can also be used for a Fas ligand assay in

CC biological samples (e.g. human blood), especially for disease  
 CC diagnosis, e.g. hepatitis, infectious mononucleosis and systemic  
 CC lupus erythematosus.  
 SQ Sequence 108 AA;

Query Match 95.7%; Score 67; DB 20; Length 108;  
 Best Local Similarity 90.9%; Pred. No. 1.05e+00;  
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisnynl 34  
 |||||:||||  
 QY 1 RASQDISSYLN 11

## RESULT 5

ID W04177 standard; Protein; 108 AA.  
 AC W04177;  
 DT 19-MAY-1997 (first entry)  
 DE Variant variable light chain of Fas ligand antibody NOK-1.  
 KW Variable region; light chain; human; Fas ligand; monoclonal;  
 KW antibody; NOK-1; hybridoma; inhibition; apoptosis; assay;  
 KW diagnosis; disease; hepatitis; infectious mononucleosis;  
 KW systemic lupus erythematosus; variant.  
 OS Mus musculus.  
 PN W09629350-A1.  
 PD 26-SEP-1996.  
 PF 21-MAR-1996; J00734.  
 PR 20-MAR-1995; JP-087420.  
 PR 27-OCT-1995; JP-303492.  
 PA (SUME ) SUMITOMO ELECTRIC IND CO.  
 PI Kayagaki N, Nakata M, Okumura K, Yagita H;  
 DR WPI: 96-443140/44.  
 DR N-PSDB; T39550.  
 PT Monoclonal antibody specifically recognising the Fas ligand - useful  
 PT for the detection of Fas ligands either on cell surface or in  
 PT solution  
 PS Claim 20; Pages 80-81; 133pp; Japanese.  
 CC The present sequence is a variant light chain variable region  
 CC of the anti-human Fas ligand monoclonal antibody (WAB) NOK-1.  
 CC is produced by the hybridoma NOK-1 (FERM BP-5044), which was  
 CC prepared by immunising mice with transformed human Fas ligand  
 CC expressing COS cells, and fusing spleen cells isolated from the  
 CC mice with myeloma P3x63Ag8.653 (ATCC CRL-1580) cells. The MAB  
 CC recognises the human Fas ligand on the cell surface or in solution,  
 CC and can be used to inhibit the apoptosis inducing cell surface Fas  
 CC ligand/Fas reaction. The MAB can also be used for a Fas ligand  
 CC assay in biological samples (e.g. human blood), especially for  
 CC disease diagnosis, e.g. hepatitis, infectious mononucleosis and  
 CC systemic lupus erythematosus.  
 SQ Sequence 108 AA;

Query Match 95.7%; Score 67; DB 20; Length 108;  
 Best Local Similarity 90.9%; Pred. No. 1.05e+00;  
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisnynl 34  
 |||||:||||  
 QY 1 RASQDISSYLN 11

## RESULT 6

ID R52039 standard; Protein; 109 AA.  
 AC R52039;  
 DT 27-SEP-1996 (first entry)  
 DE Light chain variable region of murine antibody lf19.  
 KW antibody; humanised; murine; human; heavy chain; light; variable;  
 KW framework region; complementarity determining region; reshaping;  
 KW modelling; surface residue; modify.  
 OS Mus sp.  
 PN 1.23  
 PF Key Location/Qualifiers  
 FT Region 1..23  
 FT /label= framework\_region\_1  
 FT /note= "FR 1"

FT Region 24..34  
 FT /label= complementarity\_determining\_region\_1  
 FT /note= "CDR 1"  
 FT Region 35..49  
 FT /label= FR\_2  
 FT Region 50..56  
 FT /label= CDR\_2  
 FT Region 57..88  
 FT /label= FR\_3  
 FT Region 89..97  
 FT /label= CDR\_3  
 FT Region 98..109  
 FT /label= FR\_4  
 FT EP-592106-A1.  
 PN 13-APR-1994.  
 PD 07-SEP-1993; 307051.  
 PF 09-SEP-1992; US-942245.  
 PR (PEDE/) PEDERSEN J T.  
 PA (IMMU-) IMMUNOGEN INC.  
 PI Guild BC, Pedersen JT, Rees AR, Roguska MA, Searle SMJ;  
 DR WPI: 94-120230/15.  
 PT Method of resurfacing of rodent antibodies to produce humanised  
 PT antibody forms - for producing non-human antibodies with improved  
 PT therapeutic efficiency by presenting human surface on V-region  
 PS Example 1; Fig 3A; 230pp; English.  
 CC The present sequence is that of the light chain variable (LC VR) region  
 CC of murine antibody lf19. This sequence was aligned with 11 other known  
 CC antibody LC VRs and a set of framework positions of surface exposed amino  
 CC acid residues was determined. This information can be used in a method to  
 CC determine how to modify a rodent antibody or fragment by resurfacing in  
 CC order to produce a humanised rodent antibody. Residues (determined from  
 CC alignment) at positions 1, 3, 5, 9, 15, 18, 46, 47, 51, 63, 66, 73, 86,  
 CC 87, 111, 115, 116 and 117 are accessible residues. None of the entire  
 CC combinations of surface residues in the murine sequences were found in  
 CC the human sequences and vice versa. However the residues in individual  
 CC positions appear to be conserved.  
 SQ Sequence 109 AA;

Query Match 95.7%; Score 67; DB 17; Length 109;  
 Best Local Similarity 90.9%; Pred. No. 1.05e+00;  
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisnynl 34  
 |||||:||||  
 QY 1 RASQDISSYLN 11

## RESULT 7

ID W11815 standard; Protein; 127 AA.  
 AC W11815;  
 DT 20-OCT-1997 (first entry)  
 DE Mouse anti-human Fas ligand antibody F919 light chain.  
 KW Human; Fas ligand; antigen; neutral; antibody; apoptosis; HIV;  
 KW induction; assay; enzyme linked immunosorbant assay; diagnosis;  
 KW disease; hepatitis B; hepatitis C; human immunodeficiency virus;  
 KW graft versus host disease; ulcerative colitis; sequelae;  
 KW myocardial infarction; mouse; murine; monoclonal; treatment;  
 KW complementarity determining region; CDR.  
 OS Mus spp.  
 PN Key Location/Qualifiers  
 FT Region 44..54  
 FT /label= CDR\_1  
 FT Region 70..76  
 FT /label= CDR\_2  
 FT Region 109..117  
 FT /label= CDR\_3  
 PN W09702290-A1.  
 PD 23-JAN-1997.  
 PF 01-JUL-1996; J01820.  
 PR 17-MAY-1996; JP-649100.  
 PR 30-JUN-1995; JP-188480.  
 PA (MOCH ) MOCHIDA PHARM CO LTD.  
 PA (OSAB-) OSAKA BIOSCIENCE INST.

PI CO M5, Matsusue T, Nagata S, Shirakawa K, Vasquez M;  
DR WPI: 97-108917/10.  
DR N-PSDB; T59500.  
PT Antibody reactive with Fas ligand capable of inducing apoptosis -  
PT used for diagnostic assay of Fas ligand in body fluids and for  
PT treatment of diseases in which Fas ligand/Fas antigen is involved  
PS Claim 5; Fig 10; 164pp; Japanese.  
CC The present sequence is the light chain of the mouse  
CC anti-apoptosis inducing human Fas ligand, monoclonal antibody,  
CC F919. The antibody can be used in a Fas ligand assay, e.g. an  
CC enzyme linked immunosorbent assay, to diagnose diseases in which  
CC the Fas ligand/Fas antigen system is implicated, e.g. hepatitis  
CC B/C, human immunodeficiency virus, graft/host disorders,  
CC ulcerative colitis or sequelae of myocardial infarction. The  
CC antibody may also be used to treat such diseases.  
SQ Sequence 127 AA;

Query Match 95.7%; Score 67; DB 22; Length 127;  
Best Local Similarity 90.9%; Pred. No. 1.05e+00;  
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 44 rasqdisnyln 54  
|||||:||||  
QY 1 RASQDISNYLN 11

RESULT 8  
ID W11817 standard; Protein; 127 AA.

AC W11817;  
DE Humanised mouse anti-human Fas ligand antibody F919 light chain.  
KW Human; Fas ligand; antigen; neutral; antibody; apoptosis; HIV;  
KW induction; assay; enzyme linked immunosorbent assay; diagnosis;  
KW disease; hepatitis B; hepatitis C; human immunodeficiency virus;  
KW graft versus host disease; ulcerative colitis; sequelae; chimeric;  
KW myocardial infarction; mouse; murine; monoclonal; treatment.  
OS Chimeric - Mus spp.  
OS Chimeric - Homo sapiens.  
OS Synthetic.

FH Key Location/Qualifiers  
FT Region 44..54

FT /label= CDR\_1 70..76  
FT Region  
FT /label= CDR\_2 109..117  
FT Region  
FT /label= CDR\_3  
PN W09702290-A1.

PD 23-JAN-1997.

PF 01-JUL-1996; J01820.

PR 17-MAY-1996; US-649100.

PR 30-JUN-1995; JP-188480.

PA (MOCH ) MOCHIDA PHARM CO LTD.

PI (OSAB-) OSAKA BIOSCIENCE INST.

PI CO M5, Matsusue T, Nagata S, Shirakawa K, Vasquez M;

DR WPI: 97-108917/10.

DR N-PSDB; T59502.

PT Antibody reactive with Fas ligand capable of inducing apoptosis -  
PT used for diagnostic assay of Fas ligand in body fluids and for  
PT treatment of diseases in which Fas ligand/Fas antigen is involved  
PS Claim 5; Fig 12; 164pp; Japanese.

CC The present sequence is the light chain of the humanised  
CC mouse anti-apoptosis inducing human Fas ligand, monoclonal  
CC antibody, F919. The antibody can be used in a Fas ligand assay,  
CC e.g. an enzyme linked immunosorbent assay, to diagnose diseases  
CC in which the Fas ligand/Fas antigen system is implicated, e.g.  
CC hepatitis B/C, human immunodeficiency virus, graft/host disorders,  
CC ulcerative colitis or sequelae of myocardial infarction. The  
CC antibody may also be used to treat such diseases.  
SQ Sequence 127 AA;

Query Match 95.7%; Score 67; DB 22; Length 127;  
Best Local Similarity 90.9%; Pred. No. 1.05e+00;  
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 44 rasqdisnyln 54  
|||||:||||  
QY 1 RASQDISNYLN 11

RESULT 9

ID R29010 standard; Protein; 127 AA.

AC R29010; 1993 (first entry)

DE p146-k3 protein product.

KW Human; antibody; interleukin-6; receptor; IL-6R; light chain; L; H;

KW heavy chain; variable region; mouse; monoclonal; hybridoma; AUK146-15;

KW plasmid; p146-k3; p146-h1.

OS Synthetic.

FH Key Location/Qualifiers

FT Peptide 1..20

FT /note= "Signal peptide"

FT Protein 21..127

FT /note= "Mature peptide"

PN W09219759-A.

PD 12-NOV-1992.

PF 24-APR-1992; J00544.

PR 25-APR-1991; JP-095476.

PR 19-FEB-1992; JP-032084.

PA (CHUS ) CHUGAI SEIYAKU KK.

PI Bendig MW, Jones ST, Saldanha JW, Sato K, Tsuchiya M;

DR WPI: 92-398882/48.

DR N-PSDB; Q30759.

PT Reconstituted human antibody to human interleukin-6 receptor -

PT has low antigenicity and contains mouse V-region complementarity

PT determining regions

PS Disclosure; Page 127-128; 207pp; Japanese.

CC The sequences given in R29010-11 were encoded by plasmids which were  
CC used in example to illustrate the production of a human antibody which  
CC recognises human interleukin-6 receptor (IL-6R). The antibody  
CC comprises light (L) chain and heavy (H) chain variable regions which  
CC were derived from a mouse monoclonal antibody produced from the  
CC hybridoma AUK146-15 which contained the plasmids p146-k3 and p146-h1.  
SQ Sequence 127 AA;

Query Match 95.7%; Score 67; DB 5; Length 127;

Best Local Similarity 90.9%; Pred. No. 1.05e+00;

Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 44 rasqdisnyln 54  
|||||:||||  
QY 1 RASQDISNYLN 11

RESULT 10

ID R84553 standard; Protein; 131 AA.

AC R84553;

DT 02-FEB-1996 (first entry)

DE MAB SCH94.03 light chain.

KW Monoclonal antibody; MAB; SCH94.03; hybridoma; central nervous system;

KW CNS; demyelination; multiple sclerosis; neural disease; therapeutic.

OS Mus sp.

FH Key Location/Qualifiers

FT Peptide 1..20

FT /label= Leader\_peptide

FT Region 44..54

FT /label= CDR1 70..76

FT Region

FT /label= CDR2 109..117

FT Region

FT /label= CDR3 116..128

FT Region

FT /label= Joining\_region 129..131

FT /label= C-kappa\_region

PN W09530004-A1.

PD 09-NOV-1995.

PF 27-APR-1995; U05262.  
 PR 29-APR-1994; US-236520.  
 PA (MAYO-) MAYO FOUNDATION.  
 PI Miller DJ, Rodriguez M;  
 DR WPI: 95-393077/50.  
 DR N-PSDB; T05311.  
 PT Monoclonal antibodies which stimulate central nervous system  
 PT re-myelination - are produced by hybridoma ATCC CRL 11627, for  
 PT treating multiple sclerosis, and viral or post-neural diseases of  
 PT the CNS.  
 PS Disclosure; Page 36-37; 63pp; English.  
 CC Hybridoma ATCC CRL 11627 was obtd. from a SJL/J mouse injected with  
 CC spinal cord homogenate from a mammal uninfected with any  
 CC demyelinating disease. The hybridoma produced a monoclonal antibody  
 CC (SCH94.03) useful in promoting CNS remyelination. The SCH94.03  
 CC light chain amino acid sequence is given in R84553.  
 SQ Sequence 131 AA;

Query Match 95.7%; Score 67; DB 14; Length 131;  
 Best Local Similarity 90.9%; Pred. No. 1.05e+00;  
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 44 rasqdisnyln 54  
 |||||:||||  
 QY 1 RASQDISSYLN 11

RESULT 11  
 ID R44226 standard; protein; 268 AA.  
 AC R44226;  
 DT 10-JUN-1994 (first entry)  
 DE Chimeric Ig superfamily protein analogue R19(D1.3).  
 KW CHI-protein; Immunoglobulin superfamily; multivalent antigen binding;  
 KW engineered fusion protein; beta-barrel domain; chimaeric;  
 KW complementarity determining region; cell imaging; targeting.  
 OS Synthetic.  
 FH Key Location/Qualifiers  
 FT Region 1..30  
 FT /label= H\_FR1  
 FT /note= "Heavy chain framework region from R19.9"  
 FT Region 31..35  
 FT /label= H1  
 FT /note= "Primary CDR loop from R19.9"  
 FT Region 36..39  
 FT /label= FR2A  
 FT /note= "Heavy chain framework region from R19.9"  
 FT Region 40..45  
 FT /label= H3'  
 FT /note= "CDR loop spliced into chi-site from D1.3"  
 FT Region 46..48  
 FT /label= FR2B  
 FT /note= "Heavy chain framework region from R19.9"  
 FT Region 49..65  
 FT /label= H2  
 FT /note= "Primary CDR loop from R19.9"  
 FT Region 66..89  
 FT /label= H\_FR3A  
 FT /note= "Heavy chain framework region from R19.9"  
 FT Region 90..92  
 FT /label= H1'  
 FT /note= "CDR loop spliced into chi-site from D1.3"  
 FT Region 93..97  
 FT /label= H\_FR3B  
 FT /note= "Heavy chain framework region from R19.9"  
 FT Region 98..112  
 FT /label= H3  
 FT /note= "Primary CDR loop from R19.9"  
 FT Region 113..116  
 FT /label= H\_FR4  
 FT /note= "Heavy chain framework region from R19.9"  
 FT Region 117..135  
 FT /label= H2'  
 FT /note= "CDR loop spliced into chi-site from D1.3"

FT Region 136..155  
 FT /note= "bridge/linker"  
 FT Region 156..178  
 FT /label= L\_FR1  
 FT /note= "Light chain framework region from R19.9"  
 FT Region 179..189  
 FT /label= L1  
 FT /note= "Primary CDR loop from R19.9"  
 FT Region 190..193  
 FT /label= FR2A  
 FT /note= "Light chain framework region from R19.9"  
 FT Region 194..199  
 FT /label= L3'  
 FT /note= "CDR loop spliced into chi-site from D1.3"  
 FT Region 200..203  
 FT /label= FR2B  
 FT /note= "Light chain framework region from R19.9"  
 FT Region 204..210  
 FT /label= L2  
 FT /note= "Primary CDR loop from R19.9"  
 FT Region 211..237  
 FT /label= L\_FR3A  
 FT /note= "Light chain framework region from R19.9"  
 FT Region 238..241  
 FT /label= L1'  
 FT /note= "CDR loop spliced into chi-site from D1.3"  
 FT Region 242..244  
 FT /label= FR3B  
 FT /note= "Light chain framework region from R19.9"  
 FT Region 245..253  
 FT /label= L3  
 FT /note= "Primary CDR loop from R19.9"  
 FT Region 254..255  
 FT /label= FR4  
 FT /note= "Light chain framework region from R19.9"  
 FT Region 256..268  
 FT /label= L2'  
 FT /note= "CDR loop spliced into chi-site from D1.3"  
 FT W09323357-A.  
 PN 25-NOV-1993.  
 PD 07-MAY-1993; U04338.  
 PR 08-MAY-1992; US-881109.  
 PA (CREA-) CREATIVE BIOMOLECULES.  
 PI Huston JS, Keck PC;  
 DR WPI: 93-386569/48.  
 PT Chimeric multivalent protein analogues - useful for diagnostic  
 PT imaging and cytotoxic therapy.  
 PS Example 1; Fig 14; 106pp; English.  
 CC This sequence is an example of a CHI-protein constructed according  
 CC to the invention. The novel CHI (Chimeric Immunoglobulin)-proteins  
 CC are comprised of at least 1 beta-barrel forming domain. The antigen  
 CC binding sites of the molecule are located in the beta-barrel  
 CC domain(s). Splice sites for insertion of specific binding sites are  
 CC located by computer comparisons of homology and structure. Depending  
 CC on the ligand binding specificity of the chimeric molecules, they  
 CC can be targetted for imaging, irradiating or delivering cytotoxic  
 CC substances to specific tissues.  
 SQ Sequence 268 AA;

Query Match 95.7%; Score 67; DB 8; Length 268;  
 Best Local Similarity 90.9%; Pred. No. 1.05e+00;  
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 179 rasqdisnyln 189  
 |||||:||||  
 QY 1 RASQDISSYLN 11

RESULT 12  
 ID R52865 standard; protein; 273 AA.  
 AC R52865;  
 DT 09-SEP-1994 (first entry)  
 DE Anti-influenza N10 scFv.

KW Monoclonal antibody N10; target binding polypeptide; scFv;  
 KW scFv; single chain antibody; protein secretion; FLAG;  
 KW Escherichia coli; antibody engineering; humanized antibody;  
 KW Influenza virus; neuraminidase.  
 OS Not specified.

FF Key Location/Qualifiers  
 FT Peptide 1..22  
 FT /label- Sig\_peptide  
 FT Peptide 266..273  
 FT /note= "C-terminal FLAG tail"  
 PN W09407921-A.  
 PD 14-APR-1994.  
 PR 24-SEP-1993; AU0491.  
 PR 25-SEP-1992; AU-004973.  
 PA (CSIR ) COMMONWEALTH SCI & IND RES ORG.  
 PI Atwell JL, Colman PM, Hudson PJ, Irving RA, Kortt A;  
 PI Lah M, Malbyrl, Power BE;  
 DR WPI; 94-135515/16.  
 DR P-PSDB; Q62957.  
 PT New target-binding polypeptide(s) used for diagnosis, etc. -  
 PT having a stable core polypeptide region with at least one  
 PT target-binding region covalently attached, opt. mutated to alter  
 PT specificity, etc.  
 PS Disclosure; Page 41; 67pp; English.  
 CC An scFv fragment of NC10 (a monoclonal antibody that recognises  
 CC influenza virus N9 neuraminidase) was expressed in Escherichia  
 CC coli. The N-terminal PelB signal peptide directed the scFv  
 CC fragment into the periplasm where it became associated with the  
 CC insoluble membrane fraction. An octapeptide FLAG tail was fused to  
 CC the C-terminus of scFv and used to monitor scFv during  
 CC purification.  
 SQ Sequence 273 AA;

Query Match 95.7%; Score 67; DB 9; Length 273;  
 Best Local Similarity 90.9%; Pred. No. 1.05e+00;  
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 182 rasqdisnyln 192  
 QY 1 RASQDISSYLN 11

RESULT 13  
 ID R09426 standard; Protein; 128 AA.  
 AC R09426;  
 DT 04-MAR-1993 (first entry)  
 DE ME4 Light Chain V Region (mouse).  
 KW Monoclonal antibody; chimera; light; heavy; chain; constant;  
 KW variable; antigen; diagnosis; cancer; tumour.  
 OS Mus musculus.  
 PN W09002569-A.  
 PD 22-MAR-1990.  
 PR 06-SEP-1989; U03852.  
 PR 06-SEP-1988; US-240624.  
 PR 08-SEP-1988; US-241744.  
 PR 13-SEP-1988; US-243739.  
 PR 04-OCT-1988; US-253002.  
 PR 19-JUN-1989; US-367641.  
 PR 21-JUL-1989; US-382768.  
 PA (ITGE-) INT GENETIC ENG INC.  
 PI Better MD, Horwitz AH, Robinson RR, Lei S, Chang CP;  
 DR WPI; 90-115825/15.  
 DR N-PSDB; Q08608.

PT Chimeric mouse-human antibodies - prep'd. using genes coding for  
 PT constant human region murine variable region, esp. to 3 tumour  
 PT antigen  
 PS Claim 13; Page 123 + Fig 29; 173pp; English.  
 CC The sequence is used in the prodn. of a chimeric antibody mol.  
 CC comprising two light chains and two heavy chains, each having a  
 CC constant region (human) and a variable region (murine) having  
 CC specificity to an antigen bound by murine monoclonal antibody  
 CC (MAB) ME4. The chimeric antibodies can be used for any purpose for  
 CC which the original murine MABs can be used, with the advantage that

CC they are more compatible with the human body. They are esp. used for  
 CC the diagnosis and treatment of cancer.

SQ Sequence 128 AA;

Query Match 94.3%; Score 66; DB 5; Length 128;  
 Best Local Similarity 81.8%; Pred. No. 1.37e+00;  
 Matches 9; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Db 44 rasqdittyn 54  
 QY 1 RASQDISSYLN 11

RESULT 14  
 ID W06215 standard; Protein; 128 AA.  
 AC W06215;  
 DT 13-FEB-1997 (first entry)  
 DE MAB ME4 light chain variable region.  
 KW Chimeric antibody; monoclonal antibody; ME4; antibody engineering;  
 KW tumour; antigen; breast carcinoma; colon carcinoma; lung carcinoma;  
 KW ovary carcinoma; melanoma; cancer; diagnosis; therapy; light chain.  
 OS Mus sp.  
 PN US5576184-A.  
 PD 19-NOV-1996.  
 PR 06-SEP-1988; 240624.  
 PR 08-SEP-1988; US-241744.  
 PR 13-SEP-1988; US-243739.  
 PR 04-OCT-1988; US-253002.  
 PR 19-JUN-1989; US-367641.  
 PR 21-JUL-1989; US-382768.  
 PR 06-MAY-1991; US-659401.  
 PR 27-DEC-1994; US-364001.  
 PA (XOMA ) XOMA CORP.  
 PI Better MD, Chang CP, Horwitz AH, Lei S, Robinson RR;  
 DR WPI; 97-011249/01.  
 DR N-PSDB; T43440.

PT Chimeric mouse-human antibodies - recognise a human tumour antigen,  
 PT used for the treatment and diagnosis of human cancers  
 PS Example 3; Fig 29; 102pp; English.  
 CC The light chain variable region (W06215) of mouse monoclonal  
 CC antibody ME4 is the product of a cDNA clone (T43440) isolated  
 CC from a ME4 hybridoma cDNA library. MAB ME4 (IgG1) binds to an  
 CC antigen that is expressed on the surface of human lung, breast,  
 CC colon and ovary carcinomas and melanomas, but not on most normal  
 CC adult tissues. The light chain and heavy chain variable regions  
 CC (see also W06216) of ME4 can be linked to human constant regions  
 CC and expressed in transformed host cells. Novel mouse-human  
 CC chimeric antibodies (see also W06209-14 and W06217-18) can be  
 CC produced that have specificity to human tumour antigens for use in  
 CC the treatment and diagnosis of human cancer.

SQ Sequence 128 AA;

Query Match 94.3%; Score 66; DB 19; Length 128;  
 Best Local Similarity 81.8%; Pred. No. 1.37e+00;  
 Matches 9; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Db 44 rasqdittyn 54  
 QY 1 RASQDISSYLN 11

RESULT 15  
 ID W13920 standard; peptide; 11 AA.  
 AC W13920;  
 DT 15-MAY-1997 (first entry)  
 DE Fragment of CDR-1 of light-chain variable region.  
 KW Antibody; heavy chain; light chain; variable region; human; monoclonal;  
 KW complementarity determining region; human; adr type hepatitis B virus;  
 KW HB virus; CDR; virus antigen; anti-HB antibody; vaccine.  
 OS Homo sapiens.  
 PN J09020798-A.  
 PD 21-JAN-1997.

PF 11-JUL-1995; 174752.  
 PR 11-JUL-1995; JP-174752.  
 PA (ASAH ) ASAH KASEI KOGYO KK.  
 DR WPI: 97-140911/13.  
 DR N-PSDB; T60115.  
 PT Human anti-Hepatitis B antibody - used in a adr type HB virus  
 PT vaccine  
 PS Claim 6; Page 2; 20pp; Japanese.  
 CC This sequence represents a fragment of the complementarity determining  
 CC region-1 (CDR-1) of the light chain variable region of a human  
 CC monoclonal antibody of the invention. The antibody of the invention also  
 CC contains the represented by W13912 in the CDR-1 of the heavy chain  
 CC variable region. The antibody is capable of binding to adr type  
 CC hepatitis B (HB) virus antigen. A human anti-HB virus monoclonal  
 CC antibody preparation which is highly safe and is effective to adr type HB  
 CC virus can be provided, using the monoclonal antibody. It can also be  
 CC used as a vaccine against HB infection.  
 SQ Sequence 11 AA;

Query Match 91.4%; Score 64; DB 20; Length 11;  
 Best Local Similarity 90.9%; Pred. No. 2.31e+00;  
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 1 rasgsissyln 11  
 |||||  
 Oy 1 RASQDISSYLN 11

Search completed: Tue Mar 3 11:19:50 1998  
 Job time : 13 secs.

**THIS PAGE BLANK (USPTO)**



\*\*\*\*\*  
W P E R L L  
\*\*\*\*\*  
(TM)

Release 2.1D John F. Collins, Biocomputing Research Unit.  
Copyright (c) 1993, 1994, 1995 University of Edinburgh, U.K.  
Distribution rights by IntelliGenetics, Inc.

MPsrch\_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Tue Mar 3 11:19:07 1998; MasPar time 2.96 Seconds  
113.234 Million cell updates/sec

Tabular output not generated.

Title: >US-08-137-117D-117  
Description: (1-11) from US08137117D.pep  
Perfect Score: 70  
Sequence: 1 RASQDISSYLN 11

Scoring table: PAM 150  
Gap 15

Searched: 95051 seqs, 30469580 residues

Post-processing: Minimum Match 0%  
Listing first 45 summaries

Database: pir53  
1:ann1 2:ann2 3:ann3 4:ann4 5:unann1 6:unann2 7:unann3  
8:unann4 9:unann5 10:unann6 11:unann7 12:unann8  
13:unann9 14:unann10 15:unann11 16:unann12 17:unann18:unrev

Statistics: Mean 23.804; Variance 32.457; scale 0.733

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description	Pred. No.
1	68	97.1	105	7 PH0087	Ig kappa chain V reg	3.54e-03
2	67	95.7	93	7 S38564	Ig light chain V reg	5.82e-03
3	67	95.7	107	7 S69906	Ig kappa light chain	5.82e-03
4	67	95.7	107	7 B28044	Ig kappa chain V reg	5.82e-03
5	67	95.7	107	7 B49026	Ig kappa chain V reg	5.82e-03
6	67	95.7	107	7 A28044	Ig kappa chain V reg	5.82e-03
7	67	95.7	107	7 D48677	Ig light chain V-J r	5.82e-03
8	67	95.7	107	7 S69901	Ig kappa light chain	5.82e-03
9	67	95.7	108	7 S38862	Ig kappa chain V reg	5.82e-03
10	67	95.7	108	7 S69902	Ig kappa light chain	5.82e-03
11	67	95.7	108	7 S69900	Ig kappa light chain	5.82e-03
12	67	95.7	108	7 S69900	Ig kappa light chain	5.82e-03
13	67	95.7	108	2 KMSAR	Ig kappa chain V reg	5.82e-03
14	67	95.7	108	7 C26405	Ig kappa chain V reg	5.82e-03
15	67	95.7	108	7 PL0282	Ig light chain V reg	5.82e-03
16	67	95.7	115	7 A53276	Ig kappa chain V reg	5.82e-03
17	67	95.7	115	7 JL0080	Ig light chain V reg	5.82e-03
18	67	95.7	128	7 A26406	Ig kappa chain V reg	5.82e-03
19	65	92.9	109	7 S31981	Ig kappa chain - hum	1.55e-02
20	64	91.4	86	7 S34086	Ig kappa chain V reg	2.53e-02

21	64	91.4	87	7 S34083	Ig kappa chain V reg	2.53e-02
22	64	91.4	87	7 S34084	Ig kappa chain V reg	2.53e-02
23	64	91.4	88	7 S21522	Ig kappa chain V reg	2.53e-02
24	64	91.4	88	7 S21528	Ig kappa chain V reg	2.53e-02
25	64	91.4	92	7 D28840	Ig kappa chain V reg	2.53e-02
26	64	91.4	101	7 B28840	Ig kappa chain V reg	2.53e-02
27	64	91.4	101	7 C28840	Ig kappa chain V reg	2.53e-02
28	64	91.4	107	7 B48677	Ig light chain V-J r	2.53e-02
29	64	91.4	107	7 B48677	Ig light chain V-J r	2.53e-02
30	64	91.4	107	7 S32188	Ig kappa chain V reg	2.53e-02
31	64	91.4	107	7 C48677	Ig light chain V-J r	2.53e-02
32	64	91.4	107	7 S36264	Ig lambda chain V reg	2.53e-02
33	64	91.4	108	7 S44122	Ig kappa chain V reg	2.53e-02
34	64	91.4	108	7 S47182	Ig kappa chain - hum	2.53e-02
35	64	91.4	108	7 B26405	Ig kappa chain V reg	2.53e-02
36	64	91.4	108	7 B49047	IgM monoclonal stria	2.53e-02
37	64	91.4	116	7 A27594	Ig kappa chain V reg	2.53e-02
38	64	91.4	117	7 S24206	Ig kappa chain V reg	2.53e-02
39	64	91.4	117	7 S24209	Ig kappa chain V reg	2.53e-02
40	64	91.4	122	7 A29380	Ig kappa chain V reg	2.53e-02
41	64	91.4	123	7 S40331	Ig kappa chain - hum	2.53e-02
42	64	91.4	126	7 A34904	Ig kappa chain V reg	2.53e-02
43	63	90.0	108	2 K1H00U	Ig kappa chain V-I r	4.09e-02
44	62	88.6	98	7 PH1082	Ig light chain V reg	6.60e-02
45	62	88.6	109	7 S31998	Ig kappa chain - hum	6.60e-02

ALIGNMENTS

RESULT 1  
ENTRY PH0087 #type fragment  
TITLE Ig kappa chain V region (anti-cyclosporin C and D) - mouse (fragment)  
ORGANISM #formal\_name Mus musculus #common\_name house mouse  
DATE 15-Jan-1993 #sequence\_revision 15-Jan-1993 #text\_change 16-Aug-1996  
ACCESSIONS PH0087  
REFERENCE SCHmitter, D.; Poch, O.; Zeder, G.; Heinrich, G.F.; Kocher, H.P.; Quesniaux, V.F.J.; Van Regenmortel, M.H.V.  
#journal Mol. Immunol. (1990) 27:1029-1038  
#title Analysis of the structural diversity of monoclonal antibodies to cyclosporine.  
#cross-references MUID:91042649  
#accession PH0087  
#molecule\_type mRNA  
#residues 1-105 #label SCH

CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology heterotetramer; immunoglobulin  
KEYWORDS  
FEATURE 24-34 #region complementarity-determining 1\  
50-56 #region complementarity-determining 2\  
89-97 #region complementarity-determining 3\  
SUMMARY #length 105 #checksum 9783

Query Match 97.1%; Score 68; DB 7; Length 105;  
Best Local Similarity 90.9%; Pred. No. 3.54e-03;  
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdistyln 34  
|||||:||||  
Qy 1 RASQDISSYLN 11

RESULT 2  
ENTRY S38564 #type fragment  
TITLE Ig light chain V region (ASWU1) - mouse (fragment)  
ORGANISM #formal\_name Mus musculus #common\_name house mouse  
DATE 06-Jan-1995 #sequence\_revision 06-Jan-1995 #text\_change 09-May-1997  
ACCESSIONS S38564  
REFERENCE S38559  
#authors Monestier, M.; Losman, L.J.; Novick, K.E.; Aris, J.P.

#submission submitted to the EMBL Data Library, September 1993  
#description Molecular analysis of mercury-induced anti-nucleolar  
antibodies in H-2s Mice.

#accession S38564 preliminary  
##status preliminary  
##molecule\_type mRNA  
##residues 1-93 ##label MON  
##cross-references EMBL:X75105  
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology  
KEYWORDS immunoglobulin  
SUMMARY #length 93 #checksum 1511

Query Match 95.7%; Score 67; DB 7; Length 93;  
Best Local Similarity 90.9%; Pred. No. 5.82e-03;

Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisnyln 34  
|||||:||||  
QY 1 RASQDISSYLN 11

RESULT 3  
ENTRY S69906 #type complete  
TITLE Ig kappa light chain (clone KL4A1) - mouse  
ORGANISM #formal\_name Mus musculus #common\_name house mouse  
DATE 14-Feb-1997 #sequence\_revision 13-Mar-1997 #text\_change  
09-May-1997

ACCESSIONS S69906  
REFERENCE Wysocki, L.J.; Creadon, G.; Lehmann, K.R.; Cambier, J.C.  
#authors Immunology (1992) 75:116-121  
#journal B-cell proliferation initiated by Ia cross-linking and  
#title sustained by interleukins leads to class switching but not  
somatic mutation in vitro.

#accession S69906 preliminary; translation not shown  
##status preliminary; translation not shown  
##molecule\_type DNA  
##residues 1-107 ##label WYS  
##cross-references EMBL:X55047

CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology  
SUMMARY #length 107 #molecular-weight 11827 #checksum 7550

Query Match 95.7%; Score 67; DB 7; Length 107;  
Best Local Similarity 90.9%; Pred. No. 5.82e-03;  
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisnyln 34  
|||||:||||  
QY 1 RASQDISSYLN 11

RESULT 4  
ENTRY B28044 #type complete  
TITLE Ig kappa chain V region (GP1) - mouse  
ORGANISM #formal\_name Mus musculus #common\_name house mouse  
DATE 19-May-1989 #sequence\_revision 19-May-1989 #text\_change  
16-Aug-1996

ACCESSIONS B28044  
REFERENCE Meek, K.; Sanz, I.; Rathbun, G.; Nisonoff, A.; Capra, J.D.  
#authors Proc. Natl. Acad. Sci. U.S.A. (1987) 84:6244-6248  
#journal Identity of the V-kappa-10-Ars-A gene segments of the A/J and  
#title BALB/c strains.  
#cross-references MUID:87317629

#accession B28044  
##molecule\_type mRNA

##residues 1-107 ##label NEE  
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology  
KEYWORDS heterotetramer; immunoglobulin  
SUMMARY #length 107 #molecular-weight 11738 #checksum 7011

Query Match 95.7%; Score 67; DB 7; Length 107;  
Best Local Similarity 90.9%; Pred. No. 5.82e-03;

Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Db 24 rasqdisnyln 34  
|||||:||||  
QY 1 RASQDISSYLN 11

RESULT 5  
ENTRY B49026 #type complete  
TITLE Ig kappa chain V region, anti-idiotypic monoclonal antibody -  
mouse  
ORGANISM #formal\_name Mus musculus #common\_name house mouse  
DATE 19-Dec-1993 #sequence\_revision 18-Nov-1994 #text\_change  
25-Oct-1996  
ACCESSIONS B49026; PL0220  
REFERENCE A49026

#authors Koizumi, T.; Puccetti, A.; Migliorini, P.; Barrett, K.J.;  
Schwartz, R.S.  
#journal Eur. J. Immunol. (1991) 21:2185-2193  
#title Molecular heterogeneity of auto-anti-idiotypic antibodies in  
MLR-lpr/lpr mice.  
#cross-references MUID:91364791

#accession B49026 preliminary; not compared with conceptual translation  
##status preliminary; not compared with conceptual translation  
##molecule\_type nucleic acid  
##residues 1-107 ##label KOI  
##cross-references NCBI:P:60876  
##experimental\_source MLR-lpr/lpr  
##note sequence extracted from NCBI backbone  
PL0220

REFERENCE Puccetti, A.; Koizumi, T.; Migliorini, P.; Andre-Schwartz,  
J.; Barrett, K.J.; Schwartz, R.S.  
#journal J. Exp. Med. (1990) 171:1919-1930  
#title An immunoglobulin light chain from a lupus-prone mouse  
induces autoantibodies in normal mice.  
#cross-references MUID:90278348

#accession PL0220  
##status nucleic acid sequence not shown  
##molecule\_type mRNA

##residues 1-107 ##label PUC  
##experimental\_source strain lupus-prone MRL-lpr/lpr mouse  
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology  
KEYWORDS heterotetramer; immunoglobulin  
FEATURE  
24-34 #region complementarity-determining 1\  
50-56 #region complementarity-determining 2\  
89-97 #region complementarity-determining 3\  
SUMMARY #length 107 #molecular-weight 11859 #checksum 8401

Query Match 95.7%; Score 67; DB 7; Length 107;  
Best Local Similarity 90.9%; Pred. No. 5.82e-03;  
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Db 24 rasqdisnyln 34  
|||||:||||  
QY 1 RASQDISSYLN 11

RESULT 6  
ENTRY A28044 #type complete  
TITLE Ig kappa chain V region (22B5) - mouse  
ORGANISM #formal\_name Mus musculus #common\_name house mouse  
DATE 19-May-1989 #sequence\_revision 19-May-1989 #text\_change  
16-Aug-1996

ACCESSIONS A28044  
REFERENCE A94179  
#authors Meek, K.; Sanz, I.; Rathbun, G.; Nisonoff, A.; Capra, J.D.  
#journal Proc. Natl. Acad. Sci. U.S.A. (1987) 84:6244-6248  
#title Identity of the V-kappa-10-Ars-A gene segments of the A/J and  
BALB/c strains.  
#cross-references MUID:87317629

#accession A28044  
##molecule\_type mRNA

```

##residues      1-107 ##label MFE
CLASSIFICATION  #superfamily immunoglobulin V region; immunoglobulin homology
KEYWORDS        heterotrimer; immunoglobulin
SUMMARY          #length 107 #molecular-weight 11832 #checksum 7241

Query Match      95.7%; Score 67; DB 7; Length 107;
Best Local Similarity 90.9%; Pred. No. 5.82e-03;
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisnyn 34
      |||||:||||
QY 1 RASQDISSYN 11

RESULT 7
ENTRY   D48677      #type fragment
TITLE   Ig light chain V-J region (24) - mouse (fragment)
ORGANISM #Formal_name Mus musculus #common_name house mouse
DATE    19-May-1994 #sequence_revision 19-May-1994 #text_change
        16-Aug-1996

ACCESSIONS
REFERENCE D48677
#authors  Tassignon, J.; Brait, M.; Jamila, I.; Urbain, J.; Gottlieb,
          P.; Brown, A.; Hasemann, C.A.; Capra, J.D.; Meek, K.
#journal  Proc. Natl. Acad. Sci. U.S.A. (1993) 90:9508-9512
#title    Molecular characterization of monoclonal CRI-A positive
          anti-arsonate antibodies derived from idiotypic-negative
          mice bearing a light chain polymorphism.
#accession D48677
#status    preliminary; not compared with conceptual translation
#molecule_type mRNA
##residues 1-107 ##label TMS
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology
KEYWORDS        immunoglobulin
SUMMARY          #length 107 #checksum 7155

Query Match      95.7%; Score 67; DB 7; Length 107;
Best Local Similarity 90.9%; Pred. No. 5.82e-03;
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisnyn 34
      |||||:||||
QY 1 RASQDISSYN 11

RESULT 8
ENTRY   S69901      #type complete
TITLE   Ig kappa light chain (clone KL2.21) - mouse
ORGANISM #Formal_name Mus musculus #common_name house mouse
DATE    14-Feb-1997 #sequence_revision 13-Mar-1997 #text_change
        09-May-1997

ACCESSIONS
REFERENCE S69901
#authors  Wysocki, L.J.; Creadon, G.; Lehmann, K.R.; Cambier, J.C.
#journal  Immunology (1992) 75:116-121
#title    B-cell proliferation initiated by Ia cross-linking and
          sustained by interleukins leads to class switching but not
          somatic mutation in vitro.
#accession S69901
#status    preliminary; translation not shown
#molecule_type DNA
##residues 1-107 ##label WYS
##cross-references EMBL:X55042
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology
SUMMARY          #length 107 #molecular-weight 11857 #checksum 7740

Query Match      95.7%; Score 67; DB 7; Length 107;
Best Local Similarity 90.9%; Pred. No. 5.82e-03;
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisnyn 34
      |||||:||||
QY 1 RASQDISSYN 11

```

sustained by interleukins leads to class switching but not somatic mutation in vitro.

#accession S69902  
#status preliminary; translation not shown  
#molecule\_type DNA  
#residues 1-108 #label WYS

#cross-references EMBL:X55043  
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology  
SUMMARY #length 108 #molecular-weight 11695 #checksum 1228

Query Match 95.7%; Score 67; DB 7; Length 108;  
Best Local Similarity 90.9%; Pred. No. 5.82e-03;  
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisnyln 34  
|||||:||||  
Qy 1 RASQDISSYLN 11

RESULT 12  
ENTRY S69900 #type complete  
TITLE Ig kappa light chain (clone KL2.18) - mouse  
ORGANISM #formal\_name Mus musculus #common\_name house mouse  
DATE 14-Feb-1997 #sequence\_revision 13-Mar-1997 #text\_change 09-May-1997  
ACCESSIONS S69900  
REFERENCE Wysocki, L.J.; Creadon, G.; Lehmann, K.R.; Cambier, J.C.  
#authors Immunology (1992) 75:116-121  
#journal B-cell proliferation initiated by Ia cross-linking and  
#title sustained by interleukins leads to class switching but not somatic mutation in vitro.

#accession S69900  
#status preliminary; translation not shown  
#molecule\_type DNA  
#residues 1-108 #label WYS

#cross-references EMBL:X55041  
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology  
SUMMARY #length 108 #molecular-weight 11954 #checksum 1768

Query Match 95.7%; Score 67; DB 7; Length 108;  
Best Local Similarity 90.9%; Pred. No. 5.82e-03;  
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisnyln 34  
|||||:||||  
Qy 1 RASQDISSYLN 11

RESULT 13  
ENTRY KVMSAR #type complete  
TITLE Ig kappa chain V regions (anti-arsonate hybridoma proteins) - mouse  
ORGANISM #formal\_name Mus musculus #common\_name house mouse  
DATE 06-Jul-1982 #sequence\_revision 06-Jul-1982 #text\_change 16-Aug-1996

ACCESSIONS A01927  
REFERENCE Siegelman, M.; Capra, J.D.  
#authors Proc. Natl. Acad. Sci. U.S.A. (1981) 78:7679-7683  
#journal Complete amino acid sequence of light chain variable regions  
#title derived from five monoclonal anti-p-azophenylarsonate antibodies differing with respect to a crossreactive idiotype.

#cross-references MUID:82150934  
#accession A01927  
#molecule\_type protein

#residues 1-108 #label SIE  
#experimental\_source strain A/J  
#note hp 93c7 differs in having 93-Wet; HP 123E6 differs in having 7-Ser, 92-Tyr, and 93-Met; HP 124E1 differs in having 30-Asn, 92-Lys, and 93-Thr; and HP 91A3 differs in having 8-Pro, 30-Asn, 37-Arg, 84-Ser, and 93-Ala

COMMENT The sequence shown is HP R16.7.

COMPLEX An immunoglobulin heterotetramer subunit consists of two identical light (kappa or lambda) and two identical heavy (alpha, delta, epsilon, gamma, or mu) chains usually stabilized by interchain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into larger oligomers.

CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology  
KEYWORDS heterotetramer

FEATURES

23-88 #disulfide\_bonds #status predicted

SUMMARY #length 108 #molecular-weight 11910 #checksum 1537

Query Match 95.7%; Score 67; DB 2; Length 108;

Best Local Similarity 90.9%; Pred. No. 5.82e-03;

Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisnyln 34  
|||||:||||  
Qy 1 RASQDISSYLN 11

RESULT 14  
ENTRY C26405 #type complete  
TITLE Ig kappa chain V region (3d10) - mouse  
ORGANISM #formal\_name Mus musculus #common\_name house mouse  
DATE 30-Jun-1988 #sequence\_revision 30-Jun-1988 #text\_change 16-Aug-1996

ACCESSIONS C26405  
REFERENCE A90518  
#authors Smith, J.A.; Margolies, M.N.  
#journal Biochemistry (1987) 26:604-612  
#title Complete amino acid sequences of the heavy and light chain variable regions from two A/J mouse antigen nonbinding monoclonal antibodies bearing the predominant p-azophenyl

arsonate idiotype.  
#cross-references MUID:87157677

#accession C26405

#molecule\_type protein

#residues 1-108 #label SMI

#experimental\_source strain A/J

CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology  
KEYWORDS heterotetramer; immunoglobulin

SUMMARY #length 108 #molecular-weight 11944 #checksum 1684

Query Match 95.7%; Score 67; DB 7; Length 108;

Best Local Similarity 90.9%; Pred. No. 5.82e-03;

Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisnyln 34  
|||||:||||  
Qy 1 RASQDISSYLN 11

RESULT 15

ENTRY PL0282 #type fragment

TITLE Ig light chain V region (45-49, anti p-azophenylarsonate) - mouse (fragment)

ORGANISM #formal\_name Mus musculus #common\_name house mouse

DATE 24-Feb-1994 #sequence\_revision 24-Feb-1994 #text\_change 16-Aug-1996

ACCESSIONS PL0282

REFERENCE PL0281

#authors Wysocki, L.J.; Gelfer, M.L.; Margolies, M.N.

#journal J. Exp. Med. (1990) 172:315-323

#title Parallel evolution of antibody variable regions by somatic processes: Consecutive shared somatic alterations in VH genes expressed by independently generated hybridomas apparently acquired by point mutation and selection rather than by gene conversion.

#accession PL0282

##molecule\_type mRNA

##residues 1-108 #label WYS

```
##experimental_source A/J mice
CLASSIFICATION #superfamily immunoglobulin v region; immunoglobulin homology
KEYWORDS immunoglobulin
SUMMARY #length 108 #checksum 960

Query Match 95.7%; Score 67; DB 7; Length 108;
Best Local Similarity 90.9%; Pred. No. 5.82e-03;
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisnyln 34
   |||||:|
QY 1 RASQDISSYLN 11
```

```
Search completed: Tue Mar 3 11:19:18 1998
Job time : 11 secs.
```

**THIS PAGE BLANK (USPTO)**

**THIS PAGE BLANK (USPTO)**

\*\*\*\*\*

WQREH (TM)

\*\*\*\*\*

Release 2.1D John F. Collins, Blocomputing Research Unit.  
Copyright (c) 1993, 1994, 1995 University of Edinburgh, U.K.  
Distribution rights by IntelliGenetics, Inc.

MPsrch\_pp protein - protein database search, using Smith-Waterman algorithm  
Run on: Tue Mar 3 11:18:38 1998; MasPar time 2.03 Seconds  
Tabular output not generated. 114.979 Million cell updates/sec

Title: >US-08-137-117D-117  
Description: (1-11) from US08137117D.pep  
Perfect Score: 70  
Sequence: 1 RASQDISSYLN 11

Scoring table: PAM 150  
Gap 15

Searched: 59021 seqs, 21210388 residues

Post-processing: Minimum Match 0%  
Listing first 45 summaries

Database: swiss-prot34  
1:part1 2:part2 3:part3 4:part4 5:part5 6:part6 7:part7  
8:part8 9:part9 10:part10 11:part11

Statistics: Mean 24.439; Variance 27.039; scale 0.904

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	67	95.7	108	5	KV5K_MOUSE IG KAPPA CHAIN V-V RE	2.56e-04
2	67	95.7	108	5	KV5M_MOUSE IG KAPPA CHAIN V-V RE	2.56e-04
3	67	95.7	108	5	KV5L_MOUSE IG KAPPA CHAIN V-V RE	2.56e-04
4	64	91.4	108	5	KV5Q_MOUSE IG KAPPA CHAIN V-V RE	1.50e-03
5	64	91.4	108	5	KV5N_MOUSE IG KAPPA CHAIN V-V RE	1.50e-03
6	63	90.0	108	5	KV1N_HUMAN IG KAPPA CHAIN V-I RE	2.68e-03
7	61	87.1	117	5	KV5H_MOUSE IG KAPPA CHAIN PRECUR	8.44e-03
8	61	87.1	129	5	KV1W_HUMAN IG KAPPA CHAIN PRECUR	8.44e-03
9	60	85.7	108	5	KV1H_HUMAN IG KAPPA CHAIN V-I RE	1.48e-02
10	58	82.9	108	5	KV1B_HUMAN IG KAPPA CHAIN V-I RE	4.52e-02
11	58	82.9	108	5	KV1Y_HUMAN IG KAPPA CHAIN V-I RE	4.52e-02
12	58	82.9	108	5	KV5U_MOUSE IG KAPPA CHAIN V-V RE	4.52e-02
13	58	82.9	115	5	KV5F_MOUSE IG KAPPA CHAIN PRECUR	4.52e-02
14	57	81.4	115	5	KV3I_HUMAN IG KAPPA CHAIN PRECUR	7.81e-02
15	57	81.4	128	5	KV5E_MOUSE IG KAPPA CHAIN PRECUR	7.81e-02
16	54	77.1	108	5	KV5P_MOUSE IG KAPPA CHAIN V-V RE	3.90e-01
17	53	75.7	108	5	KV1A_HUMAN IG KAPPA CHAIN V-I RE	6.57e-01
18	52	74.3	108	5	KV1M_HUMAN IG KAPPA CHAIN V-I RE	1.10e+00
19	51	72.9	108	5	KV1E_HUMAN IG KAPPA CHAIN V-I RE	1.83e+00
20	51	72.9	130	5	KV5G_MOUSE IG KAPPA CHAIN PRECUR	1.83e+00
21	51	72.9	382	2	CARA_ECOLI CARBAMOYL-PHOSPHATE S	1.83e+00
22	51	72.9	382	2	CARA_SALTY CARBAMOYL-PHOSPHATE S	1.83e+00

23	50	71.4	107	5	KVID_HUMAN	IG KAPPA CHAIN V-I RE	3.02e+00
24	50	71.4	108	5	KV5D_MOUSE	IG KAPPA CHAIN V-V RE	3.02e+00
25	50	71.4	108	5	KV1P_HUMAN	IG KAPPA CHAIN V-I RE	3.02e+00
26	50	71.4	108	5	KV07_RABIT	IG KAPPA CHAIN V REGI	3.02e+00
27	50	71.4	108	5	KV10_HUMAN	IG KAPPA CHAIN V-I RE	3.02e+00
28	50	71.4	117	5	KV10_RABIT	IG KAPPA CHAIN V REGI	3.02e+00
29	50	71.4	1342	3	ERB3_HUMAN	ERBB-3 RECEPTOR PROTE	3.02e+00
30	49	70.0	108	5	KV5J_MOUSE	IG KAPPA CHAIN V-V RE	4.95e+00
31	48	68.6	133	8	PSSR_ECOLI	POSSIBLE REGULATORY P	8.04e+00
32	48	68.6	199	7	PRL_BALBO	PROLACTIN (PRL).	8.04e+00
33	48	68.6	199	7	PRL_LOXAF	PROLACTIN (PRL).	8.04e+00
34	48	68.6	229	7	PRL_FELCA	PROLACTIN PRECURSOR	8.04e+00
35	48	68.6	312	6	NIFU_AZOVI	NIFU PROTEIN.	8.04e+00
36	47	67.1	108	5	KV1S_HUMAN	IG KAPPA CHAIN V-I RE	1.30e+01
37	47	67.1	117	5	KV1J_HUMAN	IG KAPPA CHAIN PRECUR	1.30e+01
38	47	67.1	129	5	KV1X_HUMAN	IG KAPPA CHAIN PRECUR	1.30e+01
39	47	67.1	199	11	YAGU_HAEIN	HYPOTHETICAL LIPOPROT	1.30e+01
40	47	67.1	235	11	YI01_YEAST	HYPOTHETICAL 27.1 KD	1.30e+01
41	47	67.1	274	9	T2E1_HERAU	TYPE II RESTRICTION E	1.30e+01
42	47	67.1	943	5	IROA_NEIME	IRON-REGULATED OUTER	1.30e+01
43	46	65.7	451	7	PHOQ_SALTY	VIRULENCE SENSOR PROT	2.07e+01
44	46	65.7	1132	10	VHSJ_LAMBD	HOST SPECIFICITY PROT	2.07e+01
45	46	65.7	1507	11	YY06_HUMAN	HYPOTHETICAL MYELOID	2.07e+01

ALIGNMENTS

RESULT 1  
ID KV5K\_MOUSE STANDARD; PRT; 108 AA.  
AC P01644;  
DT 21-JUL-1986 (REL. 01, CREATED)  
DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
DE IG KAPPA CHAIN V-V REGION (HP R16.7).  
OS MUS MUSCULUS (MOUSE).  
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
CC EUTHERIA; RODENTIA.  
RN [1]  
RP SEQUENCE.  
RC STRAIN-A/J;  
RX MEDLINE; 82150934.  
RA SIEGELMAN M., CAPRA J.D.;  
RL PROC. NATL. ACAD. SCI. U.S.A. 78:7679-7683(1981).  
CC -I- ANTI-ARSONATE HYBRIDOMA PROTEIN.  
DR PIR; A01927; KWSAR.  
DR HSP; P01607; 1FAI.  
KW IMMUNOGLOBULIN V REGION; ANTIARSONATE ANTIBODY.  
FT DOMAIN 1 23  
FT DOMAIN 24 34  
FT DOMAIN 35 49  
FT DOMAIN 50 56  
FT DOMAIN 57 88  
FT DOMAIN 89 97  
FT DOMAIN 98 108  
FT DISULFID 23 88  
FT NON\_TER 108 108  
SQ SEQUENCE 108 AA; 11910 MW; 64A62905 CRC32;  
Query Match 95.7%; Score 67; DB 5; Length 108;  
Best Local Similarity 90.9%; Pred. No. 2.56e-04;  
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Db 24 rasqdisynln 34  
QY 1 RASQDISSYLN 11  
RESULT 2  
ID KV5M\_MOUSE STANDARD; PRT; 108 AA.  
AC P01646;  
DT 21-JUL-1986 (REL. 01, CREATED)  
DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
DE IG KAPPA CHAIN V-V REGION (HP R16.7).  
OS MUS MUSCULUS (MOUSE).  
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
CC EUTHERIA; RODENTIA.  
RN [1]  
RP SEQUENCE.  
RC STRAIN-A/J;  
RX MEDLINE; 82150934.  
RA SIEGELMAN M., CAPRA J.D.;  
RL PROC. NATL. ACAD. SCI. U.S.A. 78:7679-7683(1981).  
CC -I- ANTI-ARSONATE HYBRIDOMA PROTEIN.  
DR PIR; A01927; KWSAR.  
DR HSP; P01607; 1FAI.  
KW IMMUNOGLOBULIN V REGION; ANTIARSONATE ANTIBODY.  
FT DOMAIN 1 23  
FT DOMAIN 24 34  
FT DOMAIN 35 49  
FT DOMAIN 50 56  
FT DOMAIN 57 88  
FT DOMAIN 89 97  
FT DOMAIN 98 108  
FT DISULFID 23 88  
FT NON\_TER 108 108  
SQ SEQUENCE 108 AA; 11910 MW; 64A62905 CRC32;

DE IG KAPPA CHAIN V-V REGION (HP 123E6).  
 OS MUS MUSCULUS (MOUSE).  
 OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
 CC EUTHERIA; RODENTIA.  
 RN [1]  
 RP SEQUENCE.  
 RC STRAIN-A/J;  
 RX MEDLINE; 82150934.  
 RA SIEGELMAN M., CAPRA J.D.;  
 RL PROC. NATL. ACAD. SCI. U.S.A. 78:7679-7683(1981).  
 CC -I- ANTI-ARSONATE HYBRIDOMA PROTEIN.  
 DR PIR; A01927; KVMAR.  
 DR HSP; P01607; IFAI.  
 KW IMMUNOGLOBULIN V REGION; ANTIARSONATE ANTIBODY.  
 FT DOMAIN 1 23 FRAMEWORK 1.  
 FT DOMAIN 24 34 COMPLEMENTARITY-DETERMINING 1.  
 FT DOMAIN 35 49 FRAMEWORK 2.  
 FT DOMAIN 50 56 COMPLEMENTARITY-DETERMINING 2.  
 FT DOMAIN 57 88 FRAMEWORK 3.  
 FT DOMAIN 89 97 COMPLEMENTARITY-DETERMINING 3.  
 FT DOMAIN 98 108 FRAMEWORK 4.  
 FT DISULFID 23 88 BY SIMILARITY.  
 FT NON\_TER 108 108  
 SQ SEQUENCE 108 AA; 11989 MW; 23B8BB67 CRC32;

Query Match 95.7%; Score 67; DB 5; Length 108;

Best Local Similarity 90.9%; Pred. No. 2.56e-04; Length 108;  
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisynln 34  
 |||||:||||  
 QY 1 RASQDISSYLN 11

RESULT 3  
 ID KV5L\_MOUSE STANDARD; PRT; 108 AA.  
 AC P01645;  
 DT 21-JUL-1986 (REL. 01, CREATED)  
 DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
 DT 01-OCT-1993 (REL. 27, LAST ANNOTATION UPDATE)  
 DE IG KAPPA CHAIN V-V REGION (HP 93G7).  
 OS MUS MUSCULUS (MOUSE).  
 OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
 CC EUTHERIA; RODENTIA.  
 RN [1]  
 RP SEQUENCE.  
 RC STRAIN-A/J;  
 RX MEDLINE; 82150934.  
 RA SIEGELMAN M., CAPRA J.D.;  
 RL PROC. NATL. ACAD. SCI. U.S.A. 78:7679-7683(1981).  
 CC -I- ANTI-ARSONATE HYBRIDOMA PROTEIN.  
 DR PIR; A01927; KVMAR.  
 DR HSP; P01607; IFAI.  
 KW IMMUNOGLOBULIN V REGION; ANTIARSONATE ANTIBODY.  
 FT DOMAIN 1 23 FRAMEWORK 1.  
 FT DOMAIN 24 34 COMPLEMENTARITY-DETERMINING 1.  
 FT DOMAIN 35 49 FRAMEWORK 2.  
 FT DOMAIN 50 56 COMPLEMENTARITY-DETERMINING 2.  
 FT DOMAIN 57 88 FRAMEWORK 3.  
 FT DOMAIN 89 97 COMPLEMENTARITY-DETERMINING 3.  
 FT DOMAIN 98 108 FRAMEWORK 4.  
 FT DISULFID 23 88 BY SIMILARITY.  
 FT NON\_TER 108 108  
 SQ SEQUENCE 108 AA; 11954 MW; A203EL30 CRC32;

Query Match 95.7%; Score 67; DB 5; Length 108;

Best Local Similarity 90.9%; Pred. No. 2.56e-04; Length 108;  
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisynln 34  
 |||||:||||  
 QY 1 RASQDISSYLN 11

RESULT 4  
 ID KV5O\_MOUSE STANDARD; PRT; 108 AA.  
 AC P01648;  
 DT 21-JUL-1986 (REL. 01, CREATED)  
 DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
 DT 01-OCT-1993 (REL. 27, LAST ANNOTATION UPDATE)  
 DE IG KAPPA CHAIN V-V REGION (HP 91A3).  
 OS MUS MUSCULUS (MOUSE).  
 OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
 CC EUTHERIA; RODENTIA.  
 RN [1]  
 RP SEQUENCE.  
 RC STRAIN-A/J;  
 RX MEDLINE; 82150934.  
 RA SIEGELMAN M., CAPRA J.D.;  
 RL PROC. NATL. ACAD. SCI. U.S.A. 78:7679-7683(1981).  
 CC -I- ANTI-ARSONATE HYBRIDOMA PROTEIN.  
 DR PIR; A01927; KVMAR.  
 DR HSP; P01607; IFAI.  
 KW IMMUNOGLOBULIN V REGION; ANTIARSONATE ANTIBODY.  
 FT DOMAIN 1 23 FRAMEWORK 1.  
 FT DOMAIN 24 34 COMPLEMENTARITY-DETERMINING 1.  
 FT DOMAIN 35 49 FRAMEWORK 2.  
 FT DOMAIN 50 56 COMPLEMENTARITY-DETERMINING 2.  
 FT DOMAIN 57 88 FRAMEWORK 3.  
 FT DOMAIN 89 97 COMPLEMENTARITY-DETERMINING 3.  
 FT DOMAIN 98 108 FRAMEWORK 4.  
 FT DISULFID 23 88 BY SIMILARITY.  
 FT NON\_TER 108 108  
 SQ SEQUENCE 108 AA; 11961 MW; 5B067780 CRC32;

Query Match 91.4%; Score 64; DB 5; Length 108;

Best Local Similarity 81.8%; Pred. No. 1.50e-03; Length 108;  
 Matches 9; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisynln 34  
 |||||:||||  
 QY 1 RASQDISSYLN 11

RESULT 5  
 ID KV5N\_MOUSE STANDARD; PRT; 108 AA.  
 AC P01647;  
 DT 21-JUL-1986 (REL. 01, CREATED)  
 DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
 DT 01-OCT-1993 (REL. 27, LAST ANNOTATION UPDATE)  
 DE IG KAPPA CHAIN V-V REGION (HP 124E1).  
 OS MUS MUSCULUS (MOUSE).  
 OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
 CC EUTHERIA; RODENTIA.  
 RN [1]  
 RP SEQUENCE.  
 RC STRAIN-A/J;  
 RX MEDLINE; 82150934.  
 RA SIEGELMAN M., CAPRA J.D.;  
 RL PROC. NATL. ACAD. SCI. U.S.A. 78:7679-7683(1981).  
 CC -I- ANTI-ARSONATE HYBRIDOMA PROTEIN.  
 DR PIR; A01927; KVMAR.  
 DR HSP; P01607; IFAI.  
 KW IMMUNOGLOBULIN V REGION; ANTIARSONATE ANTIBODY.  
 FT DOMAIN 1 23 FRAMEWORK 1.  
 FT DOMAIN 24 34 COMPLEMENTARITY-DETERMINING 1.  
 FT DOMAIN 35 49 FRAMEWORK 2.  
 FT DOMAIN 50 56 COMPLEMENTARITY-DETERMINING 2.  
 FT DOMAIN 57 88 FRAMEWORK 3.  
 FT DOMAIN 89 97 COMPLEMENTARITY-DETERMINING 3.  
 FT DOMAIN 98 108 FRAMEWORK 4.  
 FT DISULFID 23 88 BY SIMILARITY.  
 FT NON\_TER 108 108  
 SQ SEQUENCE 108 AA; 11965 MW; 84754175 CRC32;

Query Match 91.4%; Score 64; DB 5; Length 108;

Best Local Similarity 81.8%; Pred. No. 1.50e-03; Length 108;  
 Matches 9; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdisynln 34  
 |||||:||||  
 QY 1 RASQDISSYLN 11



Best Local Similarity 81.8%; Pred. No. 1.50e-03;  
Matches 9; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Db 24 rasqdinayln 34  
|||||:||||  
QY 1 RASQDISSYLN 11

RESULT 6  
ID KVIN\_HUMAN STANDARD; PRT; 108 AA.  
AC P01606;  
DT 21-JUL-1986 (REL. 01, CREATED)  
DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
DT 01-JAN-1988 (REL. 06, LAST ANNOTATION UPDATE)  
DE IG KAPPA CHAIN V-I REGION (OU).  
OS HOMO SAPIENS (HUMAN).  
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
OC EUTHERIA; PRIMATES.  
RN [1]  
RP SEQUENCE.  
RA MEDLINE; 70201507.  
RA KOHLER H., SHIMIZU A., PAUL C., PUTNAM F.W.;  
RL SCIENCE 169:56-59(1970).  
CC -!- THE C REGION OF THIS CHAIN HAS THE INV (3) MARKER.  
DR PIR; A01872; K1HUOU.  
DR HSP; P01607; 2FGW.  
KW IMMUNOGLOBULIN V REGION.  
FT DOMAIN 1 23  
FT DOMAIN 24 34  
FT DOMAIN 35 49  
FT DOMAIN 50 56  
FT DOMAIN 57 88  
FT DOMAIN 89 97  
FT DOMAIN 98 107  
FT DISULFID 23 88  
FT NON\_TER 108 108  
SQ SEQUENCE 108 AA; 11777 MW; 4B089785 CRC32;

Query Match 90.0%; Score 63; DB 5; Length 108;  
Best Local Similarity 72.7%; Pred. No. 2.68e-03;  
Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Db 24 rasztissylb 34  
|||:|||||  
QY 1 RASQDISSYLN 11

RESULT 7  
ID KV5H\_MOUSE STANDARD; PRT; 117 AA.  
AC P01641;  
DT 21-JUL-1986 (REL. 01, CREATED)  
DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
DT 01-OCT-1996 (REL. 34, LAST ANNOTATION UPDATE)  
DE IG KAPPA CHAIN PRECURSOR V-V REGION (MOPC 173B).  
OS MUS MUSCULUS (MOUSE).  
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
OC EUTHERIA; RODENTIA.  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE; 81064681.  
RA MAX E.E., SEIDMAN J.G., MILLER H., LEDER P.;  
RL CELL 21:793-799(1980).  
DR EMBL; K00860; G197444; -.  
DR PIR; A01924; KVM33B.  
DR HSP; P01607; 1FGV.  
KW IMMUNOGLOBULIN V REGION; SIGNAL.  
FT SIGNAL 1 22  
FT CHAIN 23 117  
FT DOMAIN 23 45  
FT DOMAIN 46 56  
FT DOMAIN 57 71  
FT DOMAIN 72 78  
IG KAPPA CHAIN V-V REGION (MOPC 173B).  
FRAMEWORK 1.  
COMPLEMENTARITY-DETERMINING 1.  
FRAMEWORK 2.  
COMPLEMENTARITY-DETERMINING 2.  
FRAMEWORK 3.  
COMPLEMENTARITY-DETERMINING 3.  
FRAMEWORK 4.  
BY SIMILARITY.

FT DOMAIN 79 110  
FT DOMAIN 111 >117  
FT DISULFID 45 110  
FT NON\_TER 117 117  
SQ SEQUENCE 117 AA; 12954 MW; 38F2B08C CRC32;

Query Match 87.1%; Score 61; DB 5; Length 117;  
Best Local Similarity 81.8%; Pred. No. 8.44e-03;  
Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 46 rasqdihsyln 56  
|||||:||||  
QY 1 RASQDISSYLN 11

RESULT 8  
ID KVIN\_HUMAN STANDARD; PRT; 129 AA.  
AC P04431;  
DT 13-AUG-1987 (REL. 05, CREATED)  
DT 13-AUG-1987 (REL. 05, LAST SEQUENCE UPDATE)  
DT 01-NOV-1990 (REL. 16, LAST ANNOTATION UPDATE)  
DE IG KAPPA CHAIN PRECURSOR V-I REGION (WALKER).  
OS HOMO SAPIENS (HUMAN).  
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
OC EUTHERIA; PRIMATES.  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE; 85014148.  
RA KLOBECK H.G., COMBRIATO G., ZACHAU H.G.;  
RL NUCLEIC ACIDS RES. 12:6995-7006(1984).  
DR EMBL; X00965; G296684; ALT\_TERM.  
DR PIR; A01883; K1HUWK.  
DR HSP; P01607; 2FGW.  
KW IMMUNOGLOBULIN V REGION; SIGNAL.  
FT SIGNAL 1 22  
FT CHAIN 23 129  
FT DOMAIN 23 45  
FT DOMAIN 46 56  
FT DOMAIN 57 71  
FT DOMAIN 72 78  
FT DOMAIN 79 110  
FT DOMAIN 111 119  
FT DOMAIN 120 129  
FT DISULFID 45 110  
FT NON\_TER 129 129  
SQ SEQUENCE 129 AA; 14069 MW; 99925172 CRC32;

Query Match 87.1%; Score 61; DB 5; Length 129;  
Best Local Similarity 81.8%; Pred. No. 8.44e-03;  
Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 46 rasqsisyln 56  
|||||:||||  
QY 1 RASQDISSYLN 11

RESULT 9  
ID KVIN\_HUMAN STANDARD; PRT; 108 AA.  
AC P01600;  
DT 21-JUL-1986 (REL. 01, CREATED)  
DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
DT 01-JAN-1988 (REL. 06, LAST ANNOTATION UPDATE)  
DE IG KAPPA CHAIN V-I REGION (HAU).  
OS HOMO SAPIENS (HUMAN).  
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
OC EUTHERIA; PRIMATES.  
RN [1]  
RP SEQUENCE.  
RX MEDLINE; 71032830.  
RA WATANABE S., HILSCHMANN N.;  
RL HOPPE-SEYLER S. 2. PHYSIOL. CHEM. 351:1291-1295(1970).  
CC -!- THE C REGION OF THIS CHAIN HAS THE INV (3) MARKER.  
-!- THIS IS A BENICE-JONES PROTEIN.

DR PIR: A01868; K1HUHU.  
 DR HSP: P01607; 1FVC.  
 KW IMMUNOGLOBULIN V REGION; BENGE-JONES PROTEIN.  
 FT DOMAIN 1 23 FRAMEWORK 1.  
 FT DOMAIN 24 34 FRAMEWORK 2.  
 FT DOMAIN 35 49 FRAMEWORK 3.  
 FT DOMAIN 50 56 FRAMEWORK 4.  
 FT DOMAIN 57 88 FRAMEWORK 5.  
 FT DOMAIN 89 97 FRAMEWORK 6.  
 FT DOMAIN 98 107 FRAMEWORK 7.  
 FT DISULFID 23 88 BY SIMILARITY.  
 FT NON\_TER 108 108  
 SQ SEQUENCE 108 AA; C8A2EE86 CRC32;  
 Query Match 85.7%; Score 60; DB 5; Length 108;  
 Best Local Similarity 81.8%; Pred. No. 1.48e-02;  
 Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 Db 24 rasqdisyn 34  
 QY 1 RASQDISYN 11  
 RESULT 10  
 ID KVIB\_HUMAN STANDARD; PRT; 108 AA.  
 AC P01594;  
 DT 21-JUL-1986 (REL. 01, CREATED)  
 DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
 DT 01-JAN-1988 (REL. 06, LAST ANNOTATION UPDATE)  
 DE IG KAPPA CHAIN V-I REGION (AU).  
 OS HOMO SAPIENS (HUMAN).  
 OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
 OC EUTHERIA; PRIMATES.  
 RN [1]  
 RP SEQUENCE.  
 RX SCHIEHL H., HILSCHMANN N.;  
 RX HOPE-SEVIER'S Z. PHYSIOL. CHEM. 353:345-370(1972).  
 RN [2]  
 RP X-RAY CRYSTALLOGRAPHY.  
 RX MEDLINE; 77022433.  
 RA FEHLHAMMER H., SCHIFFER M., EPP O., COLMAN P.M., LATTMAN E.E.,  
 RA SCHWAGER P., STEIGMANN W., SCHRAMM H.J.;  
 RL BIOPHYS. STRUCT. MECH. 1:139-146(1975).  
 CC -1- THE STRUCTURE OF THE V REGION WAS DETERMINED BY MOLECULAR  
 CC REPLACEMENT METHODS USING THE KNOWN STRUCTURE OF THE V REGION OF  
 CC THE KAPPA CHAIN REL.  
 CC -1- THE C REGION OF THIS CHAIN HAS THE INV (3) MARKER.  
 CC PIR: A01862; K1HUHU.  
 DR HSP: P01607; 1IGM.  
 KW IMMUNOGLOBULIN V REGION; BENGE-JONES PROTEIN.  
 FT DOMAIN 1 23 FRAMEWORK 1.  
 FT DOMAIN 24 34 COMPLEMENTARITY-DETERMINING 1.  
 FT DOMAIN 35 49 FRAMEWORK 2.  
 FT DOMAIN 50 56 COMPLEMENTARITY-DETERMINING 2.  
 FT DOMAIN 57 88 FRAMEWORK 3.  
 FT DOMAIN 89 97 FRAMEWORK 4.  
 FT DOMAIN 98 107 FRAMEWORK 5.  
 FT DISULFID 23 88 BY SIMILARITY.  
 FT NON\_TER 108 108  
 SQ SEQUENCE 108 AA; B455AF00 CRC32;  
 Query Match 82.9%; Score 58; DB 5; Length 108;  
 Best Local Similarity 81.8%; Pred. No. 4.52e-02;  
 Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 Db 24 rasqdisyn 34  
 QY 1 RASQDISYN 11  
 RESULT 11

ID KVIV\_HUMAN STANDARD; PRT; 108 AA.  
 AC P80362;  
 DT 01-NOV-1995 (REL. 32, CREATED)  
 DT 01-NOV-1995 (REL. 32, LAST SEQUENCE UPDATE)  
 DT 01-NOV-1995 (REL. 32, LAST ANNOTATION UPDATE)  
 DE IG KAPPA CHAIN V-I REGION (WAT).  
 OS HOMO SAPIENS (HUMAN).  
 OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
 OC EUTHERIA; PRIMATES.  
 RN [1]  
 RP SEQUENCE, AND X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).  
 RX MEDLINE; 95086080.  
 RX HUANG D.-B., CHANG C.-H., AINSWORTH C., BRUENGER A.T., EULITZ M.,  
 RA SOLOMON A., STEVENS F.J., SCHIFFER M.;  
 RL BIOCHEMISTRY 33:14848-14857(1994).  
 RN [2]  
 RP SEQUENCE OF 1-35.  
 RX MEDLINE; 81267384.  
 RA STEVENS F.J., WESTHOLM F.A., PANAGIOTOPOULOS N., SCHIFFER M.,  
 RA POPP R.A., SOLOMON A.;  
 RL J. MOL. BIOL. 147:185-193(1981).  
 CC -1- THIS IS A BENGE-JONES PROTEIN.  
 DR PDB; 1WTL; 01-NOV-94.  
 KW IMMUNOGLOBULIN V REGION; BENGE-JONES PROTEIN; 3D-STRUCTURE.  
 FT DOMAIN 1 23 FRAMEWORK 1.  
 FT DOMAIN 24 34 COMPLEMENTARITY-DETERMINING 1.  
 FT DOMAIN 35 49 FRAMEWORK 2.  
 FT DOMAIN 50 56 COMPLEMENTARITY-DETERMINING 2.  
 FT DOMAIN 57 88 FRAMEWORK 3.  
 FT DOMAIN 89 97 FRAMEWORK 4.  
 FT DISULFID 23 88 BY SIMILARITY.  
 FT CONFLICT 30 31 TN -> SD (IN REF. 2).  
 FT NON\_TER 108 108  
 SQ SEQUENCE 108 AA; 41A2388C CRC32;  
 Query Match 82.9%; Score 58; DB 5; Length 108;  
 Best Local Similarity 72.7%; Pred. No. 4.52e-02;  
 Matches 8; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
 Db 24 rasqdisyn 34  
 QY 1 RASQDISYN 11  
 RESULT 12  
 ID KV5U\_MOUSE STANDARD; PRT; 108 AA.  
 AC P04946;  
 DT 13-AUG-1987 (REL. 05, CREATED)  
 DT 13-AUG-1987 (REL. 05, LAST SEQUENCE UPDATE)  
 DT 01-OCT-1993 (REL. 27, LAST ANNOTATION UPDATE)  
 DE IG KAPPA CHAIN V-V REGION (N05-89.4).  
 OS MUS MUSCULUS (MOUSE).  
 OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
 OC EUTHERIA; RODENTIA.  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE; 83271467.  
 RA KAARTINEN M., GRIFFITHS G.M., MARKHAM A.F., MILSTEIN C.;  
 RL NATURE 304:320-324(1983).  
 CC -1- ANTI-2-PHENYL OXAZOLONE (PHOX) ANTIBODY.  
 DR EMBL; K00745; G196455; -.  
 DR HSP; P01607; 1FAI.  
 KW IMMUNOGLOBULIN V REGION; HYBRIDOMA.  
 FT DOMAIN 1 23 FRAMEWORK 1.  
 FT DOMAIN 24 34 COMPLEMENTARITY-DETERMINING 1.  
 FT DOMAIN 35 49 FRAMEWORK 2.  
 FT DOMAIN 50 56 COMPLEMENTARITY-DETERMINING 2.  
 FT DOMAIN 57 88 FRAMEWORK 3.  
 FT DOMAIN 89 97 FRAMEWORK 4.  
 FT DISULFID 23 88 BY SIMILARITY.  
 FT NON\_TER 108 108

```
SQ SEQUENCE 108 AA; 11866 MW; D396F142 CRC32;
Query Match 82.9%; Score 58; DB 5; Length 108;
Best Local Similarity 90.0%; Pred. No. 4.52e-02;
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 25 asqdisnyln 34
|||||:||||
QY 2 ASQDISSYLN 11

RESULT 13
ID KVSF_MOUSE STANDARD; PRT; 115 AA.
AC P01638;
DT 21-JUL-1986 (REL. 01, CREATED)
DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)
DT 01-OCT-1993 (REL. 27, LAST ANNOTATION UPDATE)
DE IG KAPPA CHAIN PRECURSOR V-V REGION (L6) (FRAGMENT).
OS MUS MUSCULUS (MOUSE).
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;
OC EUTHERIA; RODENTIA.
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE; 81220975.
RA PECH M., HOCHTL J., SCHNELL H., ZACHAU H.G.;
RL NATURE 291:668-670(1981).
DR PIR: A01921; KVM5L6.
DR HSP: P01607; 11IF.
KW IMMUNOGLOBULIN V REGION; SIGNAL.
FT SIGNAL 1 20
FT CHAIN 21 >115 IG KAPPA CHAIN V-V REGION (L6).
FT DOMAIN 21 43 FRAMEWORK 1.
FT DOMAIN 44 54 COMPLEMENTARITY-DETERMINING 1.
FT DOMAIN 55 69 FRAMEWORK 2.
FT DOMAIN 70 76 COMPLEMENTARITY-DETERMINING 2.
FT DOMAIN 77 108 FRAMEWORK 3.
FT DOMAIN 109 >115 COMPLEMENTARITY-DETERMINING 3.
FT DISULFID 43 108 BY SIMILARITY.
FT NON_TER 115 115
SQ SEQUENCE 115 AA; 12986 MW; 958689AF CRC32;

Query Match 82.9%; Score 58; DB 5; Length 115;
Best Local Similarity 72.7%; Pred. No. 4.52e-02;
Matches 8; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Db 44 kasqdisnyls 54
|||||:||||
QY 1 RASQDISSYLN 11

RESULT 14
ID KV31_HUMAN STANDARD; PRT; 115 AA.
AC P04433;
DT 13-AUG-1987 (REL. 05, CREATED)
DT 13-AUG-1987 (REL. 05, LAST SEQUENCE UPDATE)
DT 01-NOV-1990 (REL. 16, LAST ANNOTATION UPDATE)
DE IG KAPPA CHAIN PRECURSOR V-III REGION (VG) (FRAGMENT).
OS HOMO SAPIENS (HUMAN).
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;
OC EUTHERIA; PRIMATES.
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE; 85087932.
RA PECH M., ZACHAU H.G.;
RL NUCLEIC ACIDS RES. 12:9229-9236(1984).
DR EMBL; X01668; -; NOT_ANNOTATED_CDS.
DR PIR: A01900; K3HUVG.
DR HSP: P01607; 1AAG.
KW IMMUNOGLOBULIN V REGION; SIGNAL.
FT SIGNAL 1 20
FT CHAIN 21 >115 IG KAPPA CHAIN V-III REGION (VG).
FT DOMAIN 21 43 FRAMEWORK 1.
FT DOMAIN 44 54 COMPLEMENTARITY-DETERMINING 1.
```

```
FT DOMAIN 55 69 FRAMEWORK 2.
FT DOMAIN 70 76 COMPLEMENTARITY-DETERMINING 2.
FT DOMAIN 77 108 FRAMEWORK 3.
FT DOMAIN 109 115 COMPLEMENTARITY-DETERMINING 3.
FT DISULFID 43 108 BY SIMILARITY.
FT NON_TER 115 115
SQ SEQUENCE 115 AA; 12575 MW; 37E182FC CRC32;

Query Match 81.4%; Score 57; DB 5; Length 115;
Best Local Similarity 80.0%; Pred. No. 7.81e-02;
Matches 8; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 44 rasqsvssyl 53
|||||:||||
QY 1 RASQDISSYLN 10

RESULT 15
ID KV5E_MOUSE STANDARD; PRT; 128 AA.
AC P01637;
DT 21-JUL-1986 (REL. 01, CREATED)
DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)
DT 01-OCT-1996 (REL. 34, LAST ANNOTATION UPDATE)
DE IG KAPPA CHAIN PRECURSOR V-V REGION (T1).
OS MUS MUSCULUS (MOUSE).
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;
OC EUTHERIA; RODENTIA.
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE; 81052342.
RA ALTENBURGER W., STEINMETZ M., ZACHAU H.G.;
RL NATURE 287:603-607(1980).
DR EMBL; V00772; G762979; -.
DR PIR: A01920; KVM5T1.
DR HSP: P01607; 11IF.
KW IMMUNOGLOBULIN V REGION; SIGNAL.
FT SIGNAL 1 20
FT CHAIN 21 128 IG KAPPA CHAIN V-V REGION (T1).
FT DOMAIN 21 43 FRAMEWORK 1.
FT DOMAIN 44 54 COMPLEMENTARITY-DETERMINING 1.
FT DOMAIN 55 69 FRAMEWORK 2.
FT DOMAIN 70 76 COMPLEMENTARITY-DETERMINING 2.
FT DOMAIN 77 108 FRAMEWORK 3.
FT DOMAIN 109 117 COMPLEMENTARITY-DETERMINING 3.
FT DOMAIN 118 127 FRAMEWORK 4.
FT DISULFID 43 108 BY SIMILARITY.
FT NON_TER 128 128
SQ SEQUENCE 128 AA; 14385 MW; 87009E44 CRC32;

Query Match 81.4%; Score 57; DB 5; Length 128;
Best Local Similarity 80.0%; Pred. No. 7.81e-02;
Matches 8; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Db 44 kasqdisnyl 53
|||||:||||
QY 1 RASQDISSYLN 10

Search completed: Tue Mar 3 11:18:47 1998
Job time : 9 secs.
```

**THIS PAGE BLANK (USPTO)**

\*\*\*\*\*

(TW)

\*\*\*\*\*

Release 2.1D John F. Collins, Biocomputing Research Unit.  
Copyright (C) 1993, 1994, 1995 University of Edinburgh, U.K.  
Distribution rights by Intelligenetics, Inc.

MPsrch\_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Tue Mar 3 14:28:08 1998; MasPar time 8.47 Seconds  
Tabular output not generated. 11.473 Million cell updates/sec

Title: >US-08-137-117D-118  
Description: (1-7) from US08137117D.pap  
Perfect Score: 51  
Sequence: 1 YTSRLHS 7

Scoring table: PAM 150  
GAP 15

Searched: 111726 seqs, 13889129 residues

Post-processing: Minimum Match 0%  
Listing first 45 summaries

Database: a-geneseq30  
1:part1 2:part2 3:part3 4:part4 5:part5 6:part6 7:part7  
8:part8 9:part9 10:part10 11:part11 12:part12 13:part13  
14:part14 15:part15 16:part16 17:part17 18:part18  
19:part19 20:part20 21:part21 22:part22 23:part23

Statistics: Mean 15.572; Variance 37.259; scale 0.418

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	51	100.0	88	9 R47210	Chimeric human/mouse	5.83e+00
2	51	100.0	107	6 R30768	Murine anti-CD3 Mab U	5.83e+00
3	51	100.0	108	20 W00834	Variable light chain	5.83e+00
4	51	100.0	108	20 W04177	Variant variable ligh	5.83e+00
5	51	100.0	109	17 R52039	Light chain variable	5.83e+00
6	51	100.0	124	9 R47206	Human/murine IL-1 chi	5.83e+00
7	51	100.0	126	5 R29015	pUC-RV1-PM1a.	5.83e+00
8	51	100.0	126	5 R29013	pUC-RVh-PM1a.	5.83e+00
9	51	100.0	127	22 W11815	Mouse anti-human Fas	5.83e+00
10	51	100.0	127	22 W11817	Humanised mouse anti-	5.83e+00
11	51	100.0	127	5 R28670	ppM-k3 protein produc	5.83e+00
12	51	100.0	127	6 R32121	Anti-CD4 antibody MT	5.83e+00
13	51	100.0	128	19 W06215	MAB ME4 light chain v	5.83e+00
14	51	100.0	128	5 R09426	ME4 Light Chain V Reg	5.83e+00
15	51	100.0	129	9 R47207	Human/murine IL-1 chi	5.83e+00
16	51	100.0	131	14 R84553	MAB SCH94.03 light ch	5.83e+00
17	51	100.0	268	8 R44226	Chimeric Ig superfam	5.83e+00
18	51	100.0	302	10 R60206	Bispecific CD3-L6Fvlg	5.83e+00
19	46	90.2	127	19 R99003	MAB Vll17E6 light chai	2.76e+01
20	45	90.2	1422	16 R82071	Hepatitis GB virus (H	2.76e+01

21	42	82.4	107	6 R30769	huxCD3v9, humanised m	9.19e+01
22	42	82.4	140	5 R27559	Cyn d allergen Bl.	9.19e+01
23	41	80.4	107	13 R77302	Variable light chain	1.23e+02
24	41	80.4	126	2 R12237	Mouse Mab 1C11 L chai	1.23e+02
25	41	80.4	127	2 R12359	Light (kappa) chain v	1.23e+02
26	41	80.4	273	9 R52865	Anti-Influenza N10 sc	1.23e+02
27	41	80.4	539	21 W20778	H. pylori cytoplasmic	1.23e+02
28	40	78.4	127	7 R39265	Mouse C4G1 Ig light-c	1.65e+02
29	40	78.4	172	17 W00482	Human deoxycytidine k	1.65e+02
30	40	78.4	214	6 R30776	H52L6-158 murine anti	1.65e+02
31	40	78.4	214	19 W00373	Anti-CD18 chimeric an	1.65e+02
32	40	78.4	214	7 R43338	Completely humanised	1.65e+02
33	40	78.4	233	6 R30777	PH52-9.0 humanised mu	1.65e+02
34	40	78.4	706	12 R68743	BCL-6 zinc finger pro	1.65e+02
35	40	78.4	1235	22 W21572	Rat brain serine ecto	1.65e+02
36	40	78.4	1249	22 W21571	Rat brain homologue o	1.65e+02
37	39	76.5	127	5 R39010	p146-k3 protein produ	2.20e+02
38	39	76.5	432	15 R92813	Murine interleukin-11	2.20e+02
39	39	76.5	441	17 R99091	Murine Etl-2 gene pro	2.20e+02
40	39	76.5	928	14 R77399	BHV1 gI glycoprotein.	2.20e+02
41	39	76.5	933	5 R27807	Bovine herpes virus t	2.20e+02
42	39	76.5	933	7 R41343	Bovine herpesvirus ty	2.20e+02
43	38	74.5	745	13 R76110	Human ALD.	2.93e+02
44	38	74.5	794	23 W25637	Human cadherin-12.	2.93e+02
45	38	74.5	842	4 P93712	Sequence of infection	2.93e+02

## ALIGNMENTS

RESULT 1  
ID R47210 standard; Protein; 88 AA.  
AC R47210;  
DT 09-AUG-1994 (first entry)  
DE Chimeric human/mouse antibody L chain mature peptide.  
KW Probe; chimeric; recombinant; antibody; human; interleukin-1; IL-1;  
KW light; L; chain; constant; region; variable; mouse; anti-human; PCR;  
KW graft; CDR; complementarity determining region; heavy; H; detection;  
KW inflammatory disease; arteriosclerosis; polymerase chain reaction;  
KW diffused intravascular coagulation; leukemia; amplify.  
OS Chimeric - Homo sapiens.  
OS Chimeric - Mus musculus.  
PN W09402627-A.  
PD 03-FEB-1994.  
PF 08-JUL-1993; J00941.  
PR 16-JUL-1992; JP-189248.  
PA (SAKA ) OHSUKA PHARM CO LTD.  
PI Hirai Y, Nishida T, Omoto Y, Owens RJ;  
DR WPI; 94-048885/06.  
DR N-PSDB; Q56075.  
PT Mouse/human chimeric antibody against human interleukin-1 - for  
PT treatment of diseases in which production of interleukin-1 is  
PT abnormal, and for diagnostic imaging of interleukin-1 production  
PT sites in vivo  
PS Disclosure; Fig 18; 58pp; Japanese.  
CC This sequence represents the mature L chain of a chimeric recombinant  
CC antibody against human interleukin-1 (IL-1). The chimeric antibody  
CC has a light (L) chain in which the constant region is that of a human  
CC antibody and the variable region is from a mouse anti-human IL-1  
CC antibody or is a mouse-human graft containing the CDR regions of mouse  
CC anti-human IL-1 antibody, and a heavy (H) chain in which the constant  
CC region is that of a human antibody and the variable region is from a  
CC mouse anti-human IL-1 antibody or is a mouse-human graft containing  
CC the CDR regions of mouse anti-human IL-1 antibody. The chimeric  
CC antibody is used to treat diseases in which abnormal amounts of IL-1  
CC are produced, eg. inflammatory disease, arteriosclerosis, diffused  
CC intravascular coagulation or leukemia. It can also be labelled and  
CC used for diagnostic imaging of IL-1 producing sites in vivo.  
SQ Sequence 88 AA;

Query Match 100.0%; Score 51; DB 9; Length 88;  
Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 34 ytsrlhs 40  
 1 YTSRLHS 7  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 50 ytsrlhs 56  
 1 YTSRLHS 7  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 2  
 ID R30768 standard; protein; 107 AA.  
 AC R30768;  
 DT 12-MAY-1993 (first entry)  
 DE Murine anti-CD3 MAb UCHL1 light chain variable domain.  
 KW Humanisation; rapid; monoclonal antibody; mxd3.  
 OS Mus musculus.  
 PN WO9222653-A.  
 PD 23-DEC-1992.  
 PF 15-JUN-1992; U05126.  
 PR 14-JUN-1991; US-715272.  
 PA (GETH ) GENENTECH INC.  
 PI Carter PJ, Presta LG.  
 DR WPI; 93-018139/02.  
 PT Humanisation of antibodies - by molecular modelling of the variable domains and alteration by gene conversion mutagenesis.  
 PS Disclosure; Fig 5; 126pp; English.  
 CC The sequence is that of the light chain variable domain of murine anti-CD3 monoclonal antibody UCHL1 (mxd3, Shalaby 1992).  
 SQ Sequence 107 AA;

Query Match 100.0%; Score 51; DB 6; Length 107;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 50 ytsrlhs 56  
 1 YTSRLHS 7

RESULT 3  
 ID W00834 standard; Protein; 108 AA.  
 AC W00834;  
 DT 20-MAY-1997 (first entry)  
 DE Variable light chain of anti-human Fas ligand antibody NOK-1.  
 KW Variable region; light chain; human; Fas ligand; monoclonal;  
 KW antibody; NOK-1; hybridoma; inhibition; apoptosis; assay;  
 KW diagnosis; disease; hepatitis; infectious mononucleosis;  
 KW systemic lupus erythematosus.  
 OS Mus musculus.  
 PN WO9629350-A1.  
 PD 26-SEP-1996.  
 PF 21-MAR-1996; J00734.  
 PR 20-MAR-1995; JP-087420.  
 PR 27-OCT-1995; JP-303492.  
 PA (SUME ) SUMITOMO ELECTRIC IND CO.  
 PI Kiyagaki N, Nakata M, Okumura K, Yagita H;  
 DR WPI; 96-443140/44.  
 DR N-PSDB; T39560.  
 PT Monoclonal antibody specifically recognising the Fas ligand - useful for the detection of Fas ligands either on cell surface or in solution  
 PS Claim 41; Pages 93-94; 133pp; Japanese.  
 CC The present sequence is the light chain variable region of the anti-human Fas ligand monoclonal antibody (MAB) NOK-1. NOK-1 is produced by the hybridoma NOK-1 (FERM BP-5044), which was prepared by immunising mice with transformed human Fas ligand expressing COS cells, and fusing spleen cells isolated from the mice with myeloma P3x63Ag8.653 (ATCC CRL-1580) cells. The MAB recognises the human Fas ligand on the cell surface, and can be used to inhibit the apoptosis inducing cell surface Fas ligand/Fas reaction. The MAB can also be used for a Fas ligand assay in biological samples (e.g. human blood), especially for disease diagnosis, e.g. hepatitis, infectious mononucleosis and systemic lupus erythematosus.  
 SQ Sequence 108 AA;

Query Match 100.0%; Score 51; DB 20; Length 108;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 50 ytsrlhs 56  
 1 YTSRLHS 7

RESULT 4  
 ID W04177 standard; Protein; 108 AA.  
 AC W04177;  
 DT 19-MAY-1997 (first entry)  
 DE Variant variable light chain of Fas ligand antibody NOK-1.  
 KW Variable region; light chain; human; Fas ligand; monoclonal;  
 KW antibody; NOK-1; hybridoma; inhibition; apoptosis; assay;  
 KW diagnosis; disease; hepatitis; infectious mononucleosis;  
 KW systemic lupus erythematosus; variant.  
 OS Mus musculus.  
 PN WO9629350-A1.  
 PD 26-SEP-1996.  
 PF 21-MAR-1996; J00734.  
 PR 20-MAR-1995; JP-087420.  
 PR 27-OCT-1995; JP-303492.  
 PA (SUME ) SUMITOMO ELECTRIC IND CO.  
 PI Kiyagaki N, Nakata M, Okumura K, Yagita H;  
 DR WPI; 96-443140/44.  
 DR N-PSDB; T39550.  
 PT Monoclonal antibody specifically recognising the Fas ligand - useful for the detection of Fas ligands either on cell surface or in solution  
 PS Claim 20; Pages 80-81; 133pp; Japanese.  
 CC The present sequence is a variant light chain variable region of the anti-human Fas ligand monoclonal antibody (MAB) NOK-1. NOK-1 is produced by the hybridoma NOK-1 (FERM BP-5044), which was prepared by immunising mice with transformed human Fas ligand expressing COS cells, and fusing spleen cells isolated from the mice with myeloma P3x63Ag8.653 (ATCC CRL-1580) cells. The MAB recognises the human Fas ligand on the cell surface or in solution, and can be used to inhibit the apoptosis inducing cell surface Fas ligand/Fas reaction. The MAB can also be used for a Fas ligand assay in biological samples (e.g. human blood), especially for disease diagnosis, e.g. hepatitis, infectious mononucleosis and systemic lupus erythematosus.  
 SQ Sequence 108 AA;

Query Match 100.0%; Score 51; DB 20; Length 108;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 50 ytsrlhs 56  
 1 YTSRLHS 7

RESULT 5  
 ID R52039 standard; Protein; 109 AA.  
 AC R52039;  
 DT 27-SEP-1996 (first entry)  
 DE Light chain variable region of murine antibody lfl9.  
 KW antibody; humanised; murine; heavy chain; light; variable;  
 KW framework region; complementarity determining region; reshaping;  
 KW modelling; surface residue; modify.  
 OS Mus sp.  
 FH Key Location/Qualifiers  
 FT Region 1..23  
 FT /label= framework\_region\_1  
 FT /note= "FR 1"  
 FT Region 24..34  
 FT /label= complementarity\_determining\_region\_1  
 FT /note= "CDR 1"  
 FT Region 35..49  
 FT /label= FR\_2  
 FT Region 50..56

FT /label= CDR\_2 57..88  
 FT Region /label= FR\_3  
 FT Region 89..97  
 FT /label= CDR\_3 98..109  
 FT Region /label= FR\_4  
 FT /label= FR\_4  
 PN EP-592106-A1.  
 PD 13-APR-1994. 307051.  
 PF 07-SEP-1993; 307051.  
 PR 09-SEP-1992; US-942245.  
 PA (PEDE/) PEDERSEN J T.  
 PA (IMMU-) IMMUNOGEN INC.  
 PI Guild BC, Pedersen JT, Rees AR, Roguska MA, Searle SMJ;  
 DR WPI: 94-120230/15.  
 PT Method of resurfacing of rodent antibodies to produce humanised antibody forms - for producing non-human antibodies with improved therapeutic efficiency by presenting human surface on V-region Example 1; Fig 3A; 230pp; English.  
 PS The present sequence is that of the light chain variable (LC VR) region of murine antibody 1f19. This sequence was aligned with 11 other known antibody LC VRs and a set of framework positions of surface exposed amino acid residues was determined. This information can be used in a method to determine how to modify a rodent antibody or fragment by resurfacing in order to produce a humanised rodent antibody. Residues (determined from alignment) at positions 1, 3, 5, 9, 15, 18, 46, 47, 51, 63, 66, 73, 86, 87, 111, 115, 116 and 117 are accessible residues. None of the entire combinations of surface residues in the murine sequences were found in the human sequences and vice versa. However the residues in individual CC positions appear to be conserved.  
 SQ Sequence 109 AA;

Query Match 100.0%; Score 51; DB 17; Length 109;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 50 ytsrlhs 56  
 QY 1 YTSRLHS 7  
 |||||

RESULT 6  
 ID R47206 standard; Protein; 124 AA.  
 AC R47206;  
 DT 09-AUG-1994 (first entry)  
 DE Human/murine IL-1 chimeric antibody CH.  
 KW Probe; chimeric; recombinant; antibody; human; interleukin-1; IL-1; light; L; chain; constant; region; variable; mouse; anti-human; graft; CDR; complementarity determining region; heavy; H;  
 KW inflammatory disease; arteriosclerosis; detection;  
 KW diffused intravascular coagulation; leukemia.  
 OS Synthetic.  
 FH Key Location/Qualifiers  
 FT Peptide 1..17  
 FT /note= "Signal peptide"  
 FT Protein 18..124  
 FT /note= "Mature protein"  
 PN WO9402627-A.  
 PD 03-FEB-1994.  
 PF 08-JUL-1993; J00941.  
 PR 16-JUL-1992; JP-189248.  
 PA (SAKA) OTSUKA PHARM CO LTD.  
 PI Hirai Y, Nishida T, Omoto Y, Owens RJ;  
 DR WPI: 94-048885/06.  
 DR N-PSDB; Q36067.  
 PT Mouse/human chimeric antibody against human interleukin-1 - for treatment of diseases in which production of interleukin-1 is abnormal, and for diagnostic imaging of interleukin-1 production sites in vivo  
 PS Claim 1; Page 31-32; 58pp; Japanese.  
 CC The sequences given in R47205-08 represent the light and heavy chain, variable and constant regions of a chimeric recombinant antibody against human interleukin-1 (IL-1). The antibody has a light (L)

CC chain in which the constant region is that of a human antibody and the variable region is from a mouse anti-human IL-1 antibody or is a mouse-human graft containing the CDR regions of mouse anti-human IL-1 antibody, and a heavy (H) chain in which the constant region is that of a human antibody and the variable region is from a mouse anti-human IL-1 antibody or is a mouse-human graft containing the CDR regions of mouse anti-human IL-1 antibody. The chimeric antibody is used to treat diseases in which abnormal amounts of IL-1 are produced, eg. inflammatory disease, arteriosclerosis, diffused intravascular coagulation or leukemia. It can also be labelled and used for diagnostic imaging of IL-1 producing sites in vivo.  
 SQ Sequence 124 AA;

Query Match 100.0%; Score 51; DB 9; Length 124;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 67 ytsrlhs 73  
 QY 1 YTSRLHS 7  
 |||||

RESULT 7  
 ID R29015 standard; Protein; 126 AA.  
 AC R29015;  
 DT 30-MAR-1993 (first entry)  
 DE pUC-RV1-PM1a.  
 KW Human; antibody; interleukin-6; receptor; IL-6R; CDR; PCR;  
 KW complementarity determining region; mouse; monoclonal; hybridoma; plasmid; polymerase chain reaction; amplify.  
 OS Synthetic.  
 FH Key Location/Qualifiers  
 FT Peptide 1..19  
 FT /note= "Leader peptide"  
 FT Region 20..42  
 FT /label= FR1 43..53  
 FT Region /label= CDR1 54..68  
 FT /label= FR2 69..75  
 FT Region /label= CDR2 76..107  
 FT /label= FR3 108..116  
 FT Region /label= CDR3 117..126  
 FT /label= FR4  
 PN WO9219759-A.  
 PD 12-NOV-1992. J00544.  
 PF 24-APR-1992; JP-095476.  
 PR 25-APR-1991; JP-032084.  
 PR 19-FEB-1992; JP-032084.  
 PA (CHUS) CHUGAI SEIYAKU KK.  
 PI Bendig MM, Jones ST, Saldanha JW, Sato K, Tsuchiya M;  
 DR WPI: 92-398882/48.  
 DR N-PSDB; Q31366.  
 PT Reconstituted human antibody to human interleukin-6 receptor - has low antigenicity and contains mouse V-region complementarity determining regions  
 PS Disclosure; Page 144-5; 207pp; Japanese.  
 CC The sequences given in R29012-15 are portions of monoclonal antibodies which were encoded by plasmids derived from mouse hybridomas. The DNA encoding complementarity determining regions (CDR's) was isolated by polymerase chain reaction. These antibodies recognise human interleukin-6 receptor (IL-6R). The mouse hybridoma cells were transformed with the plasmids encoding these genes which caused the secretion of these antibodies from the hybridoma cells.  
 SQ Sequence 126 AA;

Query Match 100.0%; Score 51; DB 5; Length 126;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 69 ytsrlhs 75  
 QY 1 YTSRLHS 7

RESULT 8  
 ID R29013 standard; Protein; 126 AA.  
 AC R29013;  
 DT 30-MAR-1993 (first entry)  
 DE pUC-RVh-PW1a.  
 KW Human; antibody; interleukin-6; receptor; IL-6R; CDR; PCR;  
 KW complementarity determining region; mouse; monoclonal; hybridoma;  
 KW plasmid; polymerase chain reaction; amplify.  
 OS Synthetic.  
 FH Key Location/Qualifiers  
 FT Peptide 1..19  
 FT /note= "Leader peptide"  
 FT Region 20..42  
 FT /label= FR1  
 FT Region 43..53  
 FT /label= CDR1  
 FT Region 54..68  
 FT /label= FR2  
 FT Region 69..75  
 FT /label= CDR2  
 FT Region 76..107  
 FT /label= FR3  
 FT Region 108..116  
 FT /label= CDR3  
 FT Region 117..126  
 FT /label= FR4  
 PN W09219759-A.  
 PD 12-NOV-1992.  
 PF 24-APR-1992; J00544.  
 PR 25-APR-1991; JP-095476.  
 PR 19-FEB-1992; JP-032084.  
 PA (CHUS ) CHUGAI SEIYAKU KK.  
 PI Bendig MM, Jones ST, Saldanha JW, Sato K, Tsuchiya M;  
 DR WPI; 92-398882/48.  
 DR N-PSDB; Q31361.  
 PT Reconstituted human antibody to human interleukin-6 receptor -  
 PT has low antigenicity and contains mouse V-region complementarity  
 PT determining regions  
 PS Disclosure; Page 140-1; 207pp; Japanese.  
 CC The sequences given in R29012-15 are portions of monoclonal antibodies  
 CC which were encoded by plasmids derived from mouse hybridomas. The DNA  
 CC encoding complementarity determining regions (CDR's) was isolated by  
 CC polymerase chain reaction. These antibodies recognise human  
 CC interleukin-6 receptor (IL-6R). The mouse hybridoma cells were  
 CC transformed with the plasmids encoding these genes which caused the  
 CC secretion of these antibodies from the hybridoma cells.  
 SQ Sequence 126 AA;  
 Query Match 100.0%; Score 51; DB 5; Length 126;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 69 ytsrlhs 75  
 QY 1 YTSRLHS 7

RESULT 9  
 ID W11815 standard; Protein; 127 AA.  
 AC W11815;  
 DT 20-OCT-1997 (first entry)  
 DE Mouse anti-human Fas ligand antibody F919 light chain.  
 KW Human; Fas ligand; antigen; neutral; antibody; apoptosis; HIV;  
 KW induction; assay; enzyme linked immunosorbent assay; diagnosis;  
 KW disease; hepatitis B; hepatitis C; human immunodeficiency virus;  
 KW graft versus host disease; ulcerative colitis; sequelae;  
 KW myocardial infarction; mouse; murine; monoclonal; treatment;

KW complementarity determining region; CDR.  
 OS Mus spp.  
 FH Key Location/Qualifiers  
 FT Region 44..54  
 FT /label= CDR\_1  
 FT Region 70..76  
 FT /label= CDR\_2  
 FT Region 109..117  
 FT /label= CDR\_3  
 PN W09702290-A1.  
 PD 23-JAN-1997.  
 PF 01-JUL-1996; J01820.  
 PR 17-MAY-1996; US-649100.  
 PR 30-JUN-1995; JP-188480.  
 PA (MOCH ) MOCHIDA PHARM CO LTD.  
 PA (OSAB ) OSAKA BIOSCIENCE INST.  
 PI Co MS, Matsusue T, Nagata S, Shirakawa K, Vasquez M;  
 DR WPI; 97-108917/10.  
 DR N-PSDB; T59500.  
 PT Antibody reactive with Fas ligand capable of inducing apoptosis -  
 PT used for diagnostic assay of Fas ligand in body fluids and for  
 PT treatment of diseases in which Fas ligand/Fas antigen is involved  
 PS Claim 5; Fig 10; 164pp; Japanese.  
 CC The present sequence is the light chain of the mouse  
 CC anti-apoptosis inducing human Fas ligand, monoclonal antibody,  
 CC F919. The antibody can be used in a Fas ligand assay, e.g. an  
 CC enzyme linked immunosorbent assay, to diagnose diseases in which  
 CC the Fas ligand/Fas antigen system is implicated, e.g. hepatitis  
 CC B/C, human immunodeficiency virus, graft/host disorders,  
 CC ulcerative colitis or sequelae of myocardial infarction. The  
 CC antibody may also be used to treat such diseases.  
 SQ Sequence 127 AA;  
 Query Match 100.0%; Score 51; DB 22; Length 127;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 70 ytsrlhs 76  
 QY 1 YTSRLHS 7

RESULT 10  
 ID W11817 standard; Protein; 127 AA.  
 AC W11817;  
 DT 20-OCT-1997 (first entry)  
 DE Humanised mouse anti-human Fas ligand antibody F919 light chain.  
 KW Human; Fas ligand; antigen; neutral; antibody; apoptosis; HIV;  
 KW induction; assay; enzyme linked immunosorbent assay; diagnosis;  
 KW disease; hepatitis B; hepatitis C; human immunodeficiency virus;  
 KW graft versus host disease; ulcerative colitis; sequelae; chimeric;  
 KW myocardial infarction; mouse; murine; monoclonal; treatment.  
 OS Chimeric - Mus spp.  
 OS Chimeric - Homo sapiens.  
 OS Synthetic.  
 FH Key Location/Qualifiers  
 FT Region 44..54  
 FT /label= CDR\_1  
 FT Region 70..76  
 FT /label= CDR\_2  
 FT Region 109..117  
 FT /label= CDR\_3  
 PN W09702290-A1.  
 PD 23-JAN-1997.  
 PF 01-JUL-1996; J01820.  
 PR 17-MAY-1996; US-649100.  
 PR 30-JUN-1995; JP-188480.  
 PA (MOCH ) MOCHIDA PHARM CO LTD.  
 PA (OSAB ) OSAKA BIOSCIENCE INST.  
 PI Co MS, Matsusue T, Nagata S, Shirakawa K, Vasquez M;  
 DR WPI; 97-108917/10.  
 DR N-PSDB; T59502.  
 PT Antibody reactive with Fas ligand capable of inducing apoptosis -



PT used for diagnostic assay of Fas ligand in body fluids and for  
 PT treatment of diseases in which Fas ligand/Fas antigen is involved  
 PS Claim 5; Fig 12; 164pp; Japanese.  
 CC The present sequence is the light chain of the humanised  
 CC mouse anti-apoptosis inducing human Fas ligand, monoclonal  
 CC antibody, F919. The antibody can be used in a Fas ligand assay,  
 CC e.g. an enzyme linked immunosorbent assay, to diagnose diseases  
 CC in which the Fas ligand/Fas antigen system is implicated, e.g.  
 CC hepatitis B/C, human immunodeficiency virus, graft/host disorders,  
 CC ulcerative colitis or sequelae of myocardial infarction. The  
 CC antibody may also be used to treat such diseases.  
 SQ Sequence 127 AA;

Query Match 100.0%; Score 51; DB 22; Length 127;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 70 ytsrlhs 76  
 QY 1 YTSRLHS 7

RESULT 11  
 ID R28670 standard; Protein; 127 AA.

AC R28670;  
 DT 30-MAR-1993 (first entry)  
 DE pPM-k3 protein product.  
 KW Human; antibody; interleukin-6; receptor; IL-6R; light chain; L; H;  
 KW heavy chain; variable region; mouse; monoclonal; hybridoma; PM1;  
 KW plasmid; pPM-k3; pPM-hl.  
 OS Synthetic.

FH Key Location/Qualifiers  
 FT Peptide 1..20  
 FT /note= "Signal peptide"  
 FT Protein 21..127  
 FT /note= "Mature peptide"  
 PN WO9219759-A.  
 PD 12-NOV-1992.  
 PF 24-APR-1992; J00544.  
 PR 25-APR-1991; JP-095476.  
 PR 19-FEB-1992; JP-032084.  
 PA (CHUS ) CHUGAI SEIYAKU KK.  
 PI Bendig MM, Jones ST, Saldanha JW, Sato K, Tsuchiya M;  
 DR WPI: 92-398882/48.  
 DR N-PSDB: Q30755.  
 PT Reconstituted human antibody to human interleukin-6 receptor -  
 PT has low antigenicity and contains mouse V-region complementarity  
 PT determining regions

PS Disclosure: Page 121-122; 207pp; Japanese.  
 CC The sequences given in R28670-71 were encoded by plasmids which were  
 CC used in example to illustrate the production of a human antibody which  
 CC recognises human interleukin-6 receptor (IL-6R). The antibody  
 CC comprises light (L) chain and heavy (H) chain variable regions which  
 CC were derived from a mouse monoclonal antibody produced from the  
 CC hybridoma PM1 which contained the plasmids pPM-k3 and pPM-hl.  
 SQ Sequence 127 AA;

Query Match 100.0%; Score 51; DB 5; Length 127;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 70 ytsrlhs 76  
 QY 1 YTSRLHS 7

RESULT 12  
 ID R32121 standard; Protein; 127 AA.

AC R32121;  
 DT 02-JUN-1993 (first entry)  
 DE Anti-CD4 antibody MT 15.1 light chain variable region.  
 KW immunosuppression; tissue transplantation; graft; L chain; V region;  
 KW T-helper cell inhibition; transplant rejection; MAB;

KW Interleukin-2 receptor.  
 FH Key Location/Qualifiers  
 FT Peptide 1..20  
 FT /label= signal 21..115  
 FT Region  
 FT /label= Variable 116..127  
 FT Region  
 FT /label= J2  
 PN DE4143214-A.  
 PD 28-JAN-1993. 143214.  
 PF 30-DEC-1991; DE-124759.  
 PR 25-JUL-1991; DE-124759.  
 PR 30-DEC-1991; DE-143214.  
 PA (BOEF ) BOEHRINGER MANNHEIM GMBH.  
 PI Kaluza B, Rietmueller G, Scheuer W, Weidle U;  
 DR WPI: 93-037582/05.  
 DR N-PSDB: Q36607.  
 PT Synergistic antibody compsn. for use as immunosuppressant -  
 PT comprises monoclonal anti-CD4 antibodies and monoclonal anti-IL2R  
 PT alpha- or anti-IL2R beta antibodies  
 PS Claim 5; Page 9; 18pp; German.  
 CC This sequence is the light chain variable region of a preferred  
 CC anti-CD4 monoclonal antibody for use in the claimed synergistic  
 CC composition. MAB MT 15.1 is deposited as clone 15-1/F3/14 (SCACC  
 CC 90090705). The anti-CD4 antibody is used with at least one anti-IL2R  
 CC alpha or beta antibody. Individually the antibodies are strongly  
 CC inhibiting and when used together their immunosuppressive properties  
 CC are improved; they synergistically inhibit T-helper cell  
 CC proliferation to effectively inhibit transplant rejection at low  
 CC doses without significantly reducing the general immune response.  
 CC See also Q36608-Q36616.  
 SQ Sequence 127 AA;

Query Match 100.0%; Score 51; DB 6; Length 127;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 70 ytsrlhs 76  
 QY 1 YTSRLHS 7

RESULT 13

ID W06215 standard; Protein; 128 AA.

AC W06215;  
 DT 13-FEB-1997 (first entry)  
 DE MAB ME4 light chain variable region.  
 KW Chimeric antibody; monoclonal antibody; ME4; antibody engineering;  
 KW tumour; antigen; breast carcinoma; colon carcinoma; lung carcinoma;  
 KW ovary carcinoma; melanoma; cancer; diagnosis; therapy; light chain.  
 OS Mus sp.  
 PN US5576184-A.  
 PD 19-NOV-1996. 240624.  
 PF 06-SEP-1988; US-240624.  
 PR 08-SEP-1988; US-241744.  
 PR 13-SEP-1988; US-243739.  
 PR 04-OCT-1988; US-253002.  
 PR 19-JUN-1989; US-367841.  
 PR 21-JUL-1989; US-382768.  
 PR 06-MAY-1991; US-659401.  
 PR 27-DEC-1994; US-364001.  
 PA (XOMA ) XOMA CORP.  
 PI Better MD, Chang CP, Horwitz AH, Lei S, Robinson RR;  
 DR WPI: 97-011249/01.  
 DR N-PSDB: T43440.  
 PT Chimeric mouse-human antibodies - recognise a human tumour antigen,  
 PT used for the treatment and diagnosis of human cancers  
 PS Example 3; Fig 29; 102pp; English.  
 CC The light chain variable region (W06215) of mouse monoclonal  
 CC antibody ME4 is the product of a cDNA clone (T43440) isolated  
 CC from a ME4 hybridoma cDNA library. MAB ME4 (IgG1) binds to an  
 CC antigen that is expressed on the surface of human lung, breast,

CC colon and ovary carcinomas and melanomas, but not on most normal  
 CC adult tissues. The light chain and heavy chain variable regions  
 CC (see also W06216) of ME4 can be linked to human constant regions  
 CC and expressed in transformed host cells. Novel mouse-human  
 CC chimeric antibodies (see also W06209-14 and W06217-18) can be  
 CC produced that have specificity to human tumour antigens for use in  
 CC the treatment and diagnosis of human cancer.  
 SQ Sequence 128 AA;

Query Match 100.0%; Score 51; DB 19; Length 128;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 70 ytsrlhs 76  
 ||||||  
 QY 1 YTSRLHS 7

RESULT 14  
 ID R09426 standard; Protein; 128 AA.  
 AC R09426; 1993 (first entry)  
 DT ME4 Light Chain V Region (mouse).  
 DE Monoclonal antibody; chimera; light; heavy; chain; constant;  
 KW variable; antigen; diagnosis; cancer; tumour.  
 OS Mus musculus.  
 PN W09002569-A.  
 PD 22-MAR-1990. U03852.  
 PF 06-SEP-1989; US-240624.  
 PR 06-SEP-1988; US-241744.  
 PR 08-SEP-1988; US-243739.  
 PR 13-SEP-1988; US-253002.  
 PR 04-OCT-1988; US-367641.  
 PR 19-JUN-1989; US-382768.  
 PR 21-JUL-1989; US-382768.  
 PA (ITGE-) INT GENETIC ENG INC.  
 PI Better MD, Horwitz AH, Robinson RR, Lei S, Chang CP;  
 DR WPI: 90-115825/15.  
 DR N-PSDB: Q08608.  
 PT Chimeric mouse-human antibodies - prepd. using genes coding for  
 PT constant human region murine variable region, esp. to 3 tumour  
 PT antigen  
 PS Claim 13; Page 123 + Fig 29; 173pp; English.  
 CC The sequence is used in the prodn. of a chimeric antibody mol.  
 CC comprising two light chains and two heavy chains, each having a  
 CC constant region (human) and a variable region (murine) having  
 CC specificity to an antigen bound by murine monoclonal antibody  
 CC (MAB) ME4. The chimeric antibodies can be used for any purpose for  
 CC which the original murine MABs can be used, with the advantage that  
 CC they are more compatible with the human body. They are esp. used for  
 CC the diagnosis and treatment of cancer.  
 SQ Sequence 128 AA;

Query Match 100.0%; Score 51; DB 5; Length 128;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 70 ytsrlhs 76  
 ||||||  
 QY 1 YTSRLHS 7

RESULT 15  
 ID R47207 standard; Protein; 129 AA.  
 AC R47207;  
 DT 09-AUG-1994 (first entry)  
 DE Human/murine IL-1 chimeric antibody VL.  
 KW Probe; chimeric; recombinant; antibody; human; interleukin-1; IL-1;  
 KW light; L. chain; constant; region; variable; mouse; anti-human;  
 KW graft; CDR; complementarity determining region; heavy; H;  
 KW inflammatory disease; arteriosclerosis; detection;  
 KW diffused intravascular coagulation; leukemia.  
 OS Synthetic.

FH Key Location/Qualifiers  
 FT Peptide 1..20  
 FT /note= "Signal peptide"  
 FT Protein 21..129  
 FT /note= "Mature protein"  
 PN W09402627-A.  
 PD 03-FEB-1994.  
 PF 08-JUL-1993; J00941.  
 PR 16-JUL-1992; JP-189248.  
 PA (SAKA ) OTSUKA PHARM CO LTD.  
 PI Hirai Y, Nishida T, Omoto Y, Owens RJ;  
 DR WPI: 94-04885/06.  
 DR N-PSDB: Q56068.  
 PT Mouse/human chimeric antibody against human interleukin-1 - for  
 PT treatment of diseases in which production of interleukin-1 is  
 PT abnormal, and for diagnostic imaging of interleukin-1 production  
 PT sites in vivo  
 PS Claim 2; Fig 10; 58pp; Japanese.  
 CC The sequences given in R47205-08 represent the light and heavy chain,  
 CC variable and constant regions of a chimeric recombinant antibody  
 CC against human interleukin-1 (IL-1). The antibody has a light (L)  
 CC chain in which the constant region is that of a human antibody and  
 CC the variable region is from a mouse anti-human IL-1 antibody or is a  
 CC mouse-human graft containing the CDR regions of mouse anti-human IL-1  
 CC antibody, and a heavy (H) chain in which the constant region is that  
 CC of a human antibody and the variable region is from a mouse anti-human  
 CC IL-1 antibody or is a mouse-human graft containing the CDR regions of  
 CC mouse anti-human IL-1 antibody. The chimeric antibody is used to  
 CC treat diseases in which abnormal amounts of IL-1 are produced, eg.  
 CC inflammatory disease, arteriosclerosis, diffused intravascular  
 CC coagulation or leukemia. It can also be labelled and used for  
 CC diagnostic imaging of IL-1 producing sites in vivo.  
 SQ Sequence 129 AA;

Query Match 100.0%; Score 51; DB 9; Length 129;  
 Best Local Similarity 100.0%; Pred. No. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 70 ytsrlhs 76  
 ||||||  
 QY 1 YTSRLHS 7

RESULT 16  
 ID R84553 standard; Protein; 131 AA.  
 AC R84553;  
 DT 02-FEB-1996 (first entry)  
 DE MAB SCH94.03 light chain.  
 KW Monoclonal antibody; MAB; SCH94.03; hybridoma; central nervous system;  
 KW CNS; demyelination; multiple sclerosis; neural disease; therapeutic.  
 OS Mus sp.  
 FH Key Location/Qualifiers  
 FT Peptide 1..20  
 FT /label= Leader\_peptide  
 FT Region 44..54  
 FT /label= CDR1  
 FT Region 70..76  
 FT /label= CDR2  
 FT Region 109..117  
 FT /label= CDR3  
 FT Region 116..128  
 FT /label= Joining\_region  
 FT Region 129..131  
 FT /label= C-kappa\_region  
 PN W09530004-A1.  
 PD 09-NOV-1995.  
 PF 27-APR-1995; U05262.  
 PR 29-APR-1994; US-236520.  
 PA (MAYO-) MAYO FOUNDATION.  
 PI Miller DJ, Rodriguez M;  
 DR WPI: 95-393077/50.  
 DR N-PSDB: T05311.  
 PT Monoclonal antibodies which stimulate central nervous system

PT re-myelination - are produced by hybridoma ATCC CRL 11627, for  
 PT treating multiple sclerosis, and viral or post-neural diseases of  
 PT the CNS.  
 PS Disclosure; Page 36-37; 63pp; English.  
 CC Hybridoma ATCC CRL 11627 was obt'd. from a SJL/J mouse injected with  
 CC spinal cord homogenate from a mammal uninfected with any  
 CC demyelinating disease. The hybridoma produced a monoclonal antibody  
 CC (SCH94.03) useful in promoting CNS remyelination. The SCH94.03  
 CC light chain amino acid sequence is given in R84553.  
 SQ Sequence 131 AA;

Query Match 100.0%; Score 51; DB 14; Length 131;  
 Best Local Similarity 100.0%; Pred. NO. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 70 ytsrlhs 76  
 |||||  
 QY 1 YTSRLHS 7

## RESULT 17

ID R44226 standard; protein; 268 AA.  
 AC R44226;  
 DT 10-JUN-1994 (first entry)  
 DE Chimeric Ig superfamily protein analogue R19(D1.3).  
 KW CHI-protein; immunoglobulin superfamily; multivalent antigen binding;  
 KW engineered fusion protein; beta-barrel domain; chimaeric;  
 KW complementarity determining region; cell imaging; targeting.  
 OS Synthetic.

FH Key Location/Qualifiers

FT Region 1..30  
 FT /label= H\_FR1  
 FT /note= "Heavy chain framework region from R19.9"  
 FT Region 31..35  
 FT /label= H1  
 FT /note= "Primary CDR loop from R19.9"  
 FT Region 36..39  
 FT /label= FR2A  
 FT /note= "Heavy chain framework region from R19.9"  
 FT Region 40..45  
 FT /label= H3'  
 FT /note= "CDR loop spliced into chi-site from D1.3"  
 FT Region 46..48  
 FT /label= FR2B  
 FT /note= "Heavy chain framework region from R19.9"  
 FT Region 49..65  
 FT /label= H2  
 FT /note= "Primary CDR loop from R19.9"  
 FT Region 66..89  
 FT /label= H\_FR3A  
 FT /note= "Heavy chain framework region from R19.9"  
 FT Region 90..92  
 FT /label= H1'  
 FT /note= "CDR loop spliced into chi-site from D1.3"  
 FT Region 93..97  
 FT /label= H\_FR3B  
 FT /note= "Heavy chain framework region from R19.9"  
 FT Region 98..112  
 FT /label= H3  
 FT /note= "Primary CDR loop from R19.9"  
 FT Region 113..116  
 FT /label= H\_FR4  
 FT /note= "Heavy chain framework region from R19.9"  
 FT Region 117..135  
 FT /label= H2'  
 FT /note= "CDR loop spliced into chi-site from D1.3"  
 FT Region 136..155  
 FT /note= "bridge/linker"  
 FT Region 156..178  
 FT /label= L\_FR1  
 FT /note= "Light chain framework region from R19.9"  
 FT Region 179..189  
 FT /label= L1

FT /note= "primary CDR loop from R19.9"  
 FT Region 190..193  
 FT /label= FR2A  
 FT /note= "Light chain framework region from R19.9"  
 FT Region 194..199  
 FT /label= L3'  
 FT /note= "CDR loop spliced into chi-site from D1.3"  
 FT Region 200..203  
 FT /label= FR2B  
 FT /note= "Light chain framework region from R19.9"  
 FT Region 204..210  
 FT /label= L2  
 FT /note= "primary CDR loop from R19.9"  
 FT Region 211..237  
 FT /label= L\_FR3A  
 FT /note= "Light chain framework region from R19.9"  
 FT Region 238..241  
 FT /label= L1'  
 FT /note= "CDR loop spliced into chi-site from D1.3"  
 FT Region 242..244  
 FT /label= FR3B  
 FT /note= "Light chain framework region from R19.9"  
 FT Region 245..253  
 FT /label= L3  
 FT /note= "primary CDR loop from R19.9"  
 FT Region 254..255  
 FT /label= FR4  
 FT /note= "Light chain framework region from R19.9"  
 FT Region 256..268  
 FT /label= L2'  
 FT /note= "CDR loop spliced into chi-site from D1.3"  
 FT W09323537-A.  
 PD 25-NOV-1993.  
 PF 07-MAY-1993; U04338.  
 PA (CREA-) CREATIVE BIOMOLECULES.  
 PI Huston JS, Keck PC;  
 WPI: 93-386569/48.  
 PT Chimeric multivalent protein analogues - useful for diagnostic  
 PT imaging and cytotoxic therapy  
 PS Example 1; Fig 14; 106pp; English.  
 CC This sequence is an example of a CHI-protein constructed according  
 CC to the invention. The novel CHI (Chimeric Immunoglobulin)-proteins  
 CC are comprised of at least 1 beta-barrel forming domain. The antigen  
 CC binding sites of the molecule are located in the beta-barrel  
 CC domain(s). Splice sites for insertion of specific binding sites are  
 CC located by computer comparisons of homology and structure. Depending  
 CC on the ligand binding specificity of the chimeric molecules, they  
 CC can be targeted for imaging, irradiating or delivering cytotoxic  
 CC substances to specific tissues.  
 SQ Sequence 268 AA;

Query Match 100.0%; Score 51; DB 8; Length 268;  
 Best Local Similarity 100.0%; Pred. NO. 5.83e+00;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 204 ytsrlhs 210  
 |||||  
 QY 1 YTSRLHS 7

## RESULT 18

ID R60206 standard; protein; 302 AA.  
 AC R60206;  
 DT 14-MAR-1995 (first entry)  
 DE Bispecific CD3-L6Fvlg antibody derivative.  
 KW fusion protein; recombinant bispecific single chain antibody;  
 KW helical peptide linker; anti-L6 antibody; tumour cell antigen;  
 KW anti-CD3 antibody; variable region.  
 OS Synthetic.  
 FH Key Location/Qualifiers  
 FT Peptide 1..23  
 FT /label= L6\_VL\_leader

```

FT Region 24..271
FT /label= CD3_VL-VH_fusion
FT Region 134..148
FT /label= (Gly4Ser)3_linker
FT Region 272..274
FT /label= hinge
FT Region 275..302
FT /label= Fv_helical_linker
PN EP-610046-A.
PD 10-AUG-1994. 300692.
PF 31-JAN-1994; US-013420.
PR 01-FEB-1993; US-121054.
PR 13-SEP-1993; US-121054.
PA (BRIM) BRISTOL-MYERS SQUIBB CO.
PI Bajorth J, Fell PH, Gilliland LK, Hayden MS, Ledbetter JA,
PI Linsley PS;
DR WPI: 94-250885/31.
DR N-PSDB: Q81076.
PT Expression vector encoding bispecific fusion protein - having
PT binding domains for separate targets joined by helical peptide,
PT useful e.g. for diagnosis and treatment
PT Example 1, Fig 11 and Page 29-31, 50pp; English.
PS The VL and VH sequences of the anti-CD3 hybridoma G19-4 were
CC amplified by PCR methods. A gene fusion was constructed from the
CC two amplified domains and a (Gly4Ser)3 linker. The amino
CC terminus of the VL-VH fusion cassette was fused at the Sali site to
CC the L6 light chain variable region leader peptide and the
CC carboxy-terminus was fused directly to the hinge region of the FC
CC domain at the BclI site and/or to a short 'helical' peptide linker
CC to construct the bispecific CD3-L6Fvlg antibody derivative. The
CC variable regions for L6 were fused in frame to the opposite end of
CC the helical linker (not included in R60206).
SQ Sequence 302 AA;

Query Match 100.0%; Score 51; DB 10; Length 302;
Best Local Similarity 100.0%; Pred. No. 5.83e+00;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 73 ytsrlhs 79
| | | | | | | |
QY 1 YTSRLHS 7

RESULT 19
ID R99003 standard; Protein; 127 AA.
AC R99003.
DT 10-JAN-1997 (first entry)
DE MAb VL17E6 light chain (specific for human alphav integrins).
KW Monoclonal antibody; MAb; integrin; cell-matrix interaction;
KW tumour; melanoma; glioma; carcinoma; cytokine; interleukin-2; IL-2;
KW imaging; detection; radiolabel.
OS Mus musculus.
FH Key Location/Qualifiers
FT Region 21..43
FT /label= Framework region 1
FT Binding_site 44..54
FT /label= CDR1
FT Region 55..69
FT /label= Framework region 2
FT Binding_site 70..76
FT /label= CDR2
FT Region 77..108
FT /label= Framework region 3
FT Binding_site 109..117
FT /label= CDR3
FT Region 118..127
FT /label= Framework region 4
FT /label= Framework region 4
PN EP-719859-A1.
PD 03-JUL-1996.
PF 06-DEC-1995; 119233.
PR 20-DEC-1994; EP-120165.
PA (MERE) MERCK PATENT GMBH.
PI Adan J, Goodman S, Hahn D, Mitjans F, Piulats J;

```

```

PI Rosell E;
DR WPI: 96-302345/31.
DR N-PSDB: T35050.
PT New human integrin V chain-specific monoclonal antibody - and
PT related DNA and hybridomas, for treatment and diagnostic imaging of
PT tumours, esp melanoma.
PS Claim 8; Figure 17a; 54pp; English.
CC A monoclonal antibody which reacts only with the alphav chain of
CC human alphav integrins; which blocks attachment of alphav integrin
CC bearing cells to integrin substrate; which reverses established cell
CC matrix interactions caused by alphav integrin; which blocks tumour
CC development and which has no cytotoxic activity, may be used to
CC treat tumours, especially melanoma (but also glioma, carcinoma)
CC optionally coupled to a cytokine such as interleukin-2. The
CC monoclonal antibody may also be used for diagnostic imaging of
CC tumours and assessment of tumour growth when conjugated to a
CC radiolabel or a radio opaque-agent.
SQ Sequence 127 AA;

Query Match 90.2%; Score 46; DB 19; Length 127;
Best Local Similarity 85.7%; Pred. No. 2.76e+01;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 70 ytsrlhs 76
| | | | |
QY 1 YTSRLHS 7

Search completed: Tue Mar 3 14:28:25 1998
Job time : 17 secs.

```

\*\*\*\*\*

W P E R E H (TW)

\*\*\*\*\*

Release 2.1D John F. Collins, Biocomputing Research Unit.  
Copyright (c) 1993, 1994, 1995 University of Edinburgh, U.K.  
Distribution rights by Intelligentics, Inc.

MPsrch\_pp protein - protein database search, using Smith-Waterman algorithm

Run On: Tue Mar 3 14:32:15 1998; MasPar time 2.93 Seconds

Tabular output not generated.  
72.785 Million cell updates/sec

Title: >US-08-137-117D-118  
Description: (1-7) from US08137117D.pep  
Perfect Score: 51  
Sequence: 1 YTSRLHS 7

Scoring table: PAM 150  
Gap 15

Searched: 95051 seqs, 30469580 residues

Post-processing: Minimum Match 0%  
Listing first 45 summaries

Database: pir53  
1:ann1 2:ann2 3:ann3 4:ann4 5:unann1 6:unann2 7:unann3  
8:unann4 9:unann5 10:unann6 11:unann7 12:unann8  
13:unann9 14:unann10 15:unann11 16:unann12 17:unann  
18:unrev

Statistics: Mean 20.894; Variance 23.719; scale 0.881

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description	Pred. No.
1	51	100.0	93	7	S38564	Ig light chain V reg	2.38e-01
2	51	100.0	107	7	B48677	Ig light chain V-J r	2.38e-01
3	51	100.0	107	7	S69901	Ig kappa light chain	2.38e-01
4	51	100.0	107	7	S69906	Ig kappa light chain	2.38e-01
5	51	100.0	107	7	B28044	Ig kappa chain V reg	2.38e-01
6	51	100.0	107	7	B49026	Ig kappa chain V reg	2.38e-01
7	51	100.0	107	7	A28044	Ig kappa chain V reg	2.38e-01
8	51	100.0	107	7	C48677	Ig light chain V-J r	2.38e-01
9	51	100.0	107	7	S69902	Ig kappa light chain	2.38e-01
10	51	100.0	108	7	S69903	Ig kappa light chain	2.38e-01
11	51	100.0	108	7	KVMSAR	Ig kappa chain V reg	2.38e-01
12	51	100.0	108	7	S38862	Ig kappa chain V reg	2.38e-01
13	51	100.0	108	7	S69906	Ig kappa light chain	2.38e-01
14	51	100.0	108	7	S19970	Ig kappa chain V reg	2.38e-01
15	51	100.0	109	7	PH0888	Ig light chain V reg	2.38e-01
16	51	100.0	115	7	A53276	Ig kappa chain V reg	2.38e-01
17	51	100.0	115	7	JL0080	Ig light chain precu	2.38e-01
18	51	100.0	122	7	A29380	Ig kappa chain precu	2.38e-01
19	51	100.0	127	7	PH1224	Ig kappa chain precu	2.38e-01
20	51	100.0	127	7	PH1224	Ig kappa chain precu	2.38e-01

21	51	100.0	128	7	A26406	Ig kappa chain V reg	2.38e-01
22	48	94.1	107	7	A48677	Ig light chain V-J r	1.21e+00
23	48	94.1	470	9	S02068	RNA-directed RNA pol	1.21e+00
24	48	94.1	529	9	A24031	genome polyprotein -	1.21e+00
25	48	94.1	2332	4	GNNY4F	genome polyprotein -	1.21e+00
26	48	94.1	2332	4	GNNYF	genome polyprotein -	1.21e+00
27	48	94.1	2333	4	GNNY2F	genome polyprotein -	1.21e+00
28	46	90.2	126	7	A34904	Ig kappa chain precu	3.44e+00
29	45	88.2	470	9	JN0431	RNA-directed RNA po	5.75e+00
30	45	88.2	473	18	S53119	RNA-dependent RNA po	5.75e+00
31	45	88.2	2336	9	S37077	genome polyprotein -	5.75e+00
32	44	86.3	105	7	PH0087	Ig kappa chain V reg	9.53e+00
33	44	86.3	178	2	TVRTBM	transforming protein	9.53e+00
34	44	86.3	230	16	S33161	Ig kappa chain - she	9.53e+00
35	44	86.3	502	8	A23547	keratin, type II cyt	9.53e+00
36	43	84.3	847	14	JC4836	alpha-glucuronidase	1.57e+01
37	43	84.3	975	14	S4751	hypothetical protein	1.57e+01
38	42	82.4	107	7	S32186	Ig kappa chain V reg	2.55e+01
39	42	82.4	274	13	S17923	rbcL intron protein	2.55e+01
40	42	82.4	334	12	I39843	iron-uptake system c	2.55e+01
41	42	82.4	721	13	S49789	hypothetical protein	2.55e+01
42	42	82.4	747	13	S69557	hypothetical protein	2.55e+01
43	42	82.4	787	13	S56268	hypothetical protein	2.55e+01
44	42	82.4	961	15	A55380	faciogenital dysplas	2.55e+01
45	41	80.4	111	7	E38740	Ig kappa chain V reg	4.13e+01

ALIGNMENTS

RESULT	1
ENTRY	S38564
TITLE	Ig light chain V region (ASWU1) - mouse (fragment)
ORGANISM	#formal_name Mus musculus #common_name house mouse
DATE	06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 09-May-1997
ACCESSIONS	S38564
REFERENCE	S38559
#authors	Monestier, M.; Losman, L.J.; Novick, K.E.; Aris, J.P.
#description	Submitted to the EMBL Data Library, September 1993
#accession	S38564
#status	preliminary
#molecule_type	mRNA
#residues	1-93
#label	MON
#cross-references	EMBL:X75105
CLASSIFICATION	#superfamily immunoglobulin V region; immunoglobulin homology
KEYWORDS	antibodies in H-2s Mice.
SUMMARY	Immunoglobulin
Query Match	100.0%; Score 51; DB 7; Length 93;
Best Local Similarity	100.0%; Pred No. 2.38e-01;
Matches	7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db	50 ytsrlhs 56
Qy	1 YTSRLHS 7
RESULT	2
ENTRY	B48677
TITLE	Ig light chain V-J region (44.1) - mouse (fragment)
ORGANISM	#formal_name Mus musculus #common_name house mouse
DATE	19-May-1994 #sequence_revision 19-May-1994 #text_change 16-Aug-1996
ACCESSIONS	B48677
REFERENCE	A48677
#authors	Tassignon, J.; Brait, M.; Jamila, I.; Urbain, J.; Gottlieb, P.; Brown, A.; Hasemann, C.A.; Capra, J.D.; Meek, K.
#journal	Proc. Natl. Acad. Sci. U.S.A. (1993) 90:9508-9512
#title	Molecular characterization of monoclonal CRI-A-positive anti-arsonate antibodies derived from idiotype-negative mice bearing a light chain polymorphism.



```

SUMMARY      #length 107 #molecular-weight 11859 #checksum 8401
Query Match      100.0%; Score 51; DB 7; Length 107;
Best Local Similarity 100.0%; Pred. No. 2.38e-01;
Matches      7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db      50 ytsrlhs 56
      |||||
QY      1 YTSRLHS 7

RESULT      7
ENTRY
TITLE      A28044 #type complete
ORGANISM    Ig kappa chain V region (22B5) - mouse
#formal_name Mus musculus #common_name house mouse
DATE      19-May-1989 #sequence_revision 19-May-1989 #text_change
      16-Aug-1996
ACCESSIONS  A28044
REFERENCE    A28044 #molecule_type mRNA
#authors     Meek, K.; Sanz, I.; Rathbun, G.; Nisonoff, A.; Capra, J.D.
#journal     Proc. Natl. Acad. Sci. U.S.A. (1987) 84:6244-6248
#title       Identity of the V-kappa-10-Ars-A gene segments of the A/J and
      BALB/c strains.
#cross-references MUID:87317629
#accession   A28044
##residues   1-107 #label MEK
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology
KEYWORDS      heterotetramer; immunoglobulin
SUMMARY      #length 107 #molecular-weight 11832 #checksum 7241
Query Match      100.0%; Score 51; DB 7; Length 107;
Best Local Similarity 100.0%; Pred. No. 2.38e-01;
Matches      7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db      50 ytsrlhs 56
      |||||
QY      1 YTSRLHS 7

RESULT      8
ENTRY
TITLE      C48677 #type fragment
ORGANISM    Ig light chain V-J region (419.1) - mouse (fragment)
#formal_name Mus musculus #common_name house mouse
DATE      19-May-1994 #sequence_revision 19-May-1994 #text_change
      16-Aug-1996
ACCESSIONS  C48677
REFERENCE    C48677
#authors     Tassignon, J.; Brait, M.; Jamila, I.; Urbain, J.; Gottlieb,
      P.; Brown, A.; Hasemann, C.A.; Capra, J.D.; Meek, K.
#journal     Proc. Natl. Acad. Sci. U.S.A. (1993) 90:9508-9512
#title       Molecular characterization of monoclonal CRI-A-positive
      anti-arsonate antibodies derived from idiotype-negative
      mice bearing a light chain polymorphism.
#accession   C48677
##status     preliminary; not compared with conceptual translation
##molecule_type mRNA
##residues   1-107 #label TAS
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology
KEYWORDS      immunoglobulin
SUMMARY      #length 107 #checksum 7315
Query Match      100.0%; Score 51; DB 7; Length 107;
Best Local Similarity 100.0%; Pred. No. 2.38e-01;
Matches      7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db      50 ytsrlhs 56
      |||||
QY      1 YTSRLHS 7

RESULT      9
ENTRY
TITLE      D48677 #type fragment
ORGANISM    Ig kappa chain V region (22B5) - mouse
#formal_name Mus musculus #common_name house mouse
DATE      19-May-1989 #sequence_revision 19-May-1989 #text_change
      16-Aug-1996
ACCESSIONS  D48677
REFERENCE    D48677
#authors     Tassignon, J.; Brait, M.; Jamila, I.; Urbain, J.; Gottlieb,
      P.; Brown, A.; Hasemann, C.A.; Capra, J.D.; Meek, K.
#journal     Proc. Natl. Acad. Sci. U.S.A. (1993) 90:9508-9512
#title       Molecular characterization of monoclonal CRI-A-positive
      anti-arsonate antibodies derived from idiotype-negative
      mice bearing a light chain polymorphism.
#accession   D48677
##status     preliminary; not compared with conceptual translation
##molecule_type mRNA
##residues   1-107 #label TAS
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology
KEYWORDS      immunoglobulin
SUMMARY      #length 107 #checksum 7315
Query Match      100.0%; Score 51; DB 7; Length 107;
Best Local Similarity 100.0%; Pred. No. 2.38e-01;
Matches      7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db      50 ytsrlhs 56
      |||||
QY      1 YTSRLHS 7

RESULT      11
ENTRY
TITLE      S69903 #type complete
ORGANISM    Ig kappa light chain (clone KL2.29) - mouse
#formal_name Mus musculus #common_name house mouse
DATE      14-Feb-1997 #sequence_revision 13-Mar-1997 #text_change
      09-May-1997
ACCESSIONS  S69903
REFERENCE    S69903
#authors     Wysocki, L.J.; Creardon, G.; Lehmann, K.R.; Cambier, J.C.
#journal     Immunology (1992) 75:116-121
#title       B-cell proliferation initiated by Ia cross-linking and
      sustained by interleukins leads to class switching but not
      somatic mutation in vitro.
#accession   S69903

```

```

TITLE      Ig light chain V-J region (24) - mouse (fragment)
ORGANISM    #formal_name Mus musculus #common_name house mouse
DATE      19-May-1994 #sequence_revision 19-May-1994 #text_change
      16-Aug-1996
ACCESSIONS  D48677
REFERENCE    D48677
#authors     Tassignon, J.; Brait, M.; Jamila, I.; Urbain, J.; Gottlieb,
      P.; Brown, A.; Hasemann, C.A.; Capra, J.D.; Meek, K.
#journal     Proc. Natl. Acad. Sci. U.S.A. (1993) 90:9508-9512
#title       Molecular characterization of monoclonal CRI-A-positive
      anti-arsonate antibodies derived from idiotype-negative
      mice bearing a light chain polymorphism.
#accession   D48677
##status     preliminary; not compared with conceptual translation
##molecule_type mRNA
##residues   1-107 #label TAS
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology
KEYWORDS      immunoglobulin
SUMMARY      #length 107 #checksum 7155
Query Match      100.0%; Score 51; DB 7; Length 107;
Best Local Similarity 100.0%; Pred. No. 2.38e-01;
Matches      7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db      50 ytsrlhs 56
      |||||
QY      1 YTSRLHS 7

RESULT      10
ENTRY
TITLE      S69902 #type complete
ORGANISM    Ig kappa light chain (clone KL2.28) - mouse
#formal_name Mus musculus #common_name house mouse
DATE      14-Feb-1997 #sequence_revision 13-Mar-1997 #text_change
      09-May-1997
ACCESSIONS  S69902
REFERENCE    S69902
#authors     Wysocki, L.J.; Creardon, G.; Lehmann, K.R.; Cambier, J.C.
#journal     Immunology (1992) 75:116-121
#title       B-cell proliferation initiated by Ia cross-linking and
      sustained by interleukins leads to class switching but not
      somatic mutation in vitro.
#accession   S69902
##status     preliminary; translation not shown
##molecule_type DNA
##residues   1-108 #label WYS
#cross-references EMBL:X55043
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology
SUMMARY      #length 108 #molecular-weight 11895 #checksum 1228
Query Match      100.0%; Score 51; DB 7; Length 108;
Best Local Similarity 100.0%; Pred. No. 2.38e-01;
Matches      7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db      50 ytsrlhs 56
      |||||
QY      1 YTSRLHS 7

RESULT      11
ENTRY
TITLE      S69903 #type complete
ORGANISM    Ig kappa light chain (clone KL2.29) - mouse
#formal_name Mus musculus #common_name house mouse
DATE      14-Feb-1997 #sequence_revision 13-Mar-1997 #text_change
      09-May-1997
ACCESSIONS  S69903
REFERENCE    S69903
#authors     Wysocki, L.J.; Creardon, G.; Lehmann, K.R.; Cambier, J.C.
#journal     Immunology (1992) 75:116-121
#title       B-cell proliferation initiated by Ia cross-linking and
      sustained by interleukins leads to class switching but not
      somatic mutation in vitro.
#accession   S69903

```





```

Db 50 ytsrlhs 56
Qy 1 YTSRLHS 7

RESULT 16
ENTRY
TITLE Ig light chain precursor V region (anti-CD3) - mouse (fragment)
ORGANISM #formal_name Mus musculus #common_name house mouse
DATE 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change
16-Aug-1996
ACCESSIONS PH0888
REFERENCE #type fragment
#authors Shalaby, M.R.; Shepard, H.M.; Presta, L.; Rodrigues, M.L.;
Beverley, P.C.L.; Teldmann, M.; Carter, P.
#journal J. Exp. Med. (1992) 175:217-225
#title Development of humanized bispecific antibodies reactive with
cytotoxic lymphocytes and tumor cells overexpressing the
HER2 protooncogene.
#cross-references MUID:92113462
#accession PH0888
#molecule_type mRNA
#residues 1-109 #label SHA
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology
KEYWORDS immunoglobulin
SUMMARY #length 109 #checksum 4838

Query Match 100.0%; Score 51; DB 7; Length 109;
Best Local Similarity 100.0%; Pred. No. 2.38e-01;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 50 ytsrlhs 56
Qy 1 YTSRLHS 7

RESULT 17
ENTRY
TITLE Ig kappa chain V region - mouse
ORGANISM #formal_name Mus musculus #common_name house mouse
DATE 02-May-1994 #sequence_revision 18-Nov-1994 #text_change
16-Aug-1996
ACCESSIONS A53276
REFERENCE #type complete
#authors Kim, S.O.; Sanz, I.; Williams, C.; Capra, J.D.; Gottlieb,
P.D.
#journal Immunogenetics (1991) 34:231-241
#title Polymorphism in V kappa 10 genes encoding L chains of
antibodies bearing the Ars-A and A48 cross-reactive
idiotypes.
#cross-references MUID:92010099
#accession A53276
#status preliminary
#molecule_type DNA
#residues 1-115 #label KIM
#cross-references NCBN:62777; NCBIP:62780
#experimental_source AJ1 strain
#note sequence extracted from NCB1 backbone
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology
KEYWORDS heterotrimer; immunoglobulin
SUMMARY #length 115 #molecular-weight 12681 #checksum 7342

Query Match 100.0%; Score 51; DB 7; Length 115;
Best Local Similarity 100.0%; Pred. No. 2.38e-01;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 70 ytsrlhs 76
Qy 1 YTSRLHS 7

RESULT 18
ENTRY
TITLE Ig light chain precursor V region (anti-phenyloxazolone,
18C10) - mouse (fragment)
ORGANISM #formal_name Mus musculus #common_name house mouse
DATE 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change
06-Dec-1996
ACCESSIONS JL0080
REFERENCE #type fragment
#authors Kaartinen, M.; Rocca-Serra, J.; Maekela, O.
#journal Mol. Immunol. (1988) 25:859-865
#title Combinatorial association of V genes: one VH gene codes for
three non-cross-reactive monoclonal antibodies each
specific for a different antigen (phoxazolone, NP or GAT).
#cross-references MUID:8906973
#accession JL0080
#molecule_type mRNA
#residues 1-115 #label KAA
#note the authors translated the codon AGG for residue 30 as
Ser
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology
KEYWORDS immunoglobulin
FEATURE 1-6
#domain signal sequence (fragment) #status predicted
#label SIG\
7-115 #product Ig light chain #status predicted #label MAT\
30-40 #region complementarity-determining 1\
56-62 #region complementarity-determining 2
SUMMARY #length 115 #checksum 7375

Query Match 100.0%; Score 51; DB 7; Length 115;
Best Local Similarity 100.0%; Pred. No. 2.38e-01;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 56 ytsrlhs 62
Qy 1 YTSRLHS 7

RESULT 19
ENTRY
TITLE Ig kappa chain precursor V region (AC-1001) - mouse
ORGANISM #formal_name Mus musculus #common_name house mouse
DATE 31-Dec-1988 #sequence_revision 31-Dec-1988 #text_change
16-Aug-1996
ACCESSIONS A29380
REFERENCE #type fragment
#authors Chen, H.T.; Kabat, E.A.; Lundblad, A.; Ratcliffe, R.M.
#journal J. Biol. Chem. (1987) 262:13579-13583
#title Nucleotide and translated amino acid sequences of cDNA coding
for the variable regions of the light and heavy chains of
mouse hybridoma antibodies to blood group A and B
substances.
#cross-references MUID:88007582
#accession A29380
#molecule_type mRNA
#residues 1-122 #label CHE
#note the authors translated the codon TTC for residue 1 as
Leu
CLASSIFICATION #superfamily immunoglobulin V region; immunoglobulin homology
KEYWORDS heterotrimer; immunoglobulin
SUMMARY #length 122 #checksum 9064

Query Match 100.0%; Score 51; DB 7; Length 122;
Best Local Similarity 100.0%; Pred. No. 2.38e-01;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 64 ytsrlhs 70
Qy 1 YTSRLHS 7

RESULT 20
ENTRY
TITLE PH1224 #type fragment

```

Search completed: Tue Mar 3 14:32:31 1998  
Job time : 16 secs.

\*\*\*\*\*

W P E L E H (TM)

\*\*\*\*\*

Release 2.1D John F. Collins, Biocomputing Research Unit.  
Copyright (c) 1993, 1994, 1995 University of Edinburgh, U.K.  
Distribution rights by IntelliGenetics, Inc.

Mpsrch\_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Tue Mar 3 11:20:10 1998; MasPar time 1.99 Seconds  
Tabular output not generated. 74.523 Million cell updates/sec

Title: >US-08-137-117D-118  
Description: (1-7) from US08137117D.pep  
Perfect Score: 51  
Sequence: 1 YTSRLHS 7

Scoring table: PAM 150  
Gap 15

Searched: 59021 seqs, 21210388 residues

Post-processing: Minimum Match 0%  
Listing first 45 summaries

Database: swiss-prot34  
1:part1 2:part2 3:part3 4:part4 5:part5 6:part6 7:part7  
8:part8 9:part9 10:part10 11:part11

Statistics: Mean 21.579; Variance 20.158; scale 1.070

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	51	100.0	108	5	KVSM_MOUSE	IG KAPPA CHAIN V-V RE 3.04e-02
2	51	100.0	108	5	KVSN_MOUSE	IG KAPPA CHAIN V-V RE 3.04e-02
3	51	100.0	108	5	KVSL_MOUSE	IG KAPPA CHAIN V-V RE 3.04e-02
4	51	100.0	108	5	KVSK_MOUSE	IG KAPPA CHAIN V-V RE 3.04e-02
5	51	100.0	108	5	KVSO_MOUSE	IG KAPPA CHAIN V-V RE 3.04e-02
6	51	100.0	108	5	KVSU_MOUSE	IG KAPPA CHAIN V-V RE 3.04e-02
7	48	94.1	861	7	POLG_FMDV3	GENOME POLYPROTEIN (C 2.05e-01
8	48	94.1	2332	7	POLG_FMDV0	GENOME POLYPROTEIN (N 2.05e-01
9	48	94.1	2332	7	POLG_FMDV4	GENOME POLYPROTEIN (N 2.05e-01
10	48	94.1	2333	7	POLG_FMDV1	GENOME POLYPROTEIN (N 2.05e-01
11	45	88.2	2336	6	POLG_FMDV2	GENOME POLYPROTEIN (N 1.28e+00
12	44	86.3	178	6	MYCB_RAT	B-MYC TRANSFORMING PR 2.32e+00
13	44	86.3	502	5	K2C8_XENLA	KERATIN, TYPE II CYTO 2.32e+00
14	43	84.3	942	3	KDGD_HUMAN	DIACYLGLYCEROL KINASE 4.14e+00
15	42	82.4	334	3	FEUB_BACSU	IRON-UTAKE SYSTEM PR 7.32e+00
16	42	82.4	552	10	VNS1_EHDV2	NONSTRUCTURAL PROTEIN 7.32e+00
17	42	82.4	721	11	YJ11_YEAST	HYPOTHETICAL 84.0 KD 7.32e+00
18	42	82.4	787	11	YF13_YEAST	HYPOTHETICAL 90.9 KD 7.32e+00
19	42	82.4	960	3	FGD1_MOUSE	PUTATIVE RHO/RAC GUAN 7.32e+00
20	42	82.4	961	3	FGD1_HUMAN	PUTATIVE RHO/RAC GUAN 7.32e+00
21	41	80.4	108	5	KV5J_MOUSE	IG KAPPA CHAIN V-V RE 1.28e+01
22	41	80.4	226	6	MYOG_COTJA	MYOGENIC FACTOR 2 (MY 1.28e+01

23	41	80.4	348	1	AROH_ECOLI	PHOSPHO-2-DEHYDRO-3-D	1.28e+01
24	41	80.4	425	4	FTSA_HAEIN	CELL DIVISION PROTEIN	1.28e+01
25	41	80.4	665	7	NUC2_SCHPO	NUCLEAR SCAFFOLD-LIKE	1.28e+01
26	40	78.4	210	7	ORAS_DROME	PUTATIVE ODORANT-BIND	2.21e+01
27	40	78.4	323	9	SOPB_ECOLI	SOPB PROTEIN (PROTEIN	2.21e+01
28	40	78.4	536	3	DIT1_YEAST	SPORE WALL MATURATION	2.21e+01
29	40	78.4	593	8	PTN9_HUMAN	PROTEIN-TYROSINE PHOS	2.21e+01
30	40	78.4	603	7	PRIM_BACSU	DNA PRIMASE (EC 2.7.7	2.21e+01
31	40	78.4	706	1	BCL6_HUMAN	B-CELL LYMPHOMA 6 PRO	2.21e+01
32	40	78.4	707	1	BCL6_MOUSE	B-CELL LYMPHOMA 6 PRO	2.21e+01
33	40	78.4	798	4	HEPA_HCMVA	DNA HELICASE/PRIMASE	2.21e+01
34	40	78.4	1249	9	TPP2_HUMAN	TRIPETIDYL-PEPTIDASE	2.21e+01
35	40	78.4	1942	11	YY05_HUMAN	HYPOTHETICAL MYELOID	2.21e+01
36	39	76.5	152	10	VE1_FPVL	REPLICATION METHYL OXI	3.77e+01
37	39	76.5	309	3	ER25_YEAST	C-4 STEROL METHYL OXI	3.77e+01
38	39	76.5	323	8	R8SC_BACSU	RIBOSE TRANSPORT SYST	3.77e+01
39	39	76.5	335	8	RPOA_FINH	RIBOSE DIRECTED RNA POLY	3.77e+01
40	39	76.5	805	10	UBP5_YEAST	UBIQUITIN CARBOXYL-TE	3.77e+01
41	39	76.5	839	6	NI96_YEAST	96 KD NUCLEOPORIN-INT	3.77e+01
42	39	76.5	932	10	VGLB_HSVBC	GLYCOPROTEIN I PRECUR	3.77e+01
43	39	76.5	966	10	VIA_BMV	1A PROTEIN (CONTAINS	3.77e+01
44	39	76.5	1639	6	LMG1_DROME	LAMININ GAMMA-1 CHAIN	3.77e+01
45	39	76.5	2505	3	FAS_RAT	FATTY ACID SYNTHASE (	3.77e+01

ALIGNMENTS

RESULT	1	STANDARD;	PRT;	108 AA.
ID	KVSM_MOUSE			
AC	P01646;			
DT	21-JUL-1986 (REL. 01, CREATED)			
DT	21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)			
DT	01-OCT-1993 (REL. 27, LAST ANNOTATION UPDATE)			
DE	IG KAPPA CHAIN V-V REGION (HP 123E6).			
OS	MUS MUSCULUS (MOUSE).			
OC	EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;			
CC	EUTHERIA; RODENTIA.			
RN	[1]			
RP	SEQUENCE.			
RC	STRAIN-A/J;			
RA	MEDLINE; 82150934.			
RA	SIEGELMAN M., CAPRA J.D.;			
RL	PROC. NATL. ACAD. SCI. U.S.A. 78:7679-7683(1981).			
CC	-I- ANTI-ARSONATE HYBRIDOMA PROTEIN.			
DR	PIR: A01927; KVMASR.			
DR	HSSP; P01607; 1FAI			
KW	IMMUNOGLOBULIN V REGION; ANTIARSONATE ANTIBODY.			
FT	DOMAIN 1 23			
FT	DOMAIN 24 34			
FT	DOMAIN 35 49			
FT	DOMAIN 50 56			
FT	DOMAIN 57 88			
FT	DOMAIN 89 97			
FT	DOMAIN 98 108			
FT	DISULFID 23 88			
FT	NON TER 108 108			
SQ	SEQUENCE 108 AA; 11989 MW; 2388BB67 CRC32;			
Query Match 100.0%; Score 51; DB 5; Length 108;				
Best Local Similarity 100.0%; Pred. No. 3.04e-02;				
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;				
Db	50 ytsrlhs 56			
Qy	1 YTSRLHS 7			
RESULT	2	STANDARD;	PRT;	108 AA.
ID	KVSN_MOUSE			
AC	P01647;			
DT	21-JUL-1986 (REL. 01, CREATED)			
DT	21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)			
DT	01-OCT-1993 (REL. 27, LAST ANNOTATION UPDATE)			

DE IG KAPPA CHAIN V-V REGION (HP 124E1).  
OS MUS MUSCULUS (MOUSE).  
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
OC EUTHERIA; RODENTIA.  
RN [1]  
RP STRAIN-A/J;  
RC MEDLINE; 82150934.  
RX SIEGELMAN M., CAPRA J.D.;  
RA PROC. NATL. ACAD. SCI. U.S.A. 78:7679-7683(1981).  
RL -I- ANTI-ARSONATE HYBRIDOMA PROTEIN.  
CC PIR; A01927; KVSAR.  
DR HSP; P01607; 1FAI.  
KW IMMUNOGLOBULIN V REGION; ANTIARSONATE ANTIBODY.  
FT DOMAIN 1 23  
FT DOMAIN 24 34  
FT DOMAIN 35 49  
FT DOMAIN 50 56  
FT DOMAIN 57 88  
FT DOMAIN 89 97  
FT DOMAIN 98 108  
FT DISULFID 23 88  
FT NON\_TER 108 108  
SQ SEQUENCE 108 AA; 11965 MW; 84754175 CRC32;

Query Match 100.0%; Score 51; DB 5; Length 108;

Best Local Similarity 100.0%; Pred. No. 3.04e-02;

Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 50 ytsrlhs 56  
QY 1 YTSRLHS 7

RESULT 3  
ID KV5L\_MOUSE STANDARD; PRT; 108 AA.  
AC P01645;  
DT 21-JUL-1986 (REL. 01, CREATED)  
DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
DT 01-OCT-1993 (REL. 27, LAST ANNOTATION UPDATE)  
DE IG KAPPA CHAIN V-V REGION (HP 93G7).  
OS MUS MUSCULUS (MOUSE).  
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
OC EUTHERIA; RODENTIA.  
RN [1]  
RP STRAIN-A/J;  
RC MEDLINE; 82150934.  
RX SIEGELMAN M., CAPRA J.D.;  
RA PROC. NATL. ACAD. SCI. U.S.A. 78:7679-7683(1981).  
RL -I- ANTI-ARSONATE HYBRIDOMA PROTEIN.  
CC PIR; A01927; KVSAR.  
DR HSP; P01607; 1FAI.  
KW IMMUNOGLOBULIN V REGION; ANTIARSONATE ANTIBODY.  
FT DOMAIN 1 23  
FT DOMAIN 24 34  
FT DOMAIN 35 49  
FT DOMAIN 50 56  
FT DOMAIN 57 88  
FT DOMAIN 89 97  
FT DOMAIN 98 108  
FT DISULFID 23 88  
FT NON\_TER 108 108  
SQ SEQUENCE 108 AA; 11954 MW; A203E130 CRC32;

Query Match 100.0%; Score 51; DB 5; Length 108;

Best Local Similarity 100.0%; Pred. No. 3.04e-02;

Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 50 ytsrlhs 56  
QY 1 YTSRLHS 7

RESULT 4  
ID KV5K\_MOUSE STANDARD; PRT; 108 AA.  
AC P01644;  
DT 21-JUL-1986 (REL. 01, CREATED)  
DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
DT 01-OCT-1993 (REL. 27, LAST ANNOTATION UPDATE)  
DE IG KAPPA CHAIN V-V REGION (HP R16.7).  
OS MUS MUSCULUS (MOUSE).  
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
OC EUTHERIA; RODENTIA.  
RN [1]  
RP STRAIN-A/J;  
RC MEDLINE; 82150934.  
RX SIEGELMAN M., CAPRA J.D.;  
RA PROC. NATL. ACAD. SCI. U.S.A. 78:7679-7683(1981).  
RL -I- ANTI-ARSONATE HYBRIDOMA PROTEIN.  
CC PIR; A01927; KVSAR.  
DR HSP; P01607; 1FAI.  
KW IMMUNOGLOBULIN V REGION; ANTIARSONATE ANTIBODY.  
FT DOMAIN 1 23  
FT DOMAIN 24 34  
FT DOMAIN 35 49  
FT DOMAIN 50 56  
FT DOMAIN 57 88  
FT DOMAIN 89 97  
FT DOMAIN 98 108  
FT DISULFID 23 88  
FT NON\_TER 108 108  
SQ SEQUENCE 108 AA; 11910 MW; 64A62905 CRC32;

Query Match 100.0%; Score 51; DB 5; Length 108;

Best Local Similarity 100.0%; Pred. No. 3.04e-02;

Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 50 ytsrlhs 56  
QY 1 YTSRLHS 7

RESULT 5  
ID KV5O\_MOUSE STANDARD; PRT; 108 AA.  
AC P01648;  
DT 21-JUL-1986 (REL. 01, CREATED)  
DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
DT 01-OCT-1993 (REL. 27, LAST ANNOTATION UPDATE)  
DE IG KAPPA CHAIN V-V REGION (HP 91A3).  
OS MUS MUSCULUS (MOUSE).  
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
OC EUTHERIA; RODENTIA.  
RN [1]  
RP STRAIN-A/J;  
RC MEDLINE; 82150934.  
RX SIEGELMAN M., CAPRA J.D.;  
RA PROC. NATL. ACAD. SCI. U.S.A. 78:7679-7683(1981).  
RL -I- ANTI-ARSONATE HYBRIDOMA PROTEIN.  
CC PIR; A01927; KVSAR.  
DR HSP; P01607; 1FAI.  
KW IMMUNOGLOBULIN V REGION; ANTIARSONATE ANTIBODY.  
FT DOMAIN 1 23  
FT DOMAIN 24 34  
FT DOMAIN 35 49  
FT DOMAIN 50 56  
FT DOMAIN 57 88  
FT DOMAIN 89 97  
FT DOMAIN 98 108  
FT DISULFID 23 88  
FT NON\_TER 108 108  
SQ SEQUENCE 108 AA; 11961 MW; 5B067780 CRC32;

Query Match

100.0%; Score 51; DB 5; Length 108;

Best Local Similarity 100.0%; Pred. No. 3.04e-02;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 50 ytsrlhs 56  
| | | | | | |  
Qy 1 YTSRLHS 7

RESULT 6  
ID KVSU\_MOUSE STANDARD; PRT; 108 AA.  
AC P04946;  
DT 13-AUG-1987 (REL. 05, LAST SEQUENCE UPDATE)  
DT 13-AUG-1987 (REL. 05, LAST SEQUENCE UPDATE)  
DT 01-OCT-1993 (REL. 27, LAST ANNOTATION UPDATE)  
DE IG KAPPA CHAIN V-V REGION (N05-89.4).  
OS MUS MUSCULUS (MOUSE).  
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
OC EUTHERIA; RODENTIA.  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE: 83271467.  
RA KAARTINEN M., GRIFFITHS G.M., MARKHAM A.F., MILSTEIN C.;  
RL NATURE 304:320-324(1983).  
CC -1- ANTI-2-PHENYL OXAZOLONE (PHOX) ANTIBODY.  
DR EMBL: K00745; G196455; -.  
DR HSP: P01607; 1FAI.  
KW IMMUNOGLOBULIN V REGION; HYBRIDOMA.  
FT DOMAIN 1 23 FRAMEWORK 1.  
FT DOMAIN 24 34 COMPLEMENTARITY-DETERMINING 1.  
FT DOMAIN 35 49 FRAMEWORK 2.  
FT DOMAIN 50 56 COMPLEMENTARITY-DETERMINING 2.  
FT DOMAIN 57 88 FRAMEWORK 3.  
FT DOMAIN 89 97 COMPLEMENTARITY-DETERMINING 3.  
FT DOMAIN 98 107 FRAMEWORK 4.  
FT DISULFID 23 88 BY SIMILARITY.  
FT NON\_TER 108 108  
SQ SEQUENCE 108 AA; 11866 MW; D396FI42 CRC32;

Query Match 100.0%; Score 51; DB 5; Length 108;  
Best Local Similarity 100.0%; Pred. No. 3.04e-02;  
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 50 ytsrlhs 56  
| | | | | | |  
Qy 1 YTSRLHS 7

RESULT 7  
ID POLG\_FMDVS STANDARD; PRT; 861 AA.  
AC P03311;  
DT 21-JUL-1986 (REL. 01, CREATED)  
DT 01-NOV-1988 (REL. 09, LAST SEQUENCE UPDATE)  
DT 01-NOV-1995 (REL. 32, LAST ANNOTATION UPDATE)  
DE GENOME POLYPROTEIN (COAT PROTEINS VP3, VP1; CORE PROTEIN P52, PROTEASE  
DE EC 3.4.22.-); RNA-DIRECTED RNA POLYMERASE (EC 2.7.7.48)) (FRAGMENTS).  
OS FOOT-AND-MOUTH DISEASE VIRUS (STRAIN C1-SANTA PAU [C-58]) (APHTHOVIRUS  
C).  
OC VIRIDAE; SS-RNA NONENVELOPED VIRUSES; PICORNAVIRIDAE; APHTHOVIRUSES.  
RN [1]  
RP SEQUENCE OF 1-332 FROM N.A.  
RX MEDLINE: 84005890.  
RA VILLANUEVA N., DAVILA M., ORTIN J., DOMINGO E.;  
RL GENE 23:185-194(1983).  
RN [2]  
RP SEQUENCE OF 333-861 FROM N.A.  
RX MEDLINE: 85286357.  
RA MARTINEZ-SALAS E., ORTIN J., DOMINGO E.;  
RL GENE 35:55-61(1985).  
CC -1- PTM: SPECIFIC ENZYMAIC CLEAVAGES IN VIVO YIELD MATURE PROTEINS.  
CC -1- SUBUNIT: THE VIRUS CAPSID IS COMPOSED OF 60 ICOSAHERAL UNITS,  
CC EACH OF WHICH IS COMPOSED OF ONE COPY EACH OF PROTEINS VP1, VP2,  
CC VP3, AND VP4.  
CC -1- SIMILARITY: THE PROTEASE BELONGS TO PEPTIDASE FAMILY C3.

DR EMBL: M11027; G210477; -.  
DR PIR: A03913; A03913.  
DR PIR: A24031; A24031.  
DR HSP: P13899; 1FMD.  
KW POLYPROTEIN; COAT PROTEIN; CORE PROTEIN; RNA-DIRECTED RNA POLYMERASE;  
KW HYDROLASE; THIOL PROTEASE.  
FT NON\_TER 1 1  
FT CHAIN <1 46 COAT PROTEIN VP3.  
FT CHAIN 47 254 COAT PROTEIN VP1.  
FT CHAIN 255 332 COAT PROTEIN P52.  
FT NON\_CONS 332 333  
FT CHAIN <333 391 PROTEASE.  
FT CHAIN 392 861 RNA-DEPENDENT RNA POLYMERASE.  
SQ SEQUENCE 861 AA; 95554 MW; 1C8C4098 CRC32;

Query Match 94.1%; Score 48; DB 7; Length 861;  
Best Local Similarity 85.7%; Pred. No. 2.05e-01;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 472 ytsrlhs 478  
| | | | | | |  
Qy 1 YTSRLHS 7

RESULT 8  
ID POLG\_FMDVO STANDARD; PRT; 2332 AA.  
AC P03305;  
DT 21-JUL-1986 (REL. 01, CREATED)  
DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
DT 01-NOV-1995 (REL. 32, LAST ANNOTATION UPDATE)  
DE GENOME POLYPROTEIN (NONSTRUCTURAL PROTEIN P20A; COAT PROTEINS VP1 TO  
DE VP4; CORE PROTEINS P12, P34, P14; GENOME-LINKED PROTEIN VPG; PROTEASE  
DE EC 3.4.22.-); RNA-DIRECTED RNA POLYMERASE (EC 2.7.7.48)).  
OS FOOT-AND-MOUTH DISEASE VIRUS (STRAINS OIK AND OIBES) (APHTHOVIRUS O).  
OC VIRIDAE; SS-RNA NONENVELOPED VIRUSES; PICORNAVIRIDAE; APHTHOVIRUSES.  
RN [1]  
RP SEQUENCE FROM N.A.  
RX STRAIN-OIK;  
RX MEDLINE: 84297249.  
RA FORSS S., STREBEL K., BECK E., SCHALLER H.;  
RL NUCLEIC ACIDS RES. 12:6587-6601(1984).  
RN [2]  
RP SEQUENCE FROM N.A.  
RX STRAIN-OIBFS;  
RX MEDLINE: 83143292.  
RA MAKOFF A.J., PAYNTER C.A., ROWLANDS D.J., BOOTHROYD J.C.;  
RL NUCLEIC ACIDS RES. 10:8285-8295(1982).  
RN [3]  
RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS).  
RX MEDLINE: 89143740.  
RA ACHARYA R., FRY E., STUART D., FOX G., ROWLANDS D., BROWN F.;  
RL NATURE 337:709-716(1989).  
CC -1- THE STRAIN OIK SEQUENCE IS SHOWN.  
CC -1- PTM: SPECIFIC ENZYMAIC CLEAVAGES IN VIVO YIELD MATURE PROTEINS.  
CC -1- THE COAT PROTEIN VP1 CONTAINS THE MAIN ANTIGENIC DETERMINANTS OF  
CC THE VIRION; THEREFORE, CHANGES IN ITS SEQUENCE MUST BE  
CC RESPONSIBLE FOR THE HIGH ANTIGENIC VARIABILITY OF THE VIRUS.  
CC -1- SUBUNIT: THE VIRUS CAPSID IS COMPOSED OF 60 ICOSAHERAL UNITS.  
CC EACH OF WHICH IS COMPOSED OF ONE COPY EACH OF PROTEINS VP1, VP2,  
CC VP3, AND VP4.  
CC -1- SIMILARITY: THE PROTEASE BELONGS TO PEPTIDASE FAMILY C3.  
DR EMBL: X00871; G61078; -.  
DR EMBL: J02185; G210436; -.  
DR PIR: A03907; GNNYF.  
DR HSP: P08544; 1BBT.  
KW POLYPROTEIN; COAT PROTEIN; CORE PROTEIN; RNA-DIRECTED RNA POLYMERASE;  
KW HYDROLASE; THIOL PROTEASE; MYRISTYLATION.  
FT CHAIN 1 201 NONSTRUCTURAL PROTEIN P20A.  
FT CHAIN 202 286 COAT PROTEIN VP4.  
FT CHAIN 287 504 COAT PROTEIN VP2.  
FT CHAIN 505 724 COAT PROTEIN VP3.  
FT CHAIN 725 937 COAT PROTEIN VP1.  
FT CHAIN 938 1107 CORE PROTEIN P12.

FT CHAIN 1108 1425 CORE PROTEIN P34.  
FT CHAIN 1426 1578 CORE PROTEIN P14.  
FT CHAIN 1579 1649 GENOME-LINKED PROTEIN VPG.  
FT CHAIN 1649 1662 PROTEASE.  
FT CHAIN 1863 2332 RNA-DIRECTED RNA POLYMERASE.  
FT LIPID 202 202 MYRISTATE.  
FT DISULFID 511 511 INTERCHAIN (IN VP3 DIMER).  
FT DISULFID 406 858 IN VP2-VP1 DIMER.  
FT VARIANT 780 780 I -> V (IN STRAIN OIBFS).  
FT VARIANT 808 808 G -> R (IN STRAIN OIBFS).  
FT VARIANT 861 861 N -> S (IN STRAIN OIBFS).  
SQ SEQUENCE 2332 AA; 258924 MW; 251F5647 CRC32;

Query Match 94.1%; Score 48; DB 7; Length 2332;

Best Local Similarity 85.7%; Pred. No. 2.05e-01; Indels 0; Gaps 0;

Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 1943 yasrlhs 1949

QY 1 YTSRLHS 7  
|:|||||

RESULT 9  
ID POLG\_FMDVA STANDARD; PRT; 2332 AA.

DT 21-JUL-1986 (REL. 01, CREATED)  
DT 01-JAN-1988 (REL. 06, LAST SEQUENCE UPDATE)  
DT 01-NOV-1995 (REL. 32, LAST SEQUENCE UPDATE)  
DE GENOME POLYPROTEIN (NONSTRUCTURAL PROTEIN P20A; COAT PROTEINS VP1 TO  
DE VP4; CORE PROTEINS X, P14, P41, P19; GENOME-LINKED PROTEINS VPG1 TO  
DE VP3; PICORNAIN 3C (EC 3.4.22.28) (PROTEASE 3C) (P3C); RNA-DIRECTED  
DE RNA POLYMERASE (EC 2.7.7.48)).  
OS FOOT-AND-MOUTH DISEASE VIRUS (STRAIN A12) (APHTHOVIRUS A).  
OC VIRIDAE; SS-RNA NONENVELOPED VIRUSES; PICORNAVIRIDAE; APHTHOVIRUSES.  
RN [1]  
RX MEDLINE: 85211015.  
RA ROBERTSON B.H., GRUBMAN M.J., WEDDELL G.N., MOORE D.M., WELSH J.D.,  
RA FISCHER T., DOWENKO D.J., YANSURA D.G., SMALL B., KLEID D.G.;  
RA J. VIROL. 54:651-660(1985).  
[2]  
RN SEQUENCE OF 1863-2332 FROM N.A.  
RX MEDLINE: 83225613.  
RA ROBERTSON B.H., MORGAN D.O., MOORE D.M., GRUBMAN M.J., CARD J.,  
RA FISCHER T., WEDDELL G.N., DOWENKO D.J., YANSURA D.G.;  
RA VIROLOGY 126:614-623(1983).  
[3]  
RN SEQUENCE OF 715-955 FROM N.A.  
RX MEDLINE: 82061853.  
RA KLEID D.G., YANSURA D.G., SMALL B., DOWENKO D.J., MOORE D.M.,  
RA GRUBMAN M.J., MCKERCHER P.D., MORGAN D.O., ROBERTSON B.H.,  
RA BACHRACH H.L.;  
RA SCIENCE 214:1125-1129(1981).  
CC -1- PTM: SPECIFIC ENZYMOLOGICAL CLEAVAGES IN VIVO YIELD MATURE PROTEINS.  
CC -1- SUBUNIT: THE VIRUS CAPSID IS COMPOSED OF 60 ICOSAEDRAL UNITS,  
CC EACH OF WHICH IS COMPOSED OF ONE COPY EACH OF PROTEINS VP1, VP2,  
CC VP3, AND VP4.  
CC -1- SIMILARITY: THE PROTEASE BELONGS TO PEPTIDASE FAMILY C3.

DR EMBL: M10975; G210307; -.  
DR EMBL: M10975; E807; -.  
DR EMBL: J02187; G210548; -.  
DR PIR: A25794; GNNY4F.  
DR HSP: P08544; 1BBT.  
KW POLYPROTEIN; COAT PROTEIN; CORE PROTEIN; RNA-DIRECTED RNA POLYMERASE;  
KW HYDROLASE; THIOL PROTEASE; MYRISTYLATION.  
FT CHAIN 1 200 NONSTRUCTURAL PROTEIN P20A.  
FT CHAIN 201 285 COAT PROTEIN VP4.  
FT CHAIN 286 503 COAT PROTEIN VP2.  
FT CHAIN 504 723 COAT PROTEIN VP3.  
FT CHAIN 724 937 COAT PROTEIN VP1.  
FT CHAIN 938 953 CORE PROTEIN X.  
FT CHAIN 954 1107 CORE PROTEIN P14.  
FT CHAIN 1108 1425 CORE PROTEIN P41.

FT CHAIN 1426 1578 CORE PROTEIN P19.  
FT CHAIN 1579 1601 GENOME-LINKED PROTEIN VPG1.  
FT CHAIN 1602 1625 GENOME-LINKED PROTEIN VPG2.  
FT CHAIN 1626 1649 GENOME-LINKED PROTEIN VPG3.  
FT CHAIN 1650 1862 PROTEASE.  
FT CHAIN 1863 2332 RNA-DIRECTED RNA POLYMERASE.  
FT LIPID 201 201 MYRISTATE.  
SQ SEQUENCE 2332 AA; 259408 MW; BDF68BA5 CRC32;

Query Match 94.1%; Score 48; DB 7; Length 2332;

Best Local Similarity 85.7%; Pred. No. 2.05e-01; Indels 0; Gaps 0;

Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 1943 yasrlhs 1949

QY 1 YTSRLHS 7  
|:|||||

RESULT 10  
ID POLG\_FMDV1 STANDARD; PRT; 2333 AA.

AC P03306;  
DT 21-JUL-1986 (REL. 01, CREATED)  
DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)  
DT 01-NOV-1995 (REL. 32, LAST SEQUENCE UPDATE)  
DE GENOME POLYPROTEIN (NONSTRUCTURAL PROTEIN P20A; COAT PROTEINS VP1 TO  
DE VP4; CORE PROTEIN P52; GENOME-LINKED PROTEINS VPG1 TO VPG3; PICORNAIN  
DE 3C (EC 3.4.22.28) (PROTEASE 3C) (P3C); RNA-DIRECTED RNA POLYMERASE  
DE (EC 2.7.7.48)).  
OS FOOT-AND-MOUTH DISEASE VIRUS (STRAIN A10-61) (APHTHOVIRUS A).  
OC VIRIDAE; SS-RNA NONENVELOPED VIRUSES; PICORNAVIRIDAE; APHTHOVIRUSES.  
RN [1]  
RX MEDLINE: 84169547.  
RA CARROLL A.R., ROWLANDS D.J., CLARKE B.E.;  
RA NUCLEIC ACIDS RES. 12:2461-2472(1984).  
[2]  
RN SEQUENCE OF 115-1048 FROM N.A.  
RX MEDLINE: 82211814.  
RA BOOTHROYD J.C., HARRIS T.J.R., ROWLANDS D.J., LOWE P.A.;  
RA GENE 17:153-161(1982).  
CC -1- PTM: SPECIFIC ENZYMOLOGICAL CLEAVAGES IN VIVO YIELD MATURE PROTEINS.  
CC -1- SUBUNIT: THE VIRUS CAPSID IS COMPOSED OF 60 ICOSAEDRAL UNITS,  
CC EACH OF WHICH IS COMPOSED OF ONE COPY EACH OF PROTEINS VP1, VP2,  
CC VP3, AND VP4.  
CC -1- SIMILARITY: THE PROTEASE BELONGS TO PEPTIDASE FAMILY C3.

DR EMBL: V01130; G61049; -.  
DR EMBL: X00429; G61064; -.  
DR PIR: A03908; GNNY2F.  
DR HSP: P08544; 1BBT.  
KW POLYPROTEIN; COAT PROTEIN; CORE PROTEIN; RNA-DIRECTED RNA POLYMERASE;  
KW HYDROLASE; THIOL PROTEASE; MYRISTYLATION.  
FT CHAIN 1 201 NONSTRUCTURAL PROTEIN P20A.  
FT CHAIN 202 286 COAT PROTEIN VP4.  
FT CHAIN 287 504 COAT PROTEIN VP2.  
FT CHAIN 505 725 COAT PROTEIN VP3.  
FT CHAIN 726 937 COAT PROTEIN VP1.  
FT CHAIN 938 1578 CORE PROTEIN P52.  
FT CHAIN 1579 1601 GENOME-LINKED PROTEIN VPG1.  
FT CHAIN 1602 1625 GENOME-LINKED PROTEIN VPG2.  
FT CHAIN 1626 1649 GENOME-LINKED PROTEIN VPG3.  
FT CHAIN 1650 1863 PROTEASE P20B.  
FT CHAIN 1864 2333 RNA-DIRECTED RNA POLYMERASE P56A.  
FT LIPID 202 202 MYRISTATE.  
FT CONFLICT 395 396 S -> C (IN REF. 2).  
FT CONFLICT 632 632 P -> L (IN REF. 2).  
SQ SEQUENCE 2333 AA; 259645 MW; 7BF32432 CRC32;

Query Match 94.1%; Score 48; DB 7; Length 2333;

Best Local Similarity 85.7%; Pred. No. 2.05e-01; Indels 0; Gaps 0;

Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 1944 yasrlhs 1950

QY 1 YTSRLHS 7  
|:|||||

QY 1 YTSRLHS 7

RESULT 11  
 ID POLG\_FMDVZ STANDARD; PRT; 2336 AA.  
 AC P49303;  
 DT 01-FEB-1996 (REL. 33, CREATED)  
 DT 01-FEB-1996 (REL. 33, LAST SEQUENCE UPDATE)  
 DT 01-FEB-1996 (REL. 33, LAST ANNOTATION UPDATE)  
 DE GENOME POLYPROTEIN (NONSTRUCTURAL PROTEIN P20A; COAT PROTEINS VP1 TO  
 DE VP4; CORE PROTEINS X, P14, P41, P19; GENOME-LINKED PROTEINS VPGL TO  
 DE VP3; PICORNAIN 3C (EC 3.4.22.28) (PROTEASE 3C) (P3C); RNA-DIRECTED  
 DE RNA POLYMERASE (EC 2.7.7.48)).  
 OS FOOT-AND-MOUTH DISEASE VIRUS (STRAIN A22/550 AZERBAIJAN 65)  
 OS (APHTHOVIRUS A.)  
 OC VIRIDAE; SS-RNA NONENVELOPED VIRUSES; PICORNAVIRIDAE; APHTHOVIRUSES.  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA SOSNOVTSSEV S.V., ONISCHEENKO A.M., PETROV N.A., KALASHNIKOVA T.I.,  
 RA MANAEVA N.V., DRYGIN V.Y., PERVOZCHIKOVA N.A., VASILENKO S.K.;  
 RL SUBMITTED (AUG-1993) TO EMBL/GENBANK/DDBJ DATA BANKS.  
 CC -!- PTM: SPECIFIC ENZYMAIC CLEAVAGES IN VIVO YIELD MATURE PROTEINS.  
 CC -!- SUBUNIT: THE VIRUS CAPSID IS COMPOSED OF 60 ICOSAEDRAL UNITS,  
 CC EACH OF WHICH IS COMPOSED OF ONE COPY EACH OF PROTEINS VP1, VP2,  
 CC VP3, AND VP4.  
 CC -!- SIMILARITY: THE PROTEASE BELONGS TO PEPTIDASE FAMILY C3.  
 DR EMBL; X74812; G357966; -  
 KW POLYPROTEIN; COAT PROTEIN; CORE PROTEIN; RNA-DIRECTED RNA POLYMERASE;  
 KW HYDROLASE; THIOLESTERASE; MYRISTYLATION.  
 FT CHAIN 1 201 NONSTRUCTURAL PROTEIN P20A.  
 FT CHAIN 202 286 COAT PROTEIN VP4.  
 FT CHAIN 287 504 COAT PROTEIN VP2.  
 FT CHAIN 505 724 COAT PROTEIN VP3.  
 FT CHAIN 725 938 COAT PROTEIN VP1.  
 FT CHAIN 939 954 COAT PROTEIN X.  
 FT CHAIN 955 1108 CORE PROTEIN P14.  
 FT CHAIN 1109 1426 CORE PROTEIN P41.  
 FT CHAIN 1427 1579 CORE PROTEIN P19.  
 FT CHAIN 1580 1602 GENOME-LINKED PROTEIN VPGL.  
 FT CHAIN 1603 1626 GENOME-LINKED PROTEIN VPGL.  
 FT CHAIN 1627 1850 GENOME-LINKED PROTEIN VPGL.  
 FT CHAIN 1651 1863 PROTEASE.  
 FT CHAIN 1864 2236 RNA-DIRECTED RNA POLYMERASE.  
 FT LIPID 202 202 MYRISTATE (BY SIMILARITY).  
 SQ SEQUENCE 2336 AA; 259982 MW; 795073B4 CRC32;

Query Match 88.2%; Score 45; DB 7; Length 2336;  
 Best Local Similarity 71.4%; Pred. No. 1.28e+00;  
 Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Db 1944 yasrlhn 1950  
 1:||||:  
 QY 1 YTSRLHS 7

RESULT 12  
 ID MYCB\_RAT STANDARD; PRT; 178 AA.  
 AC P15063;  
 DT 01-APR-1990 (REL. 14, CREATED)  
 DT 01-AUG-1990 (REL. 15, LAST SEQUENCE UPDATE)  
 DT 01-FEB-1996 (REL. 33, LAST ANNOTATION UPDATE)  
 DE B-MYC TRANSFORMING PROTEIN (FRAGMENT).  
 GN MYCB.  
 OS RATTUS NORVEGICUS (RAT).  
 OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
 OC EUTHERIA; RODENTIA.  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-SPRAGUE-DAWLEY; TISSUE-LIVER, AND BRAIN;  
 RX MEDLINE; 90082428.  
 RA ASKER C., STEINITZ M., ANDERSSON K., SUEMEGI J., KLEIN G.,  
 RA INGVARSSON S.;  
 RA ONCOGENE 4:1523-1527(1989).

[2]  
 RN SEQUENCE OF 1-120 FROM N.A.  
 RP MEDLINE; 89096904.  
 RA INGVARSSON S., ASKER C., AXELSON H., KLEIN G., SUEMEGI J.;  
 RL MOL. CELL. BIOL. 8:3168-3174(1988).  
 DR EMBL; X17455; G55831; -  
 DR EMBL; M21133; -; NOT\_ANNOTATED\_CDS.  
 DR PIR; A31198; TVRTBM.  
 DR PIR; A45502; A45502.  
 DR PROSITE; PS00038; HELIX\_LOOP\_HELIX.  
 DR TRANSFAC; T01563; -  
 DR TRANSFORMING PROTEIN; NUCLEAR PROTEIN; DNA-BINDING.  
 FT NON\_TER 178 178  
 SQ SEQUENCE 178 AA; 19463 MW; 8AEB0433 CRC32;

Query Match 86.3%; Score 44; DB 6; Length 178;  
 Best Local Similarity 83.3%; Pred. No. 2.32e+00;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 160 yasrlh 165  
 1:||||:  
 QY 1 YTSRLH 6

RESULT 13  
 ID K2C8\_XENLA STANDARD; PRT; 502 AA.  
 AC P08776;  
 DT 01-NOV-1988 (REL. 09, CREATED)  
 DT 01-NOV-1988 (REL. 09, LAST SEQUENCE UPDATE)  
 DT 01-JUN-1994 (REL. 29, LAST ANNOTATION UPDATE)  
 DE KERATIN, TYPE II CYTOSKELETAL 8 (CYTOKERATIN 8).  
 OS XENOPUS LAEVIS (AFRICAN CLAWED FROG).  
 OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; AMPHIBIA; ANURA.  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA MEDLINE; 86313601.  
 RA FRANZ J.K., FRANK W.W.;  
 RL PROC. NATL. ACAD. SCI. U.S.A. 83:6475-6479(1986).  
 CC -!- THERE ARE TWO TYPES OF CYTOSKELETAL AND MICROFILAMENTAR KERATIN.  
 CC I (ACIDIC) AND II (NEUTRAL TO BASIC) (40-55 AND 56-70 KILODALTONS,  
 CC RESPECTIVELY).  
 CC -!- SUBUNIT: HETEROTETRAMER OF TWO TYPE I AND TWO TYPE II KERATINS.  
 CC KERATIN 8 ASSOCIATES WITH KERATIN 18.  
 CC -!- DEVELOPMENTAL STAGE: SYNTHESIZED IN THE OOCYTE IN EARLY AND LATE  
 CC EMBRYONIC STAGES.  
 CC -!- SIMILARITY: TO ALL OTHER INTERMEDIATE FILAMENT PROTEINS.

DR EMBL; M13811; G214556; -  
 DR PIR; A23547; A23547.  
 DR PROSITE; PS00226; IF.  
 KW INTERMEDIATE FILAMENT; COILED COIL; HEPTAD REPEAT PATTERN; KERATIN.  
 FT DOMAIN 1 98 HEAD.  
 FT DOMAIN 99 406 ROD.  
 FT DOMAIN 407 502 TAIL.  
 FT DOMAIN 502 502 COIL 1A.  
 FT DOMAIN 135 151 LINKER 1.  
 FT DOMAIN 152 243 COIL 1B.  
 FT DOMAIN 244 267 LINKER 12.  
 FT DOMAIN 268 406 COIL 2.  
 FT SITE 350 STUTTER.  
 SQ SEQUENCE 502 AA; 55679 MW; 79A4B1D3 CRC32;

Query Match 86.3%; Score 44; DB 5; Length 502;  
 Best Local Similarity 71.4%; Pred. No. 2.32e+00;  
 Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Db 321 ytttrls 327  
 1:||||:  
 QY 1 YTSRLHS 7

RESULT 14  
 ID KGDG\_HUMAN STANDARD; PRT; 942 AA.  
 AC P52824;

DT 01-OCT-1996 (REL. 34, CREATED)  
DT 01-OCT-1996 (REL. 34, LAST SEQUENCE UPDATE)  
DT 01-OCT-1996 (REL. 34, LAST ANNOTATION UPDATE)  
DE DIACYLGLYCEROL KINASE, DELTA (EC 2.7.1.107) (DIGLYCERIDE KINASE)  
GN DAGK4.  
OS HOMO SAPIENS (HUMAN).  
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;  
OC EUTHERIA; PRIMATES.  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE; 95331799.  
RA PILZ A., SCHAAP D., HUNT D., FITZGIBBON J.;  
RL GENOMICS 26:599-601(1995).  
CC -1- CATALYTIC ACTIVITY: ATP + 1,2-DIACYLGLYCEROL - ADP +  
CC 1,2-DIACYLGLYCEROL 3-PHOSPHATE.  
CC -1- SIMILARITY: CONTAINS 3 COPIES OF THE ZINC-DEPENDENT PHORBOL-  
CC ESTER AND DAG BINDING DOMAIN.  
DR EMBL; L38707; G606757; -.  
DR MIN; 601207; -.  
KW TRANSFERASE; KINASE; PHORBOL-ESTER BINDING; MULTIGENE FAMILY.  
FT DOMAIN 61 108 PHORBOL-ESTER AND DAG BINDING (BY  
FT SIMILARITY).  
FT DOMAIN 122 168 PHORBOL-ESTER AND DAG BINDING (BY  
FT SIMILARITY).  
FT DOMAIN 184 234 PHORBOL-ESTER AND DAG BINDING (BY  
FT SIMILARITY).  
SQ SEQUENCE 942 AA; 101403 MW; 34C318EB CRC32;

Query Match 84.3%; Score 43; DB 5; Length 942;  
Best Local Similarity 71.4%; Pred. No. 4.14e+00;  
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Db 769 ftsrlhn 775  
:|||||  
Qy 1 YTSRLHS 7

RESULT 15  
ID FEUB\_BACSU STANDARD; PRT; 334 AA.  
AC P40410;  
DT 01-FEB-1995 (REL. 31, CREATED)  
DT 01-FEB-1995 (REL. 31, LAST SEQUENCE UPDATE)  
DT 01-NOV-1995 (REL. 32, LAST ANNOTATION UPDATE)  
DE IRON-UPTAKE SYSTEM PROTEIN FEUB.  
GN FEUB.  
OS BACILLUS SUBTILIS.  
OC PROKARYOTA; FIRMICUTES; ENDOSPORE-FORMING RODS AND COCCI; BACILLACEAE.  
RN [1]  
RP SEQUENCE FROM N.A.  
RX STRAIN-BD99 / MS94;  
RX MEDLINE; 94281248.  
RA QUIRK P.G., GUFFANTI A.A., CLEJAN S., CHENG J., KRULWICH T.A.;  
RL BIOCHIM. BIOPHYS. ACTA 1186:27-34(1994).  
CC -1- FUNCTION: THIS IS ONE OF THE PROTEINS INVOLVED IN AN IRON- UPTAKE  
CC SYSTEM. PROBABLY RESPONSIBLE FOR THE TRANSLOCATION OF THE  
CC SUBSTRATE ACROSS THE MEMBRANE.  
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN.  
CC -1- SIMILARITY: TO OTHER INTEGRAL MEMBRANE PROTEINS INVOLVED IN TONB-  
CC PROTEIN-DEPENDENT TRANSPORT SYSTEMS. BELONGS TO THE FECCD  
CC SUBFAMILY.  
DR EMBL; L19954; G438459; -.  
DR SUBTILIST; BG10836; FEUB.  
DR PROSITE; PS00402; BPD\_TRANS\_INN\_MEMBER.  
KW IRON TRANSPORT; TRANSPORT; TRANSMEMBRANE.  
FT TRANSMEM 9 29 POTENTIAL.  
FT TRANSMEM 63 83 POTENTIAL.  
FT TRANSMEM 91 111 POTENTIAL.  
FT TRANSMEM 119 139 POTENTIAL.  
FT TRANSMEM 150 170 POTENTIAL.  
FT TRANSMEM 191 211 POTENTIAL.  
FT TRANSMEM 243 263 POTENTIAL.  
FT TRANSMEM 281 301 POTENTIAL.

FT TRANSMEM 305 325 POTENTIAL.  
SQ SEQUENCE 334 AA; 35896 MW; 33B73F26 CRC32;  
Query Match 82.4%; Score 42; DB 3; Length 334;  
Best Local Similarity 66.7%; Pred. No. 7.32e+00;  
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
Db 182 ytsrlh 187  
:|||||  
Qy 1 YTSRLH 6

Search completed: Tue Mar 3 11:20:19 1998  
Job time : 9 secs.